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Summary 
Spreading drug resistances among Gram-negative pathogens and the paucity of new 
agents on the antibacterial drug market against these tenacious bacteria create a pressing 
need for the development of new antibiotics. The bacterial fatty acid biosynthesis 
pathway FAS-II, especially the enoyl-ACP reductase catalyzing the last step of the 
elongation cycle, is an established drug target against tuberculosis but has not been 
extensively exploited for drug design against other bacterial pathogens. In this thesis the 
enoyl-ACP reductases of the Gram-negative biothreat organisms Burkholderia 
pseudomallei and Yersinia pestis were targeted in a structure-based drug design 
approach. The structure of the most recently identified enoyl-ACP isoenzyme FabV was 
characterized by X-ray crystallography and could be determined in three different states. 
FabV from B. pseudomallei was obtained in the apo-form of the enzyme, whereas FabV 
from Y. pestis was characterized in a binary complex with the cofactor NADH as well as in 
a ternary complex with NADH and the triclosan-based 2-pyridone inhibitors PT172 and 
PT173. Analysis of the FabV structure revealed the typical fold of the short chain 
dehydrogenase/reductase superfamily with the NADH-binding Rossmann fold and a 
substrate-binding pocket with a conserved active site geometry compared to the related 
isoenzyme FabI. Additional structural elements of FabV are located around the active site. 
The monomeric form of the enzyme is thereby stabilized and the substrate-binding loop is 
kept in a closed, helical conformation. The ternary complexes of FabV exhibited a similar 
inhibitor-binding mode as observed for triclosan inhibition in FabI and point to a potential 
substrate-binding mechanism.  
B. pseudomallei possesses FabI as an additional enoyl-ACP reductase isoenzyme, which 
was structurally characterized in the apo form and in ternary complexes with NAD+ and 
the diphenyl ether inhibitors triclosan, PT02, PT12 or PT404 as well as the 4-pyridone 
inhibitor PT155. The structural data of the ternary enoyl-ACP reductases complexes of B. 
pseudomallei and Y. pestis hold the promise for the possibility to develop antibacterials 
targeting FabV or even both isoenzymes, FabI and FabV, based on the triclosan scaffold. 
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Zusammenfassung 
Die Ausbreitung von Antibiotikaresistenzen in Gram-negativen Pathogenen sowie der 
Mangel neuer Medikamente auf dem Arzneimittelmarkt gegen diese hartnäckigen 
Bakterien weist einen dringenden Bedarf an neuen Antibiotika auf. Die bakterielle 
Fettsäurebiosynthese (FAS-II), speziell die Enoyl-ACP-Reduktase, welche den finalen 
Schritt des Elongationszyklus katalysiert, ist ein etablierter Angriffspunkt in der 
Tuberkulosetherapie. Sie wurde jedoch bisher noch nicht für die gezielte 
Wirkstoffentwicklung gegen andere bakterielle Krankheitserreger genutzt. In dieser 
Dissertation waren die Enoyl-ACP Reduktasen aus Burkholderia pseudomallei und Yersinia 
pestis Gegenstand des strukturbasierten Wirkstoffdesigns. Die Struktur des zuletzt 
gefundenen Isoenzyms der Enoyl-ACP-Reduktase, FabV, wurde röntgenstrukturanalytisch 
charakterisiert und konnte in drei verschiedenen Zuständen bestimmt werden. Die 
Struktur des FabV Proteins aus B. pseudomallei wurde in der Apo-Form gelöst, während 
FabV aus Y. pestis in binären und ternären Komplexen mit NADH bzw. NADH und einem 
Triclosan-basierten 2-Pyridon-Inhibitor, PT172 bzw. PT173 charakterisiert wurde. FabV 
weist die typische Struktur eines Mitglieds der Short-Chain-Dehydrogenase/Reduktase 
Superfamilie mit einer NADH-bindenden Rossmann-Faltung und einer 
Substratbindetasche auf mit einer, im Vergleich zu dem verwandten Isoenzym FabI, 
konservierte Geometrie des aktiven Zentrums. Zusätzliche strukturelle Elemente sind um 
das aktive Zentrum gefaltet und stabilisieren damit das Enzym in seiner monomeren 
Form. Darüber hinaus halten sie den Substratbindeloop in einer geschlossenen helikalen 
Gestalt. Die ternären FabV Komplexe zeigen Übereinstimmungen mit dem bekannten 
Bindungsmechanismus des Inhibitors Triclosan in FabI und deuten auf einen möglichen 
Substratbindungsmechanismus hin.  
B. pseudomallei besitzt FabI als zusätzliches Isoenzym der Enoyl-ACP-Reduktasen. Dieses 
Isoenzym wurde in der Apo-Form und in ternären Komplexen mit NAD+ und den 
Diphenylether-Inhibitoren Triclosan, PT02, PT12 und PT404 sowie dem 4-Pyridon-
Inhibitor PT155 strukturell charakterisiert. Die strukturellen Daten der ternären Enoyl-
ACP-Reduktase Komplexe von B. pseudomallei und Y. pestis stellen die Möglichkeit in 
Aussicht Antibiotika zu entwickeln, welche FabV oder auch beide Isoenzyme, FabI und 
FabV, inhibieren.  
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1. Introduction 
1.1  Spread of resistance provokes a pressing need for new 
antibacterials against Gram-negative pathogens 
For some decades during the last century a bacterial infection had lost its horror. 
Antibiotics seemed to be a reliable tool to combat most of the diseases caused by 
bacteria. However, due to the spread of antibiotic resistance among bacterial pathogens 
the fear of infections returned to the patient’s bedside (Bassetti et al., 2011). The 
emergence of multi drug resistant (MDR) strains, non-susceptible to three or more 
antimicrobial classes, and moreover extensively drug resistant (XDR) strains, that are non-
susceptible to all known antimicrobial classes, in the clinics have a severe impact on 
public health, illustrated by increased mortality rates, higher costs and length of hospital 
stay (Giske et al., 2008). At the same time the number of new antibacterials on the 
market decreased over the last decades, which further worsens the situation (Figure 1).  
 
Figure 1: Systemic antibacterials approved by the US Food and Drug Administration, modified from 
(Spellberg et al., 2008) 
All the recently approved antibacterials are improved members of already known 
antibiotic classes. They exhibit a broader antibacterial spectrum, improved safety, simpler 
application or insusceptibility to certain resistance mechanisms. Since 1987 no new class 
of antibiotics had been discovered, which is called the “discovery void” (Silver, 2011). 
Even the classes that reach the clinic in the last decade (linezolid (2000), daptomycin 
(2003) and retapamilin (2007)) root in more than 25 year-old discoveries (oxazolidinones 
(Fugitt and Luckenbaugh, December 1978, 5-Halomethyl-3-phenylu-2-oxazolidinones. U.S. 
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patent 4,128,654.), acid lipopeptides (Debono et al., 1987) and pleuromutilins in 1952 
(Novak and Shlaes, 2010)). 
There are diverse mechanisms of resistance, which can be disseminated among 
pathogens (and non-pathogenic bacteria) via horizontal gene transfer. Resistance genes 
can be encoded on transferable elements as plasmids or transposons. They are often 
associated in clusters and can be transferred together (Bassetti et al., 2011). Antibacterial 
action can be impaired by drug inactivation due to cleavage, as in the case of the 
abundant β-lactamases, or to modifying enzymes, changing the scaffold of the drug. 
Another way to prevent antibacterial action is to keep the drug out of the cell with 
elevated export by efflux pumps or impaired import due to an elaborated cell wall as in 
mycobacteria or mutated porins (Blair and Piddock, 2009; Meyer, 2005). On the target 
side the inhibited enzyme can be mutated to change the binding site, the expression of 
the target can be up-regulated (Tsay et al., 1992) or an isoenzyme takes over the function 
of the target. By biofilm formation the bacteria build an exopolysaccharide matrix and 
thereby create an additional impermeable physical barrier blocking antibiotic treatment 
as well as host immune defense. Cells are recruited to the biofilm via a quorum sensing 
system utilizing diffusion of small molecules, acyl-homoserine lactones. As a reaction they 
slow down growth and enhance transcription of resistance genes (Hentzer et al., 2003; 
Lewis, 2005). Closely related are the so-called persister cells, which are tolerant to 
antibiotic treatment due to a decreased growth rate, cellular biosynthesis and increased 
stress response (Balaban et al., 2004). They can persist during antibacterial treatment and 
switch back into an active phenotype as soon as the pressure is released. An additional 
way to adapt to the presence of antbiotics are mutator cells. They display defects in their 
methyl-directed mismatch repair system and therefore have 1000-fold higher mutation 
rates and an additionally higher frequency in horizontal gene transfer (Boe et al., 2000; 
Chopra et al., 2003). The impairment of the mutator phenotype is compensated by the 
ability of the cells to adapt to new environments and antibiotic stress.  
The clinically most important MDR pathogens are summarized under the catchphrase 
“ESCAPE” (Boucher et al., 2009; Peterson, 2009). They contain the three Gram-positive 
pathogens Enterococcus faecium, Staphylococcus aureus and Clostridium difficile and the 
Gram-negatives Acinetobacter baumannii, Pseudomonas aeruginosa and 
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Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae). These pathogens became 
the focus of drug development endeavors in industry and academia. Especially for 
methicillin-resistant Staphylococcus aureus (MRSA) a variety of new compounds is in the 
pipelines of the big pharmaceutical. However, for the Gram-negative pathogens most of 
the few promising drug candidates fail in the clinical phases (Bassetti et al., 2011; Silver, 
2011). This might be partially due to the huge focus on MRSA. The greater challenge is to 
overcome the Gram-negative cell wall in order to get the compound to its target. It is not 
the lack of potential drug targets but the cell entry across this effective barrier that makes 
drug discovery against Gram-negative pathogens a difficult endeavor. In contrast to the 
Gram-positive cell wall, which is composed of the cytoplasmic membrane and a thick, 
overlying peptidoglycan network traversed by lipoteichoic acid chains, in Gram-negative 
cells the peptidoglycan layer is thinner and is located in the periplasmatic space between 
the inner and the outer membrane, which is additionally decorated with 
lipopolysaccharids (LPS) (Figure 2).  
 
Figure 2: Cell wall of Gram-positive (A) and Gram-negative (B) bacteria 
To cross the outer membrane the compound has to pass the porins, water-filled channels 
that are used by the bacterium for nutrient transport into the cell. They transport 
hydrophilic, charged compounds not larger than 600 Da (in E. coli). Having passed the 
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porins the compound is in the periplasmatic space, but if the actual target is in the 
cytoplasm it has to traverse the cytoplasmic membrane which requires a hydrophobic 
portion in the compound (Silver, 2011). To meet these conditions for entry without losing 
the affinity to the target is quite a challenge for medicinal chemists in drug discovery. 
Furthermore the relative nonselective resistance-nodulation-cell division (NDR) efflux 
pumps in Gram-negatives, in particular in Pseudomonas aeruginosa, add a synergetic 
effect to this enhanced biophysical barrier, reducing the intracellular drug concentration 
even more (Blair and Piddock, 2009). This effect is mirrored by the spectra and target 
locations of antibacterials displayed in Figure 3.  
 
Figure 3: Spectra and target locations of antibacterials, modified after (Silver, 2011) 
In the red box antibacterials with cytoplasmatic targets, active against Gram-positives (exemplary S. aureus) 
only are shown, in the black box cytoplasmatic antibacterials active against Gram-positives and some Gram 
negatives (exemplary E. coli) and in the purple box cytoplasmatic antibacterials active also against the 
Gram-negative P. aeruginosa are shown. Antibacterials active at the cell wall are illustrated in blue boxes. 
 
More than half of the cytoplasmatic antibacterials are exclusively active in Gram-positives 
(Figure 3, shown in red). Among the active cytoplasmic classes against the Gram-negative 
E. coli only aminoglycosides and fluoroquinolones (Fig. 3, shown in purple) are also active 
against P. aeruginosa. The residual two classes active against P. aeruginosa (shown in 
blue in Figure 3) are targeting the cell wall. The spread of resistant Gram-negative 
pathogens, the lack of compounds in developmental pipelines and the particular difficulty 
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to ensure cell entry of the compound underline the importance of new drug 
developments against Gram-negative pathogens. 
1.2 Biothreats 
Biothreats are bacteria, viruses or toxins that are feared to be used as bioweapons. 
Bacterial examples of bioweapons are Bacillus anthracis, Yersinia pestis, Vibrio cholerae, 
Burkholderia pseudomallei or Francisella tularensis (Table 1) (Leitenberg, 2001).  
Table 1: Bioweapons: pathogens and diseases  
Bacteria Viruses Toxins 
Bacillus 
anthracis 
Anthrax Variola virus  Smallpox Botulinal toxins  Botulism  
Yersinia pestis Plague VEE virus  
Venezuelan 
equine 
encephalitis 
Ricin 
Ricin 
poisoning 
Francisella 
tularensis 
Tularemia 
Marburg 
virus, Ebola 
virus 
Hemorrhagic 
fever 
Staphylococcal 
enterotoxin 
B (SEB) 
SEB 
poisoning 
Brucella spp. Brucellosis     
Burkholderia 
pseudomallei 
Melioidosis     
Coxiella burnetii Q fever     
Vibrio cholerae Cholera     
      
 
Compared to conventional weapons only small amounts of biothreat organisms might 
cause an unpredictable disastrous outcome (Szinicz, 2005). Unlike chemical weapons, 
biological agents can amplify inside the victim and disseminate from host to host. The 
spreading of antibacterial resistance genes even increases the danger arising from these 
pathogens. Bioweapons have been classified as weapons of mass destruction, along with 
nuclear and chemical weapons. In the Biological and Toxin Weapon Convention the 
development, production, stock-piling, acquisition or retention of bioweapons and 
furthermore the research on bioweapons for offensive purpose was banned. This treaty 
was initially signed in 1972 by the USA, USSR and UK. Meanwhile only 19 countries in the 
world have not taken part in the agreement (Szinicz, 2005). Although in public there is a 
great approval of the condemnation of bioweapons, it is known from several countries, 
also from signatories of the convention, that the treaty was violated. Apart from secret 
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bioweapon programs in several countries, in particular the fear that bioweapons might be 
used in irrational terroristic attacks emphasizes the need for new therapeutic agents 
against biothreat pathogens. This thesis focuses on new antibacterials against the 
biothreat organisms B. pseudomallei and Y. pestis. 
1.2.1 Burkholderia pseudomallei and Melioidosis 
Melioidosis was first described by the pathologist Alfred Whitmore and his assistant C.S. 
Krishnaswami among morphine addicts in Burma in 1911 (Cheng and Currie, 2005). The 
infectious agent of this serious infection is the Gram-negative, motile bacillus 
Burkholderia pseudomallei, an environmental bacterium, which can be found in soil and 
surface-water (Peacock, 2006). Burkholderia pseudomallei is capable to survive in hostile 
environments and can tolerate nutrient deficiency, antiseptic and detergent solutions, 
acidic environments, wide temperature ranges and dehydration. 
 
 Figure 4: Endemic distribution of Melioidosis, modified after (Cheng and Currie, 2005) 
Melioidosis is endemic in tropical latitudes (Figure 4), predominantly in Southeast Asia 
and Northern Australia, and is highly associated with rainfall during the monsoonal 
season (Currie and Jacups, 2003). In Australia an outbreak of melioidosis was reported 
which originated by contamination of drinking water supplies (Cheng and Currie, 2005). 
Another source of exposure was the tsunami in 2004, where not only victims of the 
catastrophe but also uninjured bystanders were infected (Athan et al., 2005). The roots of 
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infections with B. pseudomallei are direct inoculation or inhalation of soil or aerosols. The 
infection can affect virtually any organ in the body, leading to a variety of clinical signs 
and symptoms. Therefore melioidosis is often called the “great mimicker”. Its most fatal 
clinical manifestation is septic shock with concomitant pneumonia and bacterial 
dissemination to distant sites (Wiersinga et al., 2006). 20% of all community-acquired 
bacteremias in Thailand are caused by melioidosis (Cheng and Currie, 2005). Crucial risk 
factors for melioidosis are underlying diseases such as diabetes, renal failure, alcohol 
abuse or immunosuppression. A common feature of these conditions is a deficiency of 
neutrophils weakening the clearance of the pathogen by the immune response (Cheng, 
2010). Diagnostic tests, essential for the rapid treatment of melioidosis, are either time-
consuming for example a bacterial culture of a clinical sampling or not reliable as shown 
for PCR assays or serological methods (Cheng, 2010; Gal et al., 2005). The antimicrobial 
therapy of melioidosis has to be commenced as soon as a melioidosis infection is 
suspected. The pathogen is intrinsically resistant to diverse groups of antibiotics such as 
cephalosporins, penicillins, rifamycins and aminoglycosides and shows reduced 
susceptibility to quinolones and macrolides (Cheng and Currie, 2005). The biphasic 
treatment starts with an initial parenteral therapy with admission of ceftazidime or a 
carbapenem for 10-14 days, followed by 12-20 weeks of an oral eradication phase with 
trimethoprim-sulfamethoxazole (TMP-SMX) and in parts additional doxycycline 
(Limmathurotsakul and Peacock, 2011). In cases involving septic shock an adjuvant 
treatment with granulocyte colony-stimulation factor (G-CSF) during the acute phase was 
reported to be associated with decreased mortality rates (Cheng et al., 2004). However, 
even with this extensive antibiotic treatment the mortality rates remain high with approx. 
50% in Thailand and 19 % in Australia (Peacock, 2006). Important for the outcome is the 
availability of intensive care facilities for all patients with severe sepsis. Another problem 
is recurrent melioidosis. In Thailand 6% of the patients are re-infected with melioidosis in 
the first year and 10% in the first 10 years, among them 75% were relapses of the original 
infection and 25% re-infected with different strains (Maharjan et al., 2005).  
B. pseudomallei is listed as a potential bioweapon. In USSR, USA and possibly in Egypt 
researchers pursued the weaponization of melioidosis. As a disease with high mortality 
rates and intrinsic antibiotic resistances in combination with its tolerance against hostile 
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environments, it would be an attractive agent for bioweapon development. One effective 
route of infection is inhalation of dust or aerosols; therefore aerosols would be a forceful 
way of distributing the disease. Yet the disease does not spread from human to human 
and it remains to be clarified whether it infects people with an intact immune system. 
Furthermore it is not known if the research ever yielded weaponized B. pseudomallei 
pathogens. Hence it should rather be called a biothreat than a bioweapon, since up to 
now there is only the fear that this deadly but rare disease could be turned into an 
effective bioweapon. In contrast, the closely related pathogen Burkholderia mallei, 
causing the animal disease glanders, had already been used by German troops during 
World War I as a biological warfare agent against the transport horses of the Russian 
army. 
1.2.2 Yersinia pestis and the Plague 
The plague is famous for several waves of 
disastrous epidemics throughout history. 
The first reports of bubonic plague were 
recorded during the plague of Justinian 
(541-542). It was estimated that about 100 
million people died of the pandemic 
(Achtman et al., 1999). The second 
pandemic caused by the plague devastated 
the world’s population in the 13th century. 
Starting in China, where it eliminated half 
of the population, the so called Black 
Death (Figure 5) disseminated following 
the Silk Road to the known world. 
Following the last great pandemic, which 
started in 1855 and hit predominantly Asia, 
Alexandre Yersin described Y. pestis for the first time as the infectious agent causing the 
plague during an outbreak of the disease in Hong Kong in 1894 (Alexandre Yersin, 2010). 
However, there were always doubts if the Black Death had its origin in Y. pestis. It was 
hypothesized that the disease was caused by viral hemorrhagic fever (Duncan and Scott, 
Figure 5: Black death, 16th century woodcut  
(Holbein, Hans. "The Dance of Death." Woodcut, 
before 1538) 
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2005). Only recently the genome of Y. pestis could be verified in plague victims from the 
13th century outbreak in London (Bos et al., 2011). The disease is enzootic mainly in 
rodents and other mammals. Humans are infected accidently by fleabites, especially 
when the susceptible rodents are dying off due to seasonal changes. Since humans play 
hardly any role in the maintenance of the disease, it cannot be eradicated by vaccination 
(Williamson, 2009). Another source of infection is direct inoculation through skin 
lacerations by handling tissues of infected mammals or inhaling aerosolized bacteria in 
close contact to an infected patient. This route of infection requires close contact to 
coughing patients in the terminal phase of the disease. (Butler, 2009; Lowell et al., 2005). 
Human plague syndromes appear predominantly in bubonic, septicaemic and pneumonic 
forms, however, most cases show primarily the bubonic form (Butler, 2009). The first 
patient typically starts with the bubonic or septicaemic disease and develops a secondary 
pneumonia. Subsequently, the coughing patient disseminates the infection to his family 
or care attendants (Kool, 2005). During the 20th century the plague caused extensive 
deaths in India and Vietnam and even in the new millennium plague remains a killer 
disease in Africa, Asia and the Americas (Perry and Fetherston, 1997; Titball and Leary, 
1998). There were 28,956 reported cases during the decade 1992-2001 with 2064 deaths, 
about 84% of them in Africa (WHO, 2004). Upon expeditious diagnosis, treatment with 
conventional antimicrobial agents like gentamycin, streptomycin or doxycycline is usually 
successful (Butler, 2009). However in 1995 two highly drug-resistant Y. pestis strains were 
reported in Madagascar. One strain was observed to be resistant to streptomycin, 
chloramphenicol, tetracycline, sulfonamide, ampicillin, kanamycin and spectinomycin, the 
second strain only to streptomycin. Both resistance genes could be located in highly 
transferable plasmids (Galimand et al., 2006; Guiyoule et al., 2001; Guiyoule et al., 1997). 
The continuous reports of cases in the endemic areas as well as in areas, where the 
plague did not occur for decades, together with the threat of resistant strains led to the 
classification of the plague as a re-emerging disease by the World Health Organization 
(WHO) (Galimand et al., 2006; WHO, 2004). Although the organism itself is not able to 
survive outside a host for a longer period of time, it was used as biological weapon 
throughout history (Richard and Grimes, 2008). In preindustrial times the plague was 
disseminated among enemies through infected corpses or clothes. The Mongols 
catapulted plague infected corpses into the besieged town of Kaffa, forcing the Genoese 
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to flee from the contaminated city. This event might have contributed to the spread of 
the plague during the second pandemic (Smart, 1997). In the 20th century technical and 
scientific advances had an impact on the dissemination of Y. pestis as a bioweapon. 
During World War II the Japanese used vector fleas against the Chinese troops and 
population and the USSR developed an aircraft-mounted dispenser, which sprayed a Y. 
pestis emulsion onto the enemy (Smart, 1997). Risks like the upcoming drug-resistant 
strains in Madagascar (1995) and the use as a biological weapon underline the threat 
arising from this unattended organism and show the demand for new targets in the 
struggle against this disease.  
1.3 Bacterial fatty acid biosynthesis pathway FAS-II as promising drug 
target 
A promising but up to now relatively unexploited drug target for antibacterial 
development is the bacterial fatty acid biosynthesis pathway FAS-II. A good drug target 
should be (I) essential for the survival of the bacteria, it should be (II) conserved among 
several bacterial pathogens and it has to be (III) absent, different or non-essential in 
humans (O’Shea and Moser, 2008). Fatty acid biosynthesis is essential for the survival of 
bacteria since it is required for membrane phospholipid synthesis (Heath and Rock, 2004). 
The steps of fatty acid biosynthesis in all organisms are the same. In the FAS-II pathway 
each step is catalyzed by a discrete enzyme. Every step in the pathway is essential for the 
completion of fatty acid biosynthesis (Egan and Russell, 1973; Zhang and Cronan, 1998). 
However, for some of the steps several isoenzymes were identified in different species, 
which can catalyze the same reaction. This is a drawback for antibacterial drug 
development, since it reduces the antibacterial spectrum of drug candidates to bacteria 
possessing the targeted isoenzyme as the sole enzyme for this step. The FAS-II pathway is 
used for fatty acid biosynthesis in bacteria, protozoa and plants (Payne et al., 2001). 
Humans as well as other mammals, birds and yeast synthesize their required fatty acids 
within the FAS-I system (Rozwarski et al., 1999). FAS-I catalyzes the same steps as FAS-II, 
but instead of a series of distinct enzymes it is a huge, dimeric multi-enzyme complex, 
catalyzing all steps of the pathway in different domains of the complex (Jenni et al., 2007; 
Smith, 1994). Since there are only minor homologies in structure and sequence of FAS-I 
and FAS-II, the enzymes of FAS-II represent specific drug targets. With the restriction, that 
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due to the presence of isoenzymes some of the steps cannot be used to develop broad 
spectrum antibiotics, the conditions for a good antibacterial target are fulfilled for the 
FAS-II pathway. 
1.3.1 FAS-II 
The mechanism of the bacterial fatty acid biosynthesis pathway was first described in E. 
coli (Egan and Russell, 1973). It starts with acetyl-CoA which is carboxylated by the 
heterotetrameric acetyl-CoA Carboxylase AccABCD to malonyl-CoA. In the following 
reaction the malonyl-CoA-ACP transacetylase FabD exchanges the carrier molecule 
Coenzyme A with the acyl-carrier protein ACP to malonyl-ACP. ACP is a small, mostly α-
helical, acidic protein, which shuffles the acyl-intermediates from enzyme to enzyme. The 
intermediate is attached by a thioester to phosphopantetheine, the prosthetic group of 
ACP, which is linked to a conserved serine of ACP (Chan and Vogel, 2010).  
 
Figure 6: Scheme of the FAS-II elongation cycle 
In the elongation cycle a two-carbon unit is added to an acyl-ACP intermediate in a condensation with 
malonyl-ACP, catalyzed by FabF (PDB ID 2gfw, shown as ribbon diagram, top left). The β-ketoacyl-ACP is 
reduced by FabG (PDB ID, 1q7c, shown as ribbon diagram, top right) to β-hydroxyacyl-ACP, which is 
dehydrated to enoyl-ACP by FabZ (PDB ID 1mkb, shown as ribbon diagram at the bottom right).  FabI (PDB 
ID 1dfi, shown in purple as ribbon diagram at the bottom left) reduces enoyl-ACP to acyl-ACP, which can re-
enter the cycle. Potential isoenzymes are shown in parentheses. A detailed description is given in the 
following text. 
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The β-ketoacyl-ACP synthase FabH initiates the elongation cycle of FAS-II by the 
condensation of acetyl-CoA and malonyl-ACP with the elimination of CO2 and CoA. In the 
first step of the elongation cycle (Figure 6) β-ketobutyryl-ACP (β-ketoacyl-ACP in general) 
is reduced by the β-ketoacyl-ACP reductase FabG in an NADPH dependent step to β-
hydroxyacyl-ACP. The β-hydroxyacyl-ACP dehydratase FabZ or the β-hydroxydecanoyl-
ACP dehydratase/isomerase FabA (C10, unsaturated fatty acid synthesis, described below) 
dehydrates β-hydroxyacyl-ACP to trans-2-enoyl-ACP, which is subsequently reduced in an 
NADH dependent reaction by an enoyl-ACP reductase (FabI, FabK, FabL or FabV) to the 
product of the cycle, acyl-ACP. To re-enter the elongation cycle and prolong the acyl chain 
by another 2 carbon atoms, the condensing enzyme FabF or FabB (for unsaturated fatty 
acids) combines the acyl-ACP with another malonyl-ACP to obtain β-ketoacyl-ACP and CO2 
(Marrakchi et al., 2002b; Wright and Reynolds, 2007).  
The FAS-II pathway exhibits some diversity among different species. One source of 
diversity is the subset of four isoenzymes of enoyl-ACP reductases (1.3.2). Another aspect 
is the generation of unsaturated fatty acids. Not all bacteria are able to produce 
unsaturated fatty acids , e.g. Gram-positives as S. aureus, and the organisms, which can 
produce them pursue different mechanisms (Marrakchi et al., 2002b). The most abundant 
mechanism (e.g. E. coli or P. aeruginosa) introduces the double bond by the β-
hydroxydecanoyl-ACP dehydratase/isomerase FabA. β-Hydroxyldecanoyl-ACP is 
dehydrated to trans-2-enoyl-ACP and subsequently changed into cis-3-enoyl-ACP by the 
isomerase activity of FabA. The enoyl-reductase step is omitted at this point and cis-3-
enoyl-ACP is re-entering the elongation cycle through a condensation with malonyl-ACP 
catalyzed by FabB instead of FabF (Clark et al., 1983). Streptococcus pneumonia uses 
another enzyme for the production of unsaturated fatty acids. Here FabZ catalyzes the 
dehydration and the trans-2-cis-3-enoyl-ACP isomerase FabM is responsible for the 
formation of the double bond into the intermediate. In this organism, FabF can conduct 
the condensation of the unsaturated intermediate (Marrakchi et al., 2002a).  
The FAS-II pathway is not an untapped target. The two natural products cerulenin and 
thiolactomycin are inhibitors of the β-ketoacyl-ACP synthase and especially 
thiolactomycin has been extensively analyzed to be exploited for drug design (Heath and 
Rock, 2002; Luckner et al., 2009; Machutta et al., 2010). For the enoyl-ACP reductase FabI 
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several inhibitors are known e.g. isoniazid (Banerjee et al., 1994; Marrakchi et al., 2000; 
Quemard et al., 1995), diazaborines (Baldock et al., 1998a) and triclosan (Stewart et al., 
1999; Ward et al., 1999). Since the enoyl-ACP reductase is an established and potent drug 
target, we focused in this study on the inhibition of this step in the Gram-negative 
biothreat pathogens B. pseudomallei and Y. pestis. 
1.3.2 Enoyl-ACP reductases 
Currently, there are four different isoenzymes of the enoyl-ACP reductase known in 
bacteria. FabI was initially identified and constitutes the most abundant isoform (Heath 
and Rock, 1995). It was first described in E. coli. After it has been discovered, that FabI is 
the target of triclosan and especially isoniazid, an important drug against tuberculosis; it 
came in the focus of antibacterial drug development. In 2000 however, two isoenzymes 
of FabI were uncovered. FabK was described in S. pneumonia as a flavoprotein with no 
significant homology to FabI (Heath and Rock, 2000) and the third isoenzyme FabL was 
found along with FabI in Bacillus subtilis (Heath et al., 2000). The latter is related to FabI 
with a sequence identity of 24% but confers resistance to triclosan just like the unrelated 
protein FabK. The most recently discovered isoenzyme FabV was described in V. cholerae 
and is related to FabI and FabL. This isoenzyme also provides resistance to triclosan 
(Massengo-Tiasse and Cronan, 2008).  
Table 2: Known enoyl-ACP reductases of important pathogens 
Enterococcus faecium FabI 
Staphylococcus aureus FabI 
Clostridium difficile FabK 
Acinetobacter baumannii FabI 
Pseudomonas aeruginosa FabI + FabV 
Escherichia coli FabI 
Klebsiella pneumoniae FabI + FabK 
Streptococcus pneumoniae FabK 
Vibrio cholerae FabV 
Burkholderia pseudomallei FabI +  FabV 
Yersinia pestis FabV 
 
Due to the emerging diversity of the enoyl-ACP reductases, the pharmaceutical industry 
lost interest in this target, since it was not suitable for the development of broad 
spectrum antibiotics. However, especially the isoenzymes FabK and FabL display only a 
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limited species distribution (Heath and Rock, 2004) and the isoenzymes FabI, FabL and 
FabV are related, there is thus the potential to develop compounds that might inhibit all 
or at least two of them efficiently. Another aspect is the increasing need for new 
antibacterials and the spread of antibiotic resistance. Specific inhibitors against resistant 
pathogens might become more valuable when resistance against broad spectrum 
antibiotics disseminates between the pathogens. The Gram-negative pathogens, which 
will be addressed in this study, exhibit different sets of the enoyl-ACP reductases. In Y. 
pestis FabV is the sole enoyl-ACP reductase; B. pseudomallei possesses both FabI and 
FabV (cf. Table 2).  
1.3.2.1  FabI 
FabI is the most intensively studied target of the FAS-II pathway. One major reason is that 
it is the target of isoniazid, one of the front-line drugs against the persevering pathogen 
Mycobacterium tuberculosis. But FabI is not only a validated drug target; it also catalyzes 
the rate-limiting step of the fatty acid pathway and is therefore tightly regulated. Fatty 
acid biosynthesis is regulated along with phospholipid synthesis. In a feedback inhibition 
pathway long chain acyl-ACPs inhibit the initiation enzymes acetyl-CoA carboxylase 
AccABCD and the condensing enzyme FabH as well as FabI, which is finalizing the 
elongation cycle (Marrakchi et al., 2002b). FabI catalyzes the NAD(P)H-dependent 
reduction of trans-2-enoyl-ACP to the product of the cycle, acyl-ACP. Since it detracts 
trans-2-enoyl-ACP from the equilibrium with β-hydroxyacyl-ACP, with the equilibrium 
being strongly on the β-hydroxyacyl-ACP side, it drives the pathway forward and is 
determining the synthesis rate of fatty acids and subsequently membrane lipids 
(Marrakchi et al., 2002b). 
FabI is a member of the short-chain dehydrogenase/reductase superfamily (SDR 
superfamily) and belongs to the subfamily of “diverse” SDR proteins (Kavanagh et al., 
2008; Oppermann et al., 2003). This subfamily has an active site motive of Y-(X6)-K, which 
is characterized by a longer linker compared to  the usual Y-(X3)-K motif in the other 
subfamilies. The catalytic residue Y156 (in E. coli) is thought to be involved in the 
reduction of the enoyl substrate. A hydride ion from the nicotinamide ring of the NADH 
cofactor attacks the double bond of the enoyl at C3, generating an enolate anion at the 
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C1 carboxyl oxygen. The enolate is likely protonated by the hydroxyl group of Y156, which 
is re-protonated by a proton wire comprising K163, the cofactor and solvent water 
molecules. K163 is mainly involved in cofactor binding (Rafferty et al., 1995). FabI proteins 
from different organisms conduct catalysis via an ordered sequential bi-bi mechanism 
with the cofactor binding first in its reduced form and leaving last in the oxidized NAD+ 
form (Liu et al., 2011; Xu et al., 2008). The FabI protein is a typical member of the SDR-
family with a size of about 260 amino acids and a homo-tetrameric assembly. Crystal 
structures of FabI showed an NADH-binding Rossmann-fold and an adjacent substrate 
binding pocket containing the catalytic residues in a hydrophobic environment (Baldock 
et al., 1996). A remarkable feature is the so-called substrate-binding loop, which is 
proposed to be flexible, but adopting a helical structure and closing the active site pocket 
upon ligand binding. The resulting helix is thought to interact hydrophobicly with the 
enoyl-substrate (Qiu et al., 1999). 
FabI is the target of a number of established and also newly developed inhibitors (cf. 
Figure 7). 
 
Figure 7: FabI Inhibitors 
Isoniazid, the most prominent drug targeting InhA, the FabI homolog of M. tuberculosis, 
has to be activated by the catalase/peroxidase KatG and is covalently attached to the 4-
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carbon of the nicotinamide ring of NADH. An additional π-stacking interaction with F149 
(M. tuberculosis) stabilizes the interaction. The binding site is distinct from triclosan and 
diazaborines (Banerjee et al., 1994; Marrakchi et al., 2000). Diazaborines are also 
covalently attached to the cofactor, but to the 2’ hydroxyl group of the nicotinamide 
ribose of NAD+. The diazaborine ring interacts via π-stacking with the nicotinamide ring 
and forms hydrogen bonds to the catalytic residues. Furthermore it exhibits van der 
Waals interactions to the hydrophobic pocket, including the hydrophobic substrate 
binding loop, which becomes ordered in its helical closed conformation (Baldock et al., 
1996). However, due to the toxic boron in the scaffold, the inhibitors are not suitable for 
drug design. Triclosan is a widely used antibacterial agent, which can be found in many 
consumer products such as soaps, cosmetics or toothpaste but also in hospital 
disinfection agents. It is non-covalently bound in the active site of FabI in a stable ternary 
triclosan-NAD+-FabI complex (Heath et al., 1998). Binding is achieved through hydrogen 
bonds of its hydroxyl group at the A-ring to Y156 (E. coli) and the cofactor as well as by a 
π-stacking interaction with the nicotinamide ring of the oxidized NAD+ cofactor. Triclosan 
also interacts with the hydrophobic pocket of FabI and recruits the hydrophobic 
substrate-binding loop for interactions. The helical ordering of the loop upon triclosan 
binding is thought to cause the slow-binding behavior of triclosan, which is highly 
favorable for drug design (Lu and Tonge, 2008; Ward et al., 1999). With respect to the M. 
tuberculosis FabI homolog InhA, triclosan acts as a rapid reversible inhibitor in vitro. Here, 
the substrate binding loop remains flexible (Kuo et al., 2003; Parikh et al., 2000). The 
closely related enoyl-ACP reductase FabL from B. subtilis is reversibly inhibited by 
triclosan but does not form a stable ternary complex and therefore confers resistance 
against this antibacterial agent (Heath et al., 2000; Kim et al., 2011). Apart from the 
known inhibitors of FabI, a number of new compounds have been developed against FabI, 
mainly to target the increasingly resistant S. aureus, which contains FabI as the sole enoyl-
ACP reductase (cf. Figure 7B). For this clinically important pathogen pharmaceutical 
companies accept the narrow spectrum of FabI inhibitors (Silver, 2011). GlaxoSmithKline 
investigated a series of aminopyridines. The best inhibitor in this series showed an 
inhibitory effect not only on FabI of S. aureus but also on FabK of S. pneumonia (Payne et 
al., 2002). The project was outsourced to Affinium, where the clinical candidate AFN-1252 
was developed. This aminopyridine inhibitor is specific for staphylococci and retained no 
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inhibition on S. pneumonia (Karlowsky et al., 2009). AFN-1252 has already been used in 
phase I trials. Park and collaborators reported on the inhibitor CG400549 which is related 
to the triclosan scaffold. They identified a hotspot in resistance against this compound in 
mutations of FabI at F204 to leucine (Park et al., 2007). Interestingly, a mutation of the 
same residue F204 to cysteine led to a loss of the slow binding behavior of triclosan for S. 
aureus FabI (Fan et al., 2002). The company Mutabilis is also working on a triclosan-based 
compound, MUT37307. This compound is active against S. aureus and other organisms 
with FabI as the sole enoyl-ACP reductase (Escaich, 2008; Silver, 2011). 
Although FabI does not carry the promise for a broad spectrum antibiotic anymore, 
several FabI inhibitors have been developed. All of them target the Gram-positive 
pathogen S. aureus. In this work we focus on Gram-negative pathogens, especially B. 
pseudomallei and Y. pestis, of which only B. pseudomallei possesses the FabI isoform. 
Since triclosan is an effective antibacterial agent against Gram-negative pathogens such 
as E. coli, it has to overcome the protective cell wall and is therefore a suitable lead 
structure for further compound developments against Gram-negatives. 
1.3.2.2  FabV 
The enoyl-ACP reductase isoform FabV occurs in several relevant Gram-negative 
pathogens such as V. cholerae, P. aeruginosa, B. pseudomallei or Y. pestis. It is the most 
recently described FabI isoenzyme and was discovered in V. cholerae, since this pathogen 
comprises none of the known enoyl-ACP reductase isoforms (Massengo-Tiasse and 
Cronan, 2008). It is related to the SDR proteins FabI and FabL but shows some distinct 
features. FabV is only about 15% identical in sequence to FabI or FabL and is with its ~400 
amino acids 60% larger than a typical SDR protein. It was shown to be monomeric in 
solution, which is also an exception in this superfamily. SDR proteins usually form dimers 
and tetramers in solution. A known exception to this “rule” is the monomeric porcine 
carbonyl reductase, which stabilizes itself by an additional α-helix in a 41 residue insertion 
(Ghosh et al., 2001). The active site motif of FabV is with Y(X8)K even longer than the 
extended Y(X6)K motif of the divergent subfamily, including FabI. It was shown, that FabV 
prefers NADH over NADPH as a cofactor (Massengo-Tiasse and Cronan, 2008). The FabV 
isoform of B. mallei catalyzes the reduction of the enoyl substrate in an ordered, 
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sequential bi-bi mechanism as demonstrated for FabI (Lu and Tonge, 2010). The enzyme 
is inhibited by triclosan, but not efficiently enough to seriously harm the bacterium. In B. 
mallei triclosan acts as a rapid reversible inhibitor with a Ki value of 0.4 µM (Lu and Tonge, 
2010). In P. aeruginosa, which contains both FabI and FabV, triclosan resistance is caused 
by FabV (Zhu et al., 2010). Previously it was thought that P. aeruginosa was resistant to 
triclosan due to depletion of the compound via its efflux pumps (Schweizer, 1998). 
However, the ΔfabV mutant of P. aeruginosa was susceptible to triclosan whereas the 
ΔfabI mutant and the wild-type were resistant to triclosan (Figure 8).  
 
The binding mode of triclosan to FabV, even if it is not of high affinity, can be used as a 
starting point for drug design. In some cases, as in Y. pestis or V. cholerae, FabV is the sole 
known enoyl-ACP reductase of the organism. For these pathogens an effective inhibitor 
targeting FabV would be sufficient to combat the bacterium. Other organisms such as B. 
pseudomallei or P. aeruginosa, also contain FabI, therefore both isoforms have to be 
inhibited to attack these organisms. Since FabV and FabI are related proteins and both 
bind triclosan, though with differing affinity, a triclosan derivative may be in reach that 
effectively inhibits both enzymes.  
  
Figure 8: Inhibition of phospholipid 
synthesis of P. aeruginosa PAO1 wild 
type and mutants by triclosan (Zhu et 
al., 2010)  
Phospholipids extracted before (lane 1, 
5, 9), at (lane 2 ,6, 10), 30 minutes (lane 
3, 7, 11) and 1h (lane 4, 8, 12)  after 
addition of 10µl/ml triclosan.  
The phospholipids are labeled with                
[1-
14
C]acetate,  
PE: phosphatidylethanolamine; PG: 
phosphatidylglycerol 1 and CL: 
cardiolipin. 
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1.4 Research objective 
In a structure-based drug design approach targeting the enoyl-ACP reductases of the 
Gram-negative pathogens B. pseudomallei and Y. pestis the structures of FabI (B. 
pseudomallei) and FabV (B. pseudomallei and Y. pestis) were characterized by X-ray 
crystallography including binary and ternary complexes with the cofactor NADH and 
newly developed, triclosan-based inhibitors. Of particular interest were the distinct 
features of the FabV isoenzyme, which was structurally characterized in this work for the 
first time, such as the stabilization of the monomeric assembly, the additional structural 
motifs of FabV or how the differing active site motif affects the 3 dimensional structure. 
For co-crystallization attempts with potential inhibitors, a selection of triclosan-based 
inhibitors, including diphenyl ethers and pyridone compounds, were provided by Peter 
Tonge’s laboratory, our collaborators from Stony Brook University, NY, USA. The 
interactions of different inhibitors with the active site pockets of FabI and FabV were 
characterized, with a focus on the behavior of the substrate-binding loop, and compared 
to examine the possibility to design an inhibitor targeting both isoenzymes with sufficient 
efficiency. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals  
All required chemicals were supplied by Applichem (Darmstadt), Carl Roth (Karlsruhe), 
Fluka (Neu-Ulm), Hampton Research (Laguna, USA) and Sigma-Aldrich (Seelze). They were 
used in at least analytical purity grade. For the purpose of crystallography only the highest 
available purity grade was accepted. 
2.1.2 Inhibitors 
The following inhibitors, apart from triclosan, were synthesized and kindly provided by 
Professor Peter Tonge's working group (Table 3). 
Table 3: Inhibitors 
 
2.1.3 Plasmids 
The plasmids pET15b and pET23b from Novagen were used as expression vectors. The 
FabI constructs from B. pseudomallei and the FabV constructs from Y. pestis, B. 
pseudomallei, B. mallei and P. aeruginosa were kindly provided by our collaboration 
partners Hao Lu (Lu and Tonge, 2010), Nina Liu (Liu et al., 2011) and Carla Neckles 
(Hirschbeck et al., 2012) from Professor Peter Tonge's laboratory (StonyBrook University, 
NY, USA) (Table 4). The expression vectors contain the gene of interest with an N-terminal 
(pET15b) or C-terminal (pET23b) hexahistidine tag regulated by the T7 RNA polymerase 
promotor. Expression is negatively controlled by the Lac operator. The LacI repressor, also 
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included in the vector, inhibits expression of the T7 RNA polymerase until it is inactivated 
by lactose or the lactose-analog IPTG (Isopropyl β-D-1-thiogalactopyranoside). As a result 
the repressor releases the DNA, the T7 RNA polymerase is transcribed and translated and 
can start with the transcription of the recombinant gene of interest. 
Table 4: Expression Vectors 
Vector Insert Source organism Restriction sites 
pET15b YpFabV  Y. pestis strain A1122 XhoI, EcoRI 
pET15b YpFabV T276S Y. pestis strain CO92 XhoI, EcoRI 
pET15b BpFabV B. pseudomallei strain Bp82 NdeI, BamHI 
pET15b BmFabV B. mallei strain ATCC 23344 NdeI, BamHI 
pET15b PaFabV P. aeruginosa strain PAO1 NdeI, BamHI 
pET23b BmFabI (=BpFabI) B. mallei strain ATCC 23344 NdeI, HindIII 
 
2.1.4 Bacterial culture 
Bacteria of different plasmid amplification and expression strains (Table 5) were grown in 
LB-medium (Carl Roth) or on LB-agar plates.  
Table 5: Escherichia coli strains 
Plasmid amplification   
DH5α E. coli F- φ80dlacZΔM15 Δ(lacZYA-argF)U169 deoR recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 λ- thi-1 gyrA96 relA1  
Clontech 
Laboratories  
 Expression   
BL21 (DE3) E. coli F
– 
ompT hsdSB(rB
–
, mB
–
) gal dcm (DE3)  Novagen  
BL21 (DE3) pLsyS E.coli F
- 
ompT hsdSB(rB
- 
mB
-
) gal dcm (DE3) pLysS (CamR)  Novagen  
Arctic express (DE3)RIL 
 
E. coli B F
–
 ompT hsdS(rB
–
 mB
–
) dcm+ Tetr gal λ(DE3) endA 
Hte [cpn10 cpn60 Gentr] [argU ileY leuW Strr] 
Stratagene 
 
2.1.5 Enzymes and Kits 
Table 6: Enzymes, Kits and Miscellaneous Reagents 
Enzymes 
DNase Invitrogen 
Thrombin GE Healtcare 
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Kits 
NucleoSpin Plasmid Kit  Machery-Nagel 
NucleoBond Xtra Midi 
 
Machery-Nagel 
Miscellaneous reagents 
Sypro Orange Invitrogen 
PageRuler prestained protein ladder Fermentas 
2.1.6 Crystallization screens 
All crystallization screens used in this study were produced according to the 
manufacturer's specifications utilizing the Lizzy 2002 pipetting robot (Zinsser Analytic) 
with the exception of Salt screen I and a PEG pH 6.5 screen, which were self-designed.  
Table 7: Crystallization screens 
Additive Screen  Hampton Research  
Crystal Screen 1  Hampton Research  
Crystal Screen 2  Hampton Research  
Index  Hampton Research  
Nextal PEGs suite  Qiagen  
Topaz OptiMix-3  Fluidigm  
Topaz OptiMix-PEG  Fluidigm  
Wizard Screen I  Emerald BioSystems  
Wizard Screen II  Emerald BioSystems  
Salt screen I Self-designed  (cf. appendix Table 28)  
PEG pH 6.5 screen Self-designed  (cf. appendix Table 29) 
 
2.1.7 Equipment 
Table 8: Technical equipment 
Autoclave Systec V-150 Systec 
Bacterial shaker ISF-1-W 
Bacterial shaker ISF-1-X 
 
Kühner 
Balances 
XS 105 Dual Range 
XS 6002S Dual Range 
 
Mettler Toledo 
 
Bio-Photometer Eppendorf 
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Camera AxioCam MRC Zeiss 
Cell disruptor 
TS-Series  
M-110P  
 
Constant Systems 
Microfluidics 
Centrifuges 
Centrifuge 5415 D 
Centrifuge 5810 R 
Avanti J-26 XP 
 
Eppendorf 
Eppendorf 
Beckmann Coulter 
Columns for affinity chromatography in batch 
Econo-Column 1,5 x 15 cm 
Econo-Column 2,5 x 20 cm  
 
Biorad 
Column / medium for affinity chromatography 
Ni-TED 
HisTrap FF crude,1 ml and 5 ml 
HiTrap Benzamidine FF, 1ml 
 
Protino 
GE Healthcare 
GE Healthcare 
Cryo loop Hampton Research 
Crystallization robot HoneyBee 963  Zinsser Analytic 
DynaPro Dynamic Light Scattering  Wyatt Technology Corporation  
Fast protein liquid chromatography systems 
ÄKTApurifier  
ÄKTAxpress 
ÄKTA avant 
 
 
GE Healthcare 
Gelelectophoresis Mini-Protean 3-cell Biorad 
Gelfiltration  
HiLoad 26/60 Superdex 200 prep grade 
HiLoad 16/60 Superdex 200 prep grade 
 
GE Healthcare 
Incubator B15 Heraeus 
Light source KL 2500 LCD Zeiss 
Liquid handling robot Lissy2002 Zinsser Analytic 
Magnetic stirrer MR 3002 Heidolph 
Microscope Stemi 2000-C  Zeiss 
Sealing robot RoboSeal HJ-Bioanalytik 
Spectrophotometer Nanodrop ND 1000  Peqlab 
pH-Electrode Schott 
pH-Meter Schott 
Pipettes Rainin 
Pipetboy easypet Eppendorf 
Pipetting robot Lizzy 2002 Zinsser Analytic  
Power supply Biorad 
Real time PCR cycler (MX3005P) Stratagene 
Rotors 
JLA 25.50 
JA 8.1000 
 
Beckmann Coulter 
Spectrophotometer Nanodrop ND 1000  Peqlab 
Thermoblock Rotilabo-Block Heater 250 Carl Roth 
Thermomix comfort  Eppendorf 
X-ray detectors 
R-Axis IV++ 
R-Axis HTC 
  
Rigaku 
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X-ray generators 
Ultra X18  
MicroMax-007 HF  
 
Rigaku 
 
Table 9: Consumable supplies 
24-well crystallization plate Crystalgen 
96-well crystallization plate Greiner 
Baysilone silicone paste GE Bayer 
Concentrator MWCO 10,000 
Vivaspin 6 
Vivaspin 20 
 
Sartorius Stedim Biotech 
Cover slides Jenabioscience 
cuvettes Carl Roth 
Filter 0,22 µm Carl Roth 
Gloves (nitril) Carl Roth 
Greiner tube 15 ml, 50 ml Greiner 
Pipette tips 10 µl, 200 µl, 1000 µl, 5000 µl Rainin 
Reaction tube 1.5 ml Eppendorf 
 
2.1.8 Computer Software 
Table 10: Software 
Software Author/Reference 
Arp/Warp (Morris et al., 2003) 
AutoSharp (Vonrhein et al., 2007) 
CCP4 program suite (CCP4, 1994) 
ChemBioDraw Ultra 12.0 CambridgeSoft 
ClustalW  (Thompson et al., 1994) 
Coot (Emsley and Cowtan, 2004) 
DaliLite server (Holm and Park, 2000) 
Dssp 
Dssp2pdb 
(Kabsch and Sander, 1983) 
(James Stroud, 2002) 
ESPript (Gouet et al., 2003) 
ExPASY Proteomics Server http://www.expasy.ch/ 
iMosflm 1.0.3  (Battye et al., 2011) 
LIGPLOT (Wallace et al., 1995) 
Microsoft Office Professional Plus 2010 
Microsoft Word 
Microsoft Excel 
Microsoft Powerpoint 
Microsoft Corporation 
OriginPro 8.5 Origin Lab Corporation 
PDBe Protein Data Bank (Velankar et al., 2012) 
Phaser (McCoy et al., 2007) 
Phenix 1.6.2-432 (Adams et al., 2010) 
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Phenix 1.7.3-938 
PRODRG server (Schuttelkopf and van Aalten, 2004) 
Pymol (Schrodinger, 2010) 
Refmac5 (Murshudov et al., 1997)  
Scala (Evans, 2006) 
TLSMD server (Painter and Merritt, 2006) 
XDS package  (Kabsch, 2010) 
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2.2 Methods 
2.2.1 Microbiology techniques 
2.2.1.1  Transformation 
For plasmid amplification and recombinant protein expression exogenous DNA had to be 
taken up by the host bacteria, which can subsequently use the genetic information to 
produce the desired product.  The artificial uptake of exogenous DNA, mostly vectors as 
plasmids, by bacteria is called transformation. With a heat shock or by electroporation 
the membrane permeability of the cells is increased, which facilitates the entry of nucleic 
acids into the bacterial cell. In this study different E. coli strains (cf. Table 5) were 
transformed with expression plasmids (cf. Table 4) by heat shock transformation. Since E. 
coli cells are not intrinsically competent for DNA uptake during the heat shock 
application, the cells have to be treated with ice-cold CaCl2 solutions in their exponential 
growth phase to become chemically competent. Although the bacteria are especially 
prepared for transformation, the uptake of DNA is still a very rare event (   0.1%) (Chen 
and Dubnau, 2004). Therefore recombinant DNA vectors usually carry an antibiotic 
resistance gene, in our plasmids a gene providing resistance against ampicillin. In growth 
medium or on agar plates with the respective antibiotic only the bacteria carrying the 
vector can grow.  
In practice an aliquot of chemo-competent E. coli cells (50 µl) was thawed on ice. The cells 
were incubated on ice with 1µl of the expression vector (10-100 ng/µl) for 10 minutes. 
The temperature of the cells was rapidly increased from 0 °C to 42 °C in a thermo block 
and heat shocked at 42 °C for 60 seconds allowing DNA uptake. Afterwards the cells were 
chilled again on ice for 2 minutes. To recover from this harsh thermal treatment, the 
bacteria were mixed with 500 µl of LB-medium (Bertani, 1951) and shaken with 600 rpm 
at 37°C in a thermo block for at least 20 minutes. To select for the transformed cells 25-
100 µl of the culture was plated on a LB-agar plate containing 100 µg/ml ampicillin. Some 
E. coli expression strains as E coli strain BL21 (DE3) pLysS contain additional resistance 
genes themselves; in this case the additional antibiotic also had to be added to the 
growth media or LB-agar plates. The LB-agar plates were incubated at 37 °C over night to 
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allow colony growth. Afterwards the plate was stored at 4 °C and the colonies could be 
picked for further experiments for about a week. 
2.2.1.2  Plasmid amplification 
Lyophilized samples of the expression vectors (Table 4) had been kindly provided by the 
working group of Professor Peter Tonge. For plasmid amplification, 1µl of the dissolved 
DNA was transformed (cf. 2.2.1.1) into DH5α E. coli cells. The DH5α strain is suitable for 
plasmid amplification since it carries an endA1 mutation that reduces endonuclease 
digestion of plasmids leading to higher plasmid yield. A single clone was picked from the 
transformation plate and used to inoculate a 5 ml or 200 ml LB culture including 100 
µg/ml ampicillin, depending on the kit which was used for plasmid isolation. The cultures 
were grown over night at 200 rpm at 37 °C and harvested by centrifugation. The amplified 
plasmid DNA of the 5 ml or 200 ml cultures was extracted using the NucleoSpin Plasmid 
Kit or the NucleoBond Xtra Midi kit (Machery-Nagel), respectively, following the 
manufacturer’s manual. The major steps of the kits are cell lysis, pelletization of the cell 
debris, loading of the DNA onto the silica membrane, washing the membrane with a 
buffer containing ethanol, drying of the membrane and finally eluting the DNA from the 
membrane with water. The final DNA concentration was assessed spectrophotometrically 
at a wavelength of 260 nm using the Nanodrop ND 1000.  
2.2.1.3  Protein expression 
For recombinant protein expression the expression plasmid (2.1.3) was transformed 
(2.2.1.1) into an E. coli expression strain (Table 5). All LB-media or LB-agar plates used for 
expression contained 100 µg/ml ampicillin to prevent contamination with bacteria other 
than the transformed clone. A colony of the transformation was used to inoculate 2 ml LB 
which was subsequently shaken at 200 rpm for approx. 8 hours at 37 °C. This small 
culture was used to inoculate the actual 200 ml pre-culture, which grew over night in a 
bacterial shaker at 200 rpm at 37 °C. Large scale expression was performed in 2 L LB 
cultures in 5 L Erlenmeyer flasks. The cultures were inoculated to an OD600 of 0.05 (25-50 
ml pre-culture) and grown in the bacterial shaker at 37 °C until it reached the exponential 
growth phase at an OD600 of 0.6. At this point the expression of the recombinant protein 
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was induced by the addition of 1 mM IPTG to inhibit the LacI repressor and permit the 
expression of the T7 RNA polymerase and subsequently the expression of the gene of 
interest. The expression was conducted for 5 h at 25 °C or for 20 h at 15 °C. Subsequently,  
bacteria were harvested by centrifugation (at 4 °C, 5000g, 20 min; rotor JLA 8.1000, 
Beckmann Coulter Avanti Centrifuge J-26 XP) and stored in aliquots of 5-10 g at -80 °C. For 
expression tests the protein expression was conducted likewise in 5 ml or 200 ml scale. 
2.2.2 Protein purification 
High purity and homogeneity of the protein sample is an important factor facilitating 
crystallization. The purification of all recombinant proteins in this work was performed in 
two predominant chromatographic steps, first a nickel affinity chromatography was 
performed to isolate the hexahistidine tagged protein from the cell lysate and in a second 
step the protein sample was separated from remaining contaminants and aggregated 
protein by size-exclusion chromatography. In the case of YpFabV the hexahistidine tag 
was removed by thrombin for the later crystallization trials. All steps were performed at 4 
°C if not stated otherwise.  
2.2.2.1  Cell lysis 
Due to the enormous overexpression 5-10 g bacterial pellet was sufficient for a large-
scale purification. The cell pellet was thawed and resuspended in Lysis Buffer (= Binding 
Buffer in Table 12) on ice. 1 g of pellet was resuspended in 10 ml of Lysis Buffer with 0.2 
µl DNase (Invitrogen). The cells were lysed in 2 passages through a cell disruptor at a 
pressure of 1.5 kbar. In order to remove the cell debris, the cell lysate was cleared by 
centrifugation (4 °C, 25000 g, 30 min; rotor JA 25.50, Beckmann Coulter Avanti Centrifuge 
J-26 XP). The cleared sample could then be used for Ni2+-affinity chromatography. 
2.2.2.2  Ni2+-affinity chromatography 
Affinity chromatography exploits reversible high affinity interactions between the protein 
of interest and certain interaction partners, which are attached to a chromatography 
matrix. The use of recombinant fusion proteins, which are connected to high affinity tags, 
makes this a universally applicable purification technique. In our case, the proteins are 
Materials and Methods 
 
31 
 
decorated with hexahistidine tags, which bind to divalent metal ions in the immobilized 
metal ion affinity chromatography (IMAC). The Nickel ions are coordinated by a chelating 
resin which is attached to the column matrix. The protein is released from the nickel by 
competition with an excess of imidazole. There were two different IMAC column 
materials in use. In the pre-packed Histrap FF crude columns the chelating group is 
coupled to a sepharose matrix and in the Ni-TED material the chelating tris 
(carboxymethyl) ethylendiamine (TED) group is attached to silica beads. The Ni-TED beads 
exhibit only one free binding site at the complexed nickel ion instead of two in the Histrap 
material. Therefore the affinity to histidine tagged proteins is weaker with respect to the 
Ni-TED beads but much more specific. Hence, the buffers for the Ni-TED purification 
contain less imidazole (Table 12). The loose Ni-TED beads had to be used in a batch 
method in contrast to the Histrap columns, the latter are designated for the automatic 
ÄKTA chromatography systems (cf. Table 8). Apart from the automated performance of 
the purification, the ÄKTA systems have the advantage that they can monitor pH, 
temperature, pressure, conductivity and the absorption at up to three different 
wavelengths which can be used to follow the steps of the purification in real time.  
The general procedure for both nickel materials is summarized in Table 11. The cleared 
cell lysate was loaded onto the column and unbound sample washed out with at least 20 
column volumes (CV) of Binding Buffer. Afterwards nonspecifically bound proteins were 
washed out with 10 CV of a separate Washing Buffer with slightly elevated imidazole 
concentrations compared to the binding buffer and 1 M NaCl (possible for both methods) 
or by a gradient over 10 CV reaching 8% Elution Buffer, which is restricted to automated 
chromatography. The protein was eluted from the Histrap column by a step elution up to 
50% Elution Buffer over 10 CV or with a 20 CV gradient reaching 100% Elution buffer. In 
general, the imidazole concentration should be kept low as imidazole can cause protein 
precipitation at high concentrations. Elution from the Ni-TED column was achieved with 
10 CV of Elution buffer. Here fractionation (5 ml) of the sample was performed manually. 
To increase the protein concentration in the elution fractions, the Elution Buffer was 
added in 1 CV portions and incubated with the Ni-beads for 1-5 minutes. The elution 
fractions of both methods were analyzed by SDS-PAGE and the pure peak fractions 
pooled for the next purification step.  
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Table 11: Different Ni-affinity chromatography procedures 
 Ni-TED (batch procedure) HisTrap FF crude (automated procedure) 
Column volume 20ml 5-10ml 
Equilibration 5CV Binding Buffer 
Sample application Loading the sample 
Wash out unbound 
sample 
at least 20 column volumes of 
Binding Buffer (5mM imidazole) 
20 column volumes of Binding Buffer (20mM 
imidazole) 
Wash step 10 CV of Washing Buffer (10mM 
imidazole, 1M NaCl) 
10 CV of Washing Buffer (60mM imidazole, 
1M NaCl), 
or 
gradient over 10 CV to 8% Elution Buffer 
(500mM imidazole) 
Elution 
10 CV of Elution Buffer (150mM 
imidazole), in 1CV steps with short 
incubation 
10 CV step elution to 50% Elution Buffer, 
or 
20 CV gradient to 100% Elution Buffer 
 
Table 12: Buffers for the affinity chromatography 
2.2.2.3  Thrombin cleavage 
The vector pET15b is designed as such that the hexahistidine tag of the recombinant gene 
product can be cleaved off with thrombin. Thrombin was purchased from GE Healthcare, 
dissolved in PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 2 mM KH2PO4, 
pH 7.4) and stored at -80 °C. The combined peak fractions containing the protein of the 
Ni-affinity chromatography were concentrated to 50 mg/ml (in case of the very stable 
YpFabV) and incubated with 1 U thrombin per mg of protein at room temperature (18-22 
°C, depending on the season) for up to 20 hours. The success of the cleavage was 
analyzed via SDS-PAGE. Thrombin was removed with a HiTrap Benzamidine FF Affinity 
 Binding Buffer  
= Lysis Buffer 
Washing buffer Elution buffer 
Ni-TED 50 mM Tris pH 7.4 
500 mM NaCl 
5 mM imidazole 
20 mM Tris pH 7.4 
1 M NaCl 
10 mM imidazole 
20 mM Tris pH 7.4 
500 mM NaCl 
150 mM imidazole 
HisTrap FF crude 5ml 50 mM Tris pH 7.4 
500 mM NaCl 
20 mM imidazole 
20 mM Tris pH 7.4 
1 M NaCl 
60 mM imidazole 
20 mM Tris pH 7.4 
500 mM NaCl 
500 mM imidazole 
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Column from GE Healthcare following the manufacturer’s manual. Benzamidine is a 
reversible inhibitor of thrombin, which is attached to the matrix of this affinity column. By 
loading the sample onto the column the thrombin is removed from the solution while the 
protein of interest should not bind. The flowthrough from the column, which was 
completely washed out of the column with 10 ml PBS buffer, was fractionized. The 
protein content of the fractions was determined spectrophotometrically at a wavelength 
of 280 nm using the Nanodrop ND 1000. The fractions with relevant protein 
concentrations were pooled and used for the final size-exclusion chromatography step. 
After size-exclusion chromatography, the pure peak fractions were incubated with small 
amounts of Ni-TED resin to remove residual uncleaved protein, which could prevent 
crystallization of the cleaved protein. 
2.2.2.4  Size-exclusion chromatography 
Size-exclusion chromatography separates components of the applied sample according to 
their size and shape. The gel filtration column contains a matrix of porous beads 
composed of agarose and dextran. The pores 
in the beads are of different sizes. The smaller 
the size of a protein, the deeper it can 
penetrate the branched channels through the 
beads (cf. Figure 9). Therefore smaller proteins 
have to cover a longer distance than bigger 
proteins and elute later from the column. 
Bigger protein aggregates cannot enter the 
beads and have to run past them. They elute 
with the void volume of the column. In this 
work size exclusion chromatographies with 
the columns HiLoad 26/60 Superdex 200 and 
HiLoad 16/60 Superdex 200 with column volumes of 330 ml and 124 ml, respectively, 
have been performed at different ÄKTA chromatography systems (cf. Table 8) and at a 
flow rate of 1.5 ml/min. The loaded protein sample was not allowed to exceed 5 ml or 10 
ml for the 16/60 or 26/60 column. The column was equilibrated in 1 CV Gel Filtration 
Figure 9: Size-exclusion chromatography 
Particles of different sizes on their way through 
a gel filtration bead 
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Buffer (Table 13). The sample was applied and eluted with at least 1 CV. Fractionation of 
the elution started after 0.3 CV. Elution was monitored by the absorption at 260 nm and 
280 nm wavelength and samples of the peak fractions were analyzed by SDS-PAGE. 
Fractions containing pure protein were pooled, concentrated, flash-frozen in liquid 
nitrogen and stored at -80 °C. 
Table 13: Gel Filtration Buffers 
FabI FabV 
20 mM Bistris pH 6.5 
500 mM NaCl 
1 mM EDTA 
20 mM PIPES pH 7.5 
300 mM KCl 
1 mM EDTA 
 
2.2.3 Protein characterization 
2.2.3.1  SDS-PAGE analysis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) is 
a method to analyze the protein content of a sample to evaluate protein purity during 
purification or the degree of overexpression in an expression test. The protein sample is 
denatured by incubation at high temperatures. Potential disulfide bridges are disrupted 
by the addition of the reducing agent DTT (dithiothreitol). The anionic detergent sodium 
dodecyl sulfate (SDS) interacts via its dodecyl chain with the peptide backbone of the 
protein covering the whole amino acid chain with its negatively charged sulfate moiety. 
The overall charge is thereby proportional to the size of the protein. The protein sample 
can be separated in polyacrylamide gel electrophoresis due to its differential migration 
velocity through the gel in an electric field. Since all proteins are negatively charged by 
SDS they migrate towards the anode. The density of the polyacrylamide gel also 
contributes to the separation of proteins of different sizes. 
In this work polyacrylamide gels with a 15% acrylamid/bisacrylamide (AA/BAA) resolving 
gel and a 5% AA/BAA stacking gel were used (cf. Table 14). In the looser stacking gel the 
proteins run faster and accumulate when they reach the resolving gel with higher density, 
thereby they all move together into the resolving gel. 10 µl of protein sample were mixed 
with 2.5 µl loading buffer (containing SDS and DTT), denatured for 5 minutes at 95 °C and 
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loaded onto the gel. To be able to estimate the size of the protein bands a protein ladder 
(PageRuler prestained protein ladder (Fermentas)) with marker proteins of 10-170 kDa 
was used. Electrophoresis was conducted at 200 V for 1 h in SDS running buffer. To stain 
the protein bands the gel was incubated with Coomassie solution (5-15 min) and 
afterwards washed in destaining solution until only the protein bands were still visible in 
blue. 
Table 14: SDS PAGE - gel recipe and solutions 
15 % Resolving Gel 
15% AA/BAA (30% mix) 
375 mM Tris pH 8.8 
0.1% SDS 
0.25% APS 
0.05% TEMED  
5 % Stacking Gel 
15% AA/ BAA (30% mix) 
125 mM Tris pH 6.8 
0.1% SDS 
0.25% APS 
0.15% TEMED 
 
Loading buffer (5x) 
50 mM Tris pH 6.8 
100 mM DTT 
2% SDS 
0.1% Bromphenol blue 
SDS Running buffer (1x) 
192 mM Glycine 
0.1% SDS 
25 mM Tris 
Coomassie Staining solution 
0.5% Coomassie brilliant  blue  
50% Methanol 
10% Acetic acid 
 
Destaining solution 
10% Ethanol 
5% Acetic acid 
 
2.2.3.2  Thermofluor analysis 
Thermofluor (Pantoliano et al., 2001) is a method to evaluate protein stability in certain 
surroundings. The influence of buffer components, pH, additives or binding partners such 
as cofactors or inhibitors on protein stability can be assessed. This method was used to 
analyze different buffer conditions for the subsequent crystallization of the protein. 
The Thermofluor assay is based on the measurement of melting curves of the protein. 
Unfolding of the protein is detected with the help of the fluorescence dye Sypro Orange 
(Invitrogen). Sypro Orange exhibits fluorescence at a wavelength of 590nm (orange), 
which is quenched in aqueous surroundings. In a hydrophobic environment the 
fluorescence of Sypro Orange is increased. During the unfolding process of a protein that 
is natively surrounded by aqueous environment, hydrophobic parts, which are usually 
protected from the solvent in the core of the protein, are exposed and can interact with 
the fluorescence dye, thereby increasing the fluorescence. The experiment is conducted 
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in a real time PCR cycler (MX3005P) since the temperature can be tightly regulated and 
real-time fluorescence detection can be achieved. The inflection point of the measured 
fluorescence curve is interpreted as melting point of the protein in the respective 
condition.  
In practice, the protein was mixed with Sypro Orange and buffers at concentrations of 
100 mM from a buffer screen covering the pH range 4.5-9.8 (Supplemental Table 27: 
Thermofluor screen) or with a reference buffer as control (cf. Table 15). The mixtures (in a 
96-well PCR plate) were heated from 25 °C to 95 °C with an increase of 1 °C per minute.  
Table 15: Thermofluor  
 Protein (0.5 mg/ml) Buffer Sypro Orange (0.5% v/v) 
Buffer screen 5 µl 15 µl buffer screen (100mM) 5 µl 
Buffer reference 5 µl 15 µl reference buffer 5 µl 
Negative control - 20 µl reference buffer 5 µl 
2.2.4 Protein Crystallization 
2.2.4.1  Vapor diffusion method  
 
Figure 10: Crystallization by vapor diffusion 
A) Phase diagram for crystallization by vapor diffusion, after (Chayen, 2004), B) sketch of a hanging drop 
setup, C) sketch of a sitting drop setup. 
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In general crystallization is achieved by bringing a very pure protein sample into the 
supersaturated state. This forces the protein to go out of solution, which can happen by 
unordered precipitation or by ordered crystallization, the latter being the desired result. 
The most common method for crystallization is vapor diffusion. A schematic phase 
diagram with this method is shown in Figure 10A. The protein solution is mixed in the 
crystallization drop with the precipitant from the reservoir solution. Thereby the protein 
concentration as well as the precipitant concentration is halved (under the condition that 
they are mixed 1:1). The drop is in a closed system together with a larger amount of 
reservoir solution (approx. 500:1). The precipitant concentrations in both solutions start 
to equilibrate by vapor diffusion of H2O and other volatiles out of the drop into the 
reservoir. Due to the loss of water, the volume of the droplet decreases and the protein 
as well as the precipitant concentration increase (arrow 1). At some point the protein is 
supersaturated and has reached the nucleation zone of the phase diagram. Now 
nucleation may take place and the crystal starts to grow. Upon crystal growth the protein 
is taken out of the solution and the protein concentration decreases again (arrow 2). Two 
different experimental setups for vapor diffusion are established. In the hanging drop 
experiment (Figure 10B) the crystallization drop is hanging from a cover slide, which 
closes the reservoir, whereas in the sitting drop experiment (Figure 10C) the 
crystallization drop is placed on a shelf above the reservoir.  
2.2.4.2  Protein preparation 
A protein sample has to be highly concentrated so that it can reach the supersaturated 
state during the crystallization trial. The proteins in this work exhibited remarkably high 
protein solubility and have been concentrated at the end of the purification procedure to 
30 mg/ml (BpFabI) or 100 mg/ml (FabVs). Furthermore, the protein solution has to be as 
homogenous as possible. This was achieved through the optimization of buffer conditions 
(cf. 2.2.3.2) and extensive centrifugation (at least 30 minutes at 16,100 g) of the sample 
to remove aggregates, which would lead to precipitation prior to crystallization. For co-
crystallization trials the protein was pre-incubated for 1 hour with the ligands to facilitate 
binding. The cofactor NAD+/NADH was dissolved in ddH2O and added to the protein 
solution in 10-fold excess. The inhibitors exhibit low water solubility. They were either 
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added pure to the protein solution (end concentration    5 mg/ml) or dissolved in the 
organic solvent DMSO at concentrations of 100 mg/ml and added to the protein solution 
to reach a final concentration of 5 mg/ml (approx. 100-fold molar excess). However, since 
the DMSO concentration was decreased to 5%, the inhibitors precipitated again so the 
actual inhibitor concentration is lower. Higher DMSO concentrations impaired crystal 
formation. The insoluble fraction of the inhibitor was removed during the centrifugation 
step. 
2.2.4.3  Screening 
Crystallization screening was performed in sitting drop setups in 96-well crystallization 
plates (Greiner). The standard screen was pipetted with the help of the HoneyBee 
crystallization robot (Zinsser Analytic) with 40 µl of reservoir solution and crystallization 
drops consisting of 0.3 µl reservoir and 0.3 µl protein solution. The screens were closed 
with an adhesive sealing foil by the sealing robot RoboSeal (HJ-Bioanalytik). Initial 
screening was performed at protein concentrations of 10 mg/ml. Depending on the 
proportion of precipitated conditions to clear drops in the first screens, the protein 
concentration was reduced or increased. If the proportion of precipitated drops to clear 
drops was around 1:1, the protein concentration was suitable for the screen. The screens 
were incubated at 20 °C and evaluated after several time points at the Stemi 2000-C 
(Zeiss) Microscope. 
2.2.4.4  Optimization 
Successful crystallization trials were reproduced in hanging drop setups at a larger scale in 
24 well crystallization plates (Crystalgen) with a reservoir solution of 1 ml and 1+1 µl 
crystallization drops. The drops were mixed on a cover slide and carefully transferred 
upside down on the reservoir. The gap between the edging of the reservoir well and the 
cover slide was sealed with silicone paste. In order to optimize crystal growth, factors 
such as the precipitant concentration, the pH or the salt concentration in the 
crystallization condition were varied on the 24-well plate. An alternative method to vary 
crystallization was to change the proportion of protein sample to reservoir solution and 
use for example 2 µl of protein and 1 µl of reservoir solution. Applying this procedure, the 
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protein advances towards the supersaturated state more slowly but reaches a higher end 
concentration. The plates were incubated at 20 °C and evaluated after several time points 
at the Microscope Stemi 2000-C (Zeiss). 
2.2.5 X-ray crystallography 
Most of the information in this chapter was derived from (Rupp, 2010). 
2.2.5.1  Data collection and processing 
To analyze protein structures at atomic resolution X-rays, i.e. electromagnetic radiation 
with a wavelength (λ) of the same order of magnitude compared to the size of atoms, are 
used. In X-ray crystallography the parallelism of the crystal lattice is exploited in the 
diffraction experiment. When an x-ray beam encounters a crystal lattice of atoms or 
molecules, it induces oscillation of the electrons in the lattice at the x-ray frequency. The 
electrons, returning to the unexcited state, emit radiation at the original energy and 
wavelength in a random direction. The scattered waves can be described as reflections at 
the lattice planes of the crystal. In most cases the scattered waves contribute to 
destructive interference and add up to zero. However, if the x-ray beam hits the lattice 
plane under the glancing angle θ and Bragg’s law (Equation 1) is satisfied, constructive 
interference takes place and reflections can be recorded on the detector. In the 
diffraction experiment the intensity and the position of the reflections are recorded. The 
Miller indices h, k, l can be deduced from the position of the reflections after the 
orientation of the crystal latticed with respect to a reference coordinate system has been 
determined (Blow, 2003). 
             
Equation 1: Bragg's law 
(d = distance between crystal lattices, θ = incidence angle of x-ray, n = integer, λ = 
wavelength) 
In practice the crystals were fished with a nylon loop, transferred into a cryo-solution and 
subsequently frozen in liquid nitrogen. The cryo-solution contains an increased 
precipitate concentration compared to the mother liquor and additional cryo-protectants 
like glycerol or PEG 400 (10-30%). The cryo-protectants prevent the frozen drop in the 
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loop from the formation of ice crystals and result in a vitrification of the crystal. Ice 
crystals contribute to the total diffraction and disturb the protein diffraction pattern.  
To collect x-ray diffraction images the crystal is mounted on a goniometer and positioned 
in an x-ray beam. It is cooled to -180 °C by a nitrogen cryo-stream. A lead beam-stop in 
the center of the x-ray beam keeps the high energy beam from directly hitting the 
detector. The detector is very sensitive since it is designed to register weak reflections. 
The beam-stop therefore saves it from overloads. There are several types of detectors, in 
this study the diffraction images were recorded by either imaging plate detectors or CCD 
(charge-coupled device) detectors. As X-ray sources, in-house x-ray generators (Ultra X18 
and MicroMax-007 HF, Rigaku) with a rotating Cu-Anode emitting radiation at a fixed 
wavelength of 1.54 Å and imaging plate detectors (R-Axis IV++ and R-Axis HTC, Rigaku) 
were available as well as beam time at different synchrotron facilities (European 
Synchrotron radiation Facility ESRF, Grenoble; Bessy II, Berlin).The circulating electrons in 
the synchrotron emit high energy radiation, which is utilized in the surrounding 
beamlines. A monochromator can filter certain wavelengths out of the polychromatic 
primary beam. This is essential for multi-wavelength experiments such as MAD (multi-
wavelength anomalous diffraction). The mounted crystals were rotated during the 
exposure around the phi axis. The degree of rotation per frame depended on the quality 
of diffraction, the crystal mosaicity and the unit cell dimension and was usually 0.1°-1° to 
obtain well-separated diffraction spots. The minimal angle range for the collection of 
complete datasets was determined by iMosflm (Battye et al., 2011) . 
The diffraction images were indexed and integrated with the help of the programs 
iMosflm (Battye et al., 2011) and XDS (Kabsch, 2010). If the space group assignment was 
questionable, the program Pointless (CCP4, 1994) was used to identify the space group 
with the highest probability. The scaling of the datasets was performed with Scala (Evans, 
2006). Scala also provides a number of markers helping to assess data quality such as 
completeness, redundancy, <I/σI> and Rmerge. The Rmerge (Equation 2) is a commonly used 
quality indicator of N merged reflections h within a certain resolution range. Weak 
reflections in the higher resolution shells lead to higher Rmerge values indicating an 
increased measurement error. Rmerge is often used to determine the high-resolution cutoff 
of the dataset. A rough guideline states that it should not exceed 60% in the highest 
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resolution shell. The overall Rmerge should be better than 15%. Since the Rmerge displays the 
cumulative error of the dataset, it gets worse with higher redundancy. The precision-
indicating merging R-value Rpim (Equation 3) takes into account that the intensities 
become more accurate with an increasing number of observations in redundant datasets. 
So although the Rmerge was the first indicator to judge the high-resolution cutoff, in cases 
of high redundancy also Rpim was considered. 
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Equation 2: Linear merging R-value 
(N=number of reflections h) 
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Equation 3: Precision-indicating merging R-value 
(N=number of reflections h) 
 
2.2.5.2  Phase determination 
The objective of the experimental structure solution approach in x-ray crystallography is 
an electron density map of the protein, which can be used for model building to generate 
a 3-D model of the protein of interest. The Fourier transformation can be used to 
calculate the electron density distribution ρ (x,y,z) from the structure factor F (hkl) and 
vice versa (Equation 4) 
 (     )  
 
 
∑∑∑ (   )       (        ) 
   
 
Equation 4: Inverse Fourier transform 
 (ρ = electron density, V = volume of unit cell, F = structure factor, h/k/l = Miller-
Indices, x/y/z = coordinates) 
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The square of the amplitude of the structure factor |F(hkl)| is proportional to the 
measured intensity (I(hkl)) of a reflection (Equation 5).  
 (   ) | (   )|  
Equation 5: Relation of structure factor and amplitudes 
 (   )  | (   )|   (   ) 
Equation 6: Calculation of structure factors 
(I=intensity, F = structure factor, h/k/l = Miller-Indices, = phase angle) 
The information which can be extracted from the diffraction images only contains the 
amplitudes (=intensities) but not the phase information of the scattered X-rays. However, 
also the phase  of the wave is needed for the calculation of the structure factor F(hkl) 
and therefore for the generation of an electron density map (Equation 6). The fact that 
the phases cannot be measured directly is termed the phase problem in crystallography. 
There are different methods available to solve the phase problem (Taylor, 2010). They 
have in common that they involve additional information to deduce initial phases for the 
electron density calculation. In this study molecular replacement and single isomorphous 
replacement combined with anomalous scattering (SIRAS) were conducted to overcome 
the phase problem. 
2.2.5.3  Molecular replacement - MR 
The molecular replacement (MR) method exploits phase information derived from a 
known homologous structure. The proteins have to share at least 25-30% sequence 
identity. MR is favored over the experimental techniques since it requires only one native 
dataset. The probability to find a suitable model structure increases with the number of 
published crystal structures. To apply the phases of the model structure to the electron 
density calculation the structures have to superpose in the unit cell.  
      
 
 
 ∑|    |
 
   
     |   (        )| 
Equation 7: Patterson function Puvw 
 (F = structure factor, h/k/l = Miller-Indices, u/v/w = Patterson-coordinates) 
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The correct orientation is obtained with the help of the phase-independent Patterson 
function (Patterson, 1934; Patterson, 1935) (Equation 7) representing the structures by 
the sum of their interatomic vectors. The maximal correlation of the Patterson maps is 
determined in a 6-dimensional search, including 3 axes of rotation and 3 axes of 
translation. To decrease computational complexity, the search is separated in a rotation 
and translation step to pursue a 3-dimentional search twice. Important is also the number 
of molecules (n) present in the asymmetric unit which can be deduced from the 
Matthews’s coefficient VM (Matthews, 1968) (Equation 8), taking the volume of the unit 
cell, the space group symmetry and the molecular weight of the protein into account. 
    
          
     
 
Equation 8: Matthew's coefficient 
 (Vunit cell = volume of the unit cell, M = molecular weight of the protein, z = number of 
symmetry operators of the space group) 
In protein crystals the Matthews’s coefficient is usually between 1.7 and 4.0 Å3/Da 
corresponding to a solvent content of 30-70%. This is of course a probability-driven rule of 
thumb. In the case of ypFabV in the crystal form including the hexahistidine tag, the 
Matthew’s coefficient suggested a higher probability for 2 molecules in the asymmetric unit, 
but it turned out that it was actually only one molecule with the very high solvent content of 
70%. 
In practice the molecular replacement search was performed with the help of the 
program Phaser (McCoy et al., 2007) included in the CCP4 suite (CCP4, 1994).  
2.2.5.4  Single isomorphous replacement with anomalous scattering – SIRAS 
When no homologous protein structure is available, the phase problem has to be solved 
experimentally. The additional information to determine the phases is hereby deduced 
from changes in the measured intensities. The SIRAS approach takes advantage of two 
different phasing methods, isomorphous replacement and anomalous scattering (Taylor, 
2010).  
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For isomorphous replacement the crystal is soaked with heavy atom compounds (Perutz, 
1956). When these atoms bind to the protein in the crystal, the electron-rich heavy atoms 
(H) provoke measureable changes in the structure factor amplitudes of the diffraction 
dataset |   | compared to a native dataset |  |. Both datasets have to be isomorphous 
with no major changes in the unit cell parameters. 
|  |  |   |  |  | 
Equation 9: Isomorphous difference 
This isomorphous difference (Equation 9) is utilized to determine the heavy atom 
structure factor amplitude|  |. The phase of FH is determined with the Patterson method 
or direct methods. With this information the phase angle of the native structure factor 
|  | can be narrowed down with the help of a Harker construction (cf. Figure 11) to two 
possible solutions.  
 
To break this so-called phase ambiguity of single isomorphous replacement (SIR) the 
second method in SIRAS is used – anomalous scattering. Anomalous scattering occurs if 
the x-ray energy is sufficiently high (at the absorption edge of a heavy atom) to excite an 
electron and promote it from the inner to a higher shell. When it returns to the lower 
energy level it emits electromagnetic radiation which, also contributes to the measured 
intensities. The anomalous contribution f’’ of the heavy atom is retarded by 90 ° in phase 
and therefore orthogonal to its native structure factors. This anomalous difference 
disrupts the symmetry of the Friedel pair (|    |  |    |). In the Harker construction 
Figure 11: Harker construction for the SIR approach  
Adapted from (Taylor, 2010) 
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(cf. Figure 12) the anomalous phase information is used to resolve the phase ambiguity 
and define an initial phase, which can be utilized to generate the first electron density 
map of the protein. In this study a crystal of YpFabV was soaked with 200 mM NaI and the 
anomalous scattering of the bound iodine atoms was exploited. The dataset was 
measured at a wavelength of 1.25 Å at beamline ID29 (ESRF) to a resolution of 3.1 Å. 15 
bound iodine atoms contributed to the isomorphous and anomalous signal of the dataset. 
An isomorphous native dataset was collected at beamline MX14.1 at Bessy II at a 
wavelength 0.918 Å to a resolution of 2.1 Å. The SIRAS phasing was performed with the 
help of the program autoSHARP (Vonrhein et al., 2007) (cf. Table 10). 
2.2.5.5  Model building, refinement and validation 
The initial error-prone electron density map was used to build a first model. In case of 
molecular replacement the search model was utilized, the amino acid sequence was 
corrected and the model adapted to the electron density map. In case of the SIRAS result 
an ab initio model was generated with the help of the automated model building 
software ARP/wARP (Langer et al., 2008) which created a partial model which was 
extended and improved manually. Model building and improvement was performed in 
the program Coot (Emsley and Cowtan, 2004) using the 2Fo-Fc map. The Fo-Fc difference 
Figure 12: Harker construction for the SIRAS approach 
Adapted from (Taylor, 2010) 
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map supported the model building process by emphasizing missing or wrong parts of the 
model. The preliminary model could then be used in intermediary refinement cycles to 
improve the phases and thereby the electron density map. Repeated cycles of model 
building and refinement further improved both model and phases until convergence was 
achieved. The refinement was performed with the programs Refmac5 (Pannu et al., 1998) 
or phenix.refine (Adams et al., 2010). Both programs utilize maximum likelihood 
refinement which aims to maximize the congruence of the observed (|Fo|) and the 
calculated (|Fc|) structure factor amplitudes and restrain protein geometry features, like 
bond lengths and angles, near their optimal values. Non-crystallographic symmetry (NCS) 
restrains contributed to the improvement of the model. NCS restrains are only applicable 
if the asymmetric unit contains more than one molecule. It is based on the assumption 
that all symmetric chains share the same conformation and geometry. In addition, a 
considerable improvement during refinement was achieved by TLS refinement 
(translation, libration, screw motion). TLS refinement considers the uniform anisotropy of 
groups of atoms, in their concerted rigid body motions. The number and size of the 
groups can be optimized. They can be defined using prior knowledge about the protein 
(domains, hinge regions, secondary structure elements, etc.) or by the analysis of the 
isotropic B-factor, which was conducted in this study with the help of the TLSMD server 
(Painter and Merritt, 2006). For every TLS group 20 additional parameters are introduced 
to the refinement. TLS does not only support the refinement process, the movement of 
groups and domains described in TLS can also provide information about the dynamics of 
the protein. 
A common measure for the convergence of the refinement is the R-factor Rcryst (Equation 
10). It expresses the difference between the calculated and observed structure factor 
amplitudes. The R-factor should be as small as possible indicating good agreement of 
model and experiment. At a resolution of 2.5 Å the Rcryst is usually about 20% for a 
successfully refined structure. 
   
∑  ||  |  |  ||   
∑  |  |   
 
Equation 10: R-value 
 (Fo = observed structure factor, Fc = calculated structure factor) 
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The Rcryst, however, is prone to model bias, since it is based on data, which is used during 
refinement. To prevent overfitting of the model a second quality marker, the Rfree, was 
established. The Rfree is derived from data which was excluded from refinement (5% of the 
data, randomly chosen) and is therefore not affected by the refinement. The Rfree is 
usually approx. 3-6%  higher than Rcryst (cf. PDBe statistics). 
Once the refinement of the protein structure has reached convergence, the model has to 
be validated. Validation of the structures was carried out using the MolProbity server 
(Chen et al., 2010), independently of the experimental data only relying on protein 
geometry and potential clashes of atoms in the structure. In terms of geometry the server 
analyzes the deviation of the bond angles and lengths from their ideal values, the Cβ 
deviation and the Ramachandran plot, describing the accordance of the dihedral angles φ 
and ψ of the peptide backbone to the ideal. The plot is separated in the most favored 
region, the allowed region and the disallowed region containing outliers. Also unusual 
rotamers of amino acid side chains are analyzed. All these quality markers are based on 
statistics on protein libraries and outliers are not automatically wrong. If an outlier was 
detected, the corresponding residue was evaluated in its electron density map and if the 
map supported this more unlikely conformation of the residue, it was accepted. 
Furthermore, the server searches for potential atomic clashes of the protonated model. It 
provides a clash score which is defined as the number of serious steric overlaps (> 0.4 Å) 
per 1000 atoms. Prior to analysis the MolProbity server suggests side chain flips of 
histidines, glutamines and asparagines, if the hydrogen bond network of the surrounding 
structures is improved by the flip. After evaluation, the secondary structure elements 
were assigned with the program dssp (Kabsch and Sander, 1983). Structural features were 
analyzed with the help of several PDBe tools (Velankar et al., 2012) (cf. 2.1.8). Ligand 
interactions were examined utilizing Ligplot (Wallace et al., 1995) and Pymol 
(Schrodinger, 2010). Pymol was further used to create most of the illustrations describing 
the structures.  
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3. Results 
The enoyl-ACP reductases of Y. pestis and B. pseudomallei, YpFabV, BpFabI and BpFabV 
were expressed, purified and crystallized. For the first structural characterization of FabV 
the x-ray structure had to be solved by experimental phasing (SIRAS). Further FabV 
structures as well as the FabI structures were solved by molecular replacement. 
Subsequently, to follow the structure based drug design approach, the drugability of both 
proteins with diphenyl ether and pyridone inhibitors was probed using co-crystallization 
trials with FabI and FabV. 
3.1 FabV 
In the course of the project on FabV, several FabV constructs from various species were 
utilized for our structure based drug design approach (cf. Table 4). In first experiments the 
expression and purification of FabV was established with BmFabV (FabV from B. mallei). 
Since crystallization trials with BmFabV were not successful, the source organism was 
switched to Y. pestis. However, the initially utilized YpFabV construct, with which the 
structure was solved by experimental phasing, contained a T276S mutation. This mutation 
was revealed when binary and ternary complexes with this variant had been solved. To 
exclude the possibility, that the missing methyl group of S276 in the variant has an impact 
on the structure of the protein, the binary complex structures were reproduced with wild 
type YpFabV. The structural description in the following chapter therefore focuses first on 
the T276S variant and follows with the description of the wild-type protein.  
3.1.1 Expression of FabV from different Pathogens 
For the expression of FabV from different pathogens (B. mallei, B. pseudomallei, P. 
aeruginosa and Y. pestis) the vectors were kindly provided by Professor Peter Tonge 
(Stony Brook University, New York, USA). The different fabV genes were cloned into the 
pET15b expression vector with an N-terminal hexahistidine tag in a T7-promotor 
controlled region with an ampicillin resistance gene for selection. A first expression test 
was performed with BmFabV. The vector was transformed into different chemo-
competent E. coli strains (BL21 (DE3), BL21 (DE3) pLsyS and BL21 (DE3) arctic express). 
Overnight cultures were inoculated with a single colony of each strain. This pre-culture 
was used to inoculate small-scale test expression vials. Expression was induced at an 
Results 
 
49 
 
OD600 of 0.6 with 1 mM IPTG and the expression temperature (i.e the temperature after 
induction) set to 15 °C or 25 °C. The expression was analyzed in a time course. The best 
result could be observed for BL21 (DE3) cells at 15 °C as shown in Figure 13A for FabV 
from B. mallei (BmFabV). 
 
Figure 13: FabV Expression 
A) SDS-PAGE of test expression of BmFabV in BL21 (DE3) cells at 15 °C. B) SDS-PAGE of high scale 
expressions of YpFabV (1+2), BpFabV (3+4) and PaFabV (5+6) in BL21 (DE3) cells (20 h at 15 °C), samples 
1/3/5 were diluted 1:5.  
 In the SDS-PAGE a prominent band next to the 40 kDa marker band appears already 2 
hour after induction of the expression with 1 mM IPTG and increases over time. Including 
the recombinant part of the gene product, the FabV proteins have a molecular weight of 
45 kDa indicating that the appearing band most likely represents BmFabV. The highest 
expression was achieved in an overnight expression, which was used for the following 
high scale expressions. This protocol was also successful for the remaining FabV 
constructs BpFabV, PaFabV and YpFabV. The expression levels of the proteins are shown 
in the respective SDS-PAGE (Figure 13B) with clearly overexpressed proteins visible as a 
thick band slightly above the 40 kDa marker band. The expression of the FabV T276S 
variant worked equally well. In general, the overexpression of the protein was increased 
in high scale expression compared to low scale expression tests. 
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3.1.2 Buffer optimization using Thermofluor analysis 
Pure BmFabV obtained from a first small scale purification (final purification described in 
detail in 2.2.2 and 3.1.3) precipitated in the preliminary gel filtration buffer (30 mM PIPES 
pH 6.8, 150 mM NaCl and 1 mM EDTA). To improve the solubility of the protein a 
Thermofluor analysis (2.2.3.2) was performed testing the thermal stability of BmFabV in 
different buffer solutions and at different pH values (buffer list see appendix Table 27). 
The Thermofluor analysis is based on the fluorescence dye Sypro Orange, which gives rise 
to an elevated fluorescence signal upon binding to the unfolded protein.  
 
Figure 14: Thermofluor analysis of BmFabV 
A) Buffer screen B) Thermofluor with PIPES pH 7.5 and with (black) and without (red) 300mM KCl.  
In general, the resulting melting temperatures of BmFabV were very low and varied 
between 35 °C and 39 °C. The gel filtration buffer was used as a reference. Buffers with 
pH values between 7.5 and 8.0 led to the highest melting temperatures with the best 
buffer being PIPES pH 7.5, elevating the melting point from 36 °C to 39 °C (Figure 14A). 
This didn’t seem to be a dramatic effect, but the second batch of protein, purified in PIPES 
pH 7.5 buffer, was in general more stable with a melting temperature of 46 °C, which 
could be further improved by the addition of 300 mM KCl to 49 °C (Figure 14B). The 
resulting buffer (20 mM PIPES pH 7.5, 300 mM KCl and 1 mM EDTA) was used for size-
exclusion chromatography and as final protein buffer. 
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3.1.3 Purification 
For protein crystallography the purity and homogeneity of the protein is of particular 
importance. The purification of the different FabV proteins was achieved with the same 
protocol. Herein, the purification of T276S variant of YpFabV (Figure 15) and of its wild 
type (Figure 16) is presented. Furthermore, the BpFabV purification is displayed in the 
Supplemental Figure 57 of the appendix. The overexpressed protein was isolated from 
the cell lysate by affinity chromatography utilizing its N-terminal hexahistidine tag and 
afterwards separated from remaining impurities and aggregated protein, which might 
prevent crystallization, by size-exclusion chromatography. 
 
Figure 15: Purification of YpFabV T276S 
A) SDS-PAGE of a Ni-TED purification: (1) Load, (2) Flowthrough, (3) Wash out of the unbound sample, (4) 
Additional wash step, (5-12) Elution. B) SDS PAGE after size exclusion chromatography: (1) Peak 1, (2-5) 
Peak 2, (6-12) peak 3. C) Chromatogram of the size exclusion chromatography; the absorption at 280 nm is 
shown in black and at 260 nm in red. 
For the nickel affinity chromatography two equivalent approaches were used, a batch 
method using Ni-TED (Protino) material (Figure 15A) or pre-packed HisTrap FF crude 
columns (5-10 ml bed volume, GE healthcare) using the ÄKTA chromatography systems 
(Figure 16A+B). In both methods cleared cell lysate was loaded onto the equilibrated 
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column, the unbound sample was washed out and unspecific binding contaminants were 
removed in an additional washing step using small concentrations of imidazole. FabV was 
eluted from the column with a step to 150 mM or 250mM imidazole (for details see 
2.2.2.1). The elution of the protein was followed at the chromatography system using its 
absorption at wavelengths of 280 nm and 260 nm. Samples from every step and the peak 
fractions were analyzed via SDS-PAGE. Due to the stringent cleaning procedure all elution 
fractions reached high purity and were used for the second step of purification (see 
Figure 15A, Figure 16B).  
 
Figure 16: Purification of wild-type YpFabV  
A) Chromatogram of a Histrap purification with a step gradient, absorption at 280 nm (black) and 260 nm 
(red), % Elution buffer (blue). B) SDS-PAGE of Histrap purification: (1) Load, (2) Flowthrough, (3) wash out of 
the unbound sample, (4) extra wash, (5-12) elution. C) Chromatogram of size exclusion chromatography, 
absorption at 280 nm (black) and 260 nm (red). B) SDS PAGE of size exclusion chromatography: (1-12) main 
peak. 
 
Although both Ni-chromatography methods led to similar results, the Histrap purification 
prevailed in practice due to the higher binding capacity of the column material (50 mg 
protein /ml bed volume instead of 5 mg protein /ml Ni-TED resin) and the automated 
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performance at the chromatography system leading to a highly concentrated peak in the 
elution (see Figure 16A+B). The following size-exclusion chromatography was conducted 
using a HiLoad Superdex 200 26/60 gel filtration column with a maximal sample volume 
of 10 ml. The elution fractions of the Ni-TED purification had to be concentrated with a 
Vivaspin 20 concentrator (10 kDa cutoff) to meet this condition. The elution fractions of 
the Histrap column commonly could be used directly. After the FabV sample was applied 
to the equilibrated column, it was eluted with one column volume of the gel filtration 
buffer. The elution profile was composed of four characteristic peaks (see Figure 15C). 
Samples from each peak were analyzed in SDS-PAGE. The first peak, shortly after the void 
volume of the column, represents aggregated protein, mainly FabV (Figure 15B, lane 1). 
At an elution volume of 200 ml a small FabV dimer peak appeared (lanes 2-5), which was 
interpreted as a purification artifact due to the extremely high concentrations of FabV. 
The following peak contained the vast majority of the protein sample and corresponds to 
the FabV monomer (lanes 6-12) as it was previously described (Massengo-Tiasse and 
Cronan, 2008). The last small peak corresponds to imidazole, which was used during the 
affinity chromatography step. The percentage of FabV aggregate and dimer peak varied 
between the purifications. In a batch with good, soluble protein, which was processed 
very fast during purification, these peaks hardly appear (Figure 16C). The fractions of the 
monomer peak displayed very high purity (99%). They were pooled, concentrated to 50-
100 mg/ml, flash-frozen in liquid nitrogen and stored at -80 °C. To modify the 
crystallization behavior of the enzyme, the buffer was partly exchanged by ddH2O during 
protein concentration. 
3.1.3.1  Removal of the hexahistidine tag 
An additional approach to change the YpFabV crystallization behavior was the removal of 
the recombinant hexahistidine tag using thrombin. A thrombin cleavage site is inserted in 
the pET15b vector between the hexahistidine tag and the actual start of the fabV gene. 
17 of the 23 recombinant residues at the N-terminus of the YpFabV construct are 
removed by the thrombin cleavage, generating a size difference of about 2 kDa. The 
efficiency of the cleavage was tested at different protein concentrations (1 mg/ml and 50 
mg/ml), at different temperatures (4 °C and 22 °C), with different thrombin 
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concentrations (0.01-1 U/mg YpFabV T276S), after different incubation times and with 
the addition of 500 mM imidazole (Figure 17A+B). 
 
Figure 17: Thrombin cleavage 
A) SDS-PAGE of thrombin (1 U/mg protein) test-cleavage of YpFabV T276S (1 mg/ml). B) SDS-PAGE of 
thrombin (different concentrations) test-cleavage of YpFabV T276S (50 mg/ml), last lane contains 500 mM 
imidazole C) Chromatogram of size exclusion chromatography, absorption at 280 nm (black) and 260 nm 
(red). D) SDS PAGE of size exclusion chromatography: fractions of main peak. 
In the time course test at low protein concentrations with 1 U thrombin per mg of YpFabV 
a second band appears below the YpFabV band at both temperatures but delayed at 4 °C 
(Figure 17A). At 20 °C the majority of the protein is cut after 20 hours. With respect to the 
thrombin-concentration test at a higher FabV concentration (50 mg/ml) the protein 
seems to be cleaved with 1 U of thrombin after 20 hours at 22 °C irrespective of the 
presence of 500 mM imidazole (Figure 17B). These experiments show that the protein can 
be directly cleaved after nickel affinity chromatography without a prior need for the 
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removal of imidazole. The eluate of the affinity column was concentrated up to 50 mg/ml, 
mixed with thrombin and incubated overnight at room temperature. The success of the 
cleavage was analyzed by SDS-PAGE. Thrombin was removed from the sample using a 
benzamidine column (GE healthcare), which binds thrombin but not FabV. The 
flowthrough, containing the FabV sample, was subsequently applied to the size-exclusion 
column as described for the uncleaved protein Figure 17C+D). Prior to concentrating the 
sample after size exclusion chromatography, the peak fractions were incubated shortly 
with Ni-TED resin to remove residual uncleaved FabV from the sample, since it could 
interfere with the crystallization of the cleaved protein. The Ni-TED resin was separated 
by centrifugation and the protein sample concentrated to 50-100 mg/ml, flash-frozen in 
liquid nitrogen and stored at -80 °C. 
3.2 Crystal structures of FabV from Y. pestis –T276S variant and wild 
type 
3.2.1 Binary cofactor complex of YpFabV 
3.2.1.1  Crystallization 
To obtain the first crystal structure of FabV, the recombinant protein from Y.pestis in 
complex with its cofactor NADH was used in crystallization trials. Due to the very high 
solubility of YpFabV T276S the screens were performed with protein concentrations of 
30-100 mg/ml with the addition of a 10-fold molar excess of NADH. The screens were 
performed as small-scale sitting-drop vapor diffusion experiments with the commercially 
available crystallization screens Hampton Crystal Screens I+II, Hampton Index Screen, 
Emerald Wizard Screens I+II, Nextal PEG suite and OptiMix Screens 3+4 (TOPAZ) as well as 
with the self-designed Salt Screen I, which was developed on the basis of well-diffracting 
crystals grown in salt-containing conditions (Table 7). 
YpFabV T276S crystallized in various conditions, predominantly in the Nextal PEG screen 
and in the OptiMix Screen 3, in either PEG-containing conditions or crystallization 
conditions at high salt concentrations (see Figure 18). The crystals grown in PEG 
conditions (Figure 18 A+E) did not diffract to a resolution better than 8 Å and could not be 
improved with the help of small molecule additives (Additive Screen HT, Hampton 
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Research). The crystals grown in salt conditions in the initial screens diffracted already to 
a resolution of 3 Å (Figure 18 B, C, D, F, G + H)) and could be optimized in hanging drop 
setups to a resolution of ~2 Å using 1.2-1.5 M sodium malonate as a precipitant. The 
sodium malonate condition was successful in various buffers and pH ranges with the best 
diffracting crystals in 100 mM imidazole pH 8.25 or 100mM sodium citrate pH 5.6. The 
screens and the optimization were accomplished with the T276S variant of YpFabV and 
could also be utilized for wild-type YpFabV without changes in protocol. 
 
Figure 18: T276S YpFabV crystals from different crystallization screens  
 
3.2.1.2  Data collection and structure solution (SIRAS) 
For the initial solution of the FabV structure experimental phasing with the SIRAS phasing 
method was conducted. Well-diffracting YpFabV T276S crystals were soaked in cryo-
protectant solution containing 30% glycerol and 300 mM sodium iodine. For native 
diffraction datasets crystals of the T276S variant and the wild-type YpFabV were treated 
likewise but without sodium iodine as additive. A diffraction dataset of the iodine-soaked 
crystal was collected at beamline ID29 at the European Synchrotron Radiation Facility 
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(ESRF) at a wavelength of 1.25 Å to a maximal resolution of 3.1 Å (Table 16). An example 
of a YpFabV crystal and its diffraction pattern is shown in Figure 19.  
 
Figure 19: Diffraction pattern and crystal (corner) of YpFabV 
The dataset was integrated and scaled using iMosflm (Battye et al., 2011) and Scala 
(CCP4, 1994; Evans, 2006), respectively. The data quality was examined in the Scala 
report files. The crystals belong to space group P6522 with the unit cell dimensions of 
a=b= 103.8 Å, c = 220.2 Å, α=β = 90° and γ = 120°. The dataset was 100% complete and 
33.8-fold redundant with an anomalous completeness and redundancy of 100% and 18.8, 
respectively at 3.1 Å resolution. A native dataset at a wavelength of 0.918 Å with a better 
resolution to 2.1 Å could be obtained at beamline MX14.1 at the synchrotron facility 
BESSY II in Berlin and was merged with the anomalous dataset (Table 16). The anomalous 
signal was analyzed in SHELX (Sheldrick, 2008) and the processed data was utilized by the 
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program AutoSHARP (Vonrhein et al., 2007) for heavy atom refinement and phasing. 15 
iodine atoms were found and contributed to the anomalous signal of the soaked YpFabV 
T276S crystal (Figure 20).  
 
Figure 20: YpFabV structure (teal) as ribbon diagram with bound iodines (purple). 
The centric, acentric and anomalous phasing power was 0.95, 1.0 and 0.69, respectively 
at a resolution of 3.1 Å. The electron density map after density modification was used by 
the automated model building program ARP/wARP (Langer et al., 2008) to build an initial 
model containing 9 chains with 384 of 422 residues. 3 of the nine chains (338 residues) 
were assigned with the amino acid sequence. The model was extended and improved 
manually with the model building software Coot (Emsley and Cowtan, 2004) with 
intermediary maximum likelihood refinement cycles including TLS refinement in Refmac5 
(CCP4, 1994; Pannu et al., 1998) and phenix.refine (Adams et al., 2010). Additional density 
could be assigned to the co-crystallized NADH cofactor. The fitting of ligands into the 
electron density was facilitated by ligand library files generated by the Prodrg server 
(Schuttelkopf and van Aalten, 2004). The library files contain geometrical restrains which 
were used for real space refinement by Coot. The final model contained 415 amino acids.  
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Table 16: Data collection and refinement statistics of YpFabV structures (incl. hexahistidine tag) 
 
 ypFabV (T276S) ypFabV (T276S) ypFabV wt 
 
Iodine Native Incl. tag 
Phasing SIRAS SIRAS MR 
Data collection 
  
 
Wavelength (Å) 1.25 0.918 0.918 
Space group P6522 P6522 P6522 
Unit cell parameters 
  
 
a/b/c (Å) 103.8/103.8/220.2 104.2/104.2/219.1 102.6/102.6/214.9 
α/β/γ 90°/90°/120° 90°/90°/120° 90°/90°/120° 
Resolution (Å) 89.9 - 3.1 39.4 – 2.1 45.98-2.3 
Total reflections 455,984 344,333 320,803 
Unique reflections 13,483 48,035 30,614 
Completeness (%)* 100 (100) 99.8 (100) 100 (100) 
Redundancy* 33.8 (35.3) 7.2 (7.3) 10.5 (11.3) 
Anomalous completeness 100 
 
 
Anomalous redundancy 18,8 
 
 
Rmerge (%)* 11 (93) 6 (62) 6.0 (82.4) 
<I/σ(I)*> 26.9 (5.4) 15.8 (3) 20.1 (2.6) 
Phasing 
  
 
Iodide per ASU 15   
Phasing power 
(centric/acentric/anomalous) 0.95/1.00/0.69   
Figure of merit (after phasing) 
(centric/acentric) 0.127/ 0.092   
Figure of merit (after density 
modification) 0.598   
Refinement    
Total number of atoms 3,399 
 
3,256 
Rcryst (%) 19.9 
 
19.4 
Rfree (%) 22.8 
 
23.0 
RMSD from ideal 
  
 
Bond length (Å) 0.007 
 
0.007 
Bond angles (°) 1.140 
 
1.122 
Average B-values  
(Å
2
 and # of atoms) 
  
 
All atoms (3,399) 72.8 
 
(3,256) 70.8 
Protein (3,195) 74.7 
 
(3,179) 71.2 
NAD(H) (44) 54.2 
 
(44) 50.63 
Water (160) 60.7 
 
(33) 52.8 
Na
+
 (1) 58.3 
 
 
Ramachandran plot  
most favored / allowed/ disallowed (%) 96.2/3.6/0.2 
 
97.3/2.7/0.0 
PDB code 3zu2   
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All 399 residues of the original YpFabV protein (with the exception of the T276S 
exchange) could be built into the electron density map and additionally 15 recombinant 
amino acids including three histidine residues of the hexahistidine tag. Furthermore, the 
model comprised the NADH cofactor, 160 water molecules and one sodium ion, which 
was distinguished from water due to its hydrogen bonding pattern. The last refinement 
step reached Rcryst and Rfree factors of 19.9% and 22.8%, respectively. The wild-type 
YpFabV dataset was collected at beamline MX14.1 at BESSY II with a wavelength of 0.918 
Å and reached a resolution of 2.3 Å (Table 16). The dataset was indexed and integrated in 
iMosflm (Battye et al., 2011) and scaled using Scala (Evans, 2006). The data was 100% 
complete and had 10.5-fold redundancy with an Rmerge of 6.0% and 82.4% in the highest 
resolution shell (see Table 16).  
This time experimental phasing was obsolete since the SIRAS model of the T276S YpFabV 
variant was available as search model for molecular replacement. Phasing was performed 
with the help of the program Phaser (McCoy et al., 2007). The initial model was improved 
in iterative cycles of manual model building in Coot (Emsley and Cowtan, 2004) and 
maximum likelihood refinement in Refmac5 (Pannu et al., 1998) until convergence at Rcryst 
and Rfree factors of 19.4% and 23.0%, respectively, was achieved. 
 
3.2.1.3  Validation 
The YpFabV structures were validated with the help of the Molprobity server (Chen et al., 
2010). The analysis mainly regards the chemical geometry of the protein and clashes 
between the atoms of the model. For the first model of YpFabV T276S gained by SIRAS 
phasing, the RMSD from ideal bond lengths (0.007 Å) and angles (1.14°) are in an 
acceptable range. No Cβ deviations are present, 1.5% of the residues have unusual 
rotamers and only one outlier (0.2%) is present in the Ramachandran plot, namely 
Thr376, which was reviewed in the electron density map. The Ramachandran plot 
describes the dihedral angles φ and ψ of the amino acid backbone (Ramachandran et al., 
1963). 3.6% of the residues reside in the allowed region of the plot and 96.2% in the most 
favored areas (Figure 21).  
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Figure 21: Ramachandran plots for the YpFabV T276S variant (A) and wild-type (B) structures 
The most favored region is framed in cyan and the accepted region in blue. 
The subsequent wild-type structure of YpFabV showed RMSD from ideal bond lengths and 
angles of 0.007Å and 1.12°, respectively. There were no residues with Cβ deviation and 
only 0.9% of the residues appeared in unusual rotamer conformations. There was no 
Ramachandran outlier and 97.3% of the residues reside within the most favored areas. In 
addition, the molprobity clash score improved from 19.5 to 14.1 from the first to the 
second structure. The clashscore represents the number of serious steric overlaps (> 0.4 
Å) per 1000 atoms. In general, the quality markers have improved in the YpFabV wild type 
structure. However, the overall structure of both models is very similar. A structural 
comparison of YpFabV in the binary and tertiary complexes with the cleaved hexahistidine 
tag on the basis of secondary structure matching using the PDBeFold server (Krissinel and 
Henrick, 2004) resulted in an RMSD value of 0.44 Å. 
In Figure 22A the structure of YpFabV T276S with the hexahistidine tag is shown as a 
ribbon diagram. The N-terminus which includes 15 amino acids beyond the N-terminus of 
the native YpFabV points away from the otherwise very compact protein fold of YpFabV. 
The N-terminal residues interact with the neighboring FabV molecule in the crystal and 
thereby build an artificial FabV dimer with an interface area of 1369 Å2 (PDBePISA server) 
(Krissinel and Henrick, 2007) (Figure 22B). As the majority of interactions is mediated by 
the recombinant part of the protein this is most likely a crystallization artifact. However 
this artificial feature of the YpFabV structure might have an influence on the overall 
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structure of the protein. Since the interaction site was located in close proximity to the 
active site pocket the decision was made to solve an additional FabV structure with most 
of the recombinant amino acids removed prior to crystallization to assure the validity of 
the structure. 
 
 
Figure 22: Artificial dimer interface in YpFabV T276S structure 
A) Overview of YpFabV T276S structure, colored according to secondary structure elements with helices in 
red, β-sheets in yellow and loop regions in green. B) Crystallographic interface between two YpFabV 
molecules in the crystal with the recombinant vector part of the protein in all-bonds representation. 
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3.2.2 Binary and ternary complexes of cleaved YpFabV 
3.2.2.1  Crystallization 
 
Figure 23: Crystallization conditions of binary cofactor complexes of cleaved YpFabV 
To exclude an influence of the recombinant part at the N-terminus of YpFabV on the 
overall structure, the hexahistidine tag was removed by thrombin (see 3.1.3.1). 
Crystallization screens were performed with cleaved YpFabV T276S at a concentration of 
58 mg/ml and 10 mM NADH (molar ratio ≈ 1:10) utilizing Hampton Crystal Screens I+II, 
Hampton Index Screen, Emerald Wizard Screens I+II , Nextal PEG suite, Protein complex 
and OptiMix Screens 3+4 (TOPAZ) in sitting drop vapor diffusion setups. Needle-like 
crystals diffracting up to 2.5 Å at the x-ray home source (MicroMax-007 HF, Rigaku) grew 
in condition C10 of the Protein complex screen, containing 150 mM (NH4)2SO4, 25% PEG 
4000 and 100 mM MES pH 5.5. In reproduction and optimization trials of the 
crystallization condition in hanging drop setups the PEG 4000 concentration was 
successfully varied between 25-39% and yielded rod-like crystals of the variant and 
YpFabV wild-type diffracting to 2 Å or better (Figure 23). High protein concentrations (≥ 
40mg/ml) were pivotal for crystallization, causing immediate precipitation of the protein 
upon mixing with the reservoir solution with subsequent crystal growth. At lower protein 
concentrations the protein only precipitated without crystal growth. 
Apart from the binary complex of YpFabV with the cofactor NADH, co-crystallization with 
the 2-pyridone inhibitors PT172 and PT173 was successful utilizing the same 
crystallization condition (Figure 24). Prior to crystallization, YpFabV T276S was incubated 
for at least one hour with the cofactor (1:10) and the inhibitor (5 mg/ml; approx. 1:100) 
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to facilitate binding. The ternary inhibitor complexes crystallized at higher PEG 
concentrations compared to the binary complex (30-39% PEG 4000). The inhibitor 
complex crystals diffracted to 2 Å resolution at the x-ray home source (MicroMax-007 HF, 
Rigaku). 
 
Figure 24: Co-crystallization (A-C) with 2-pyridone inhibitors PT172 (D) and PT173 (E) 
 
3.2.2.2  Data collection and structure solution 
For data collection the crystals were frozen in cryo protectant solution containing high 
PEG 4000 concentrations (37-39%) and 12-15% glycerol and/or up to 10% DMSO. The 
diffraction datasets of YpFabV wild-type and the T276S variant were collected at 
beamline MX 14.1 (Bessy II, Berlin) at a wavelength of 0.918 Å reaching a maximal 
resolution of 1.8 Å (data collection and refinement statistics see Table 17). The dataset of 
the inhibitor containing crystals were collected at the in-house X-ray source (MicroMax-
007 HF, Rigaku) at the typical wavelength of 1.54 Å emitted by the copper rotating anode 
of this x-ray generator. The cleaved protein crystallized in space group P3121. The 
diffraction images were indexed and integrated with iMosflm (Battye et al., 2011) and 
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scaled using Scala (Evans, 2006). All datasets showed a completeness of 100% with high 
redundancies (4.4-7.4-fold).  
Table 17: Data collection and refinement statistics for the cleaved YpFabV structures 
 
 
ypFabV wt ypFabV (T276S) ypFabV (T276S) ypFabV (T276S) 
 
cleaved His-tag cleaved His-tag PT172 PT173 
Data collection  
   
Wavelength (Å) 0.918 0.918 1.54 1.54 
Space group P3121 P3121 P3121 P3121 
Unit cell parameters  
   
    a/b/c (Å) 102.6/102.6/85.0 102.2/102.2/86.8 101.7/101.7/84.6 101.7/101.7/84.6 
    α/β/γ 90°/90°/120° 90°/90°/120° 90°/90°/120° 90°/90°/120° 
Resolution (Å) 33.58-1.8 33.4-1.80 44.1-2.0 42.2-2.0 
Total reflections 357,386 352,957 151,845 202,752 
Unique reflections 48,371 47,522 34,293 34,559 
Completeness (%)* 100 (100) 100 (100) 100 (100) 100 (100) 
Redundancy* 7.4 (7.3) 7.4 (7.4) 4.4 (4.3) 5.9 (5.7) 
Rmerge (%)* 7.7 (38) 10.6 (63) 6.6 (46) 7.6 (54) 
<I/σ(I)*> 17.6 (4.9) 13.2 (3.3) 14.2 (3.0) 13.1 (2.5) 
Refinement  
   
Total number of atoms 3,849 3,777 3,605 3,569 
Rcryst (%) 18.1 16.8 17.6 18.8 
Rfree (%) 21.6 21.2 22.1 22.8 
RMSD from ideal  
   
     Bond length (Å) 0.007 0.007 0.014 0.015 
     Bond angles (°) 1.08 1.07 1.48 1.51 
Average B-values  
(Å2 and # of atoms) 
 
   
    All atoms (3,849) 24.4 (3,777) 26.0 (3,605) 26.7 (3,570) 31.8 
    Protein (3,281) 22.8 (3,284) 24.4 (3,303) 25.9 (3,288) 31.0 
     NAD(H) (44) 11.8 (44) 16.5 (44) 31.2 (44) 36.2 
     Water (507) 35.5 (425) 38.0 (237) 34.0 (215) 39.4 
     Glycerin (12) 53.1 (24) 50.8 
  
     Inhibitor  
 
(21) 48.2 (22) 55.5 
     Na (1) 21.1 (1) 22.8 (1) 40.1 (1) 50.0 
     DMSO (4) 41.5 
   
Ramachandran plot  
most favored / allowed/ 
disallowed (%) 
97.3/2.7/0.0 97.8/2.2/0.0 97.3/2.7/0.0 97.3/2.7/0.0 
PDB code 
 
 
3zu3 
 
3zu4 
 
3zu5 
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The good data quality was reflected in the overall Rmerge values of 7.7% and 10.6% for the 
wild-type and the variant protein in the binary complexes, respectively.The inhibitor 
complex crystals generated data with Rmerge values of 6.6% and 7.6% for PT172 and 
PT173, respectively. The first structure (binary YpFabV T276S) was solved by molecular 
replacement in Phaser (McCoy et al., 2007) using the previously solved uncleaved T276S 
YpFabV structure as a search model. At a later stage, the refined structure of the cleaved 
YpFabV model served as search model. The models were improved in alternating cycles of 
manual model building in Coot (Emsley and Cowtan, 2004) and maximum likelihood 
refinement in phaser.refine (predominantly) (Adams et al., 2010) and Refmac5 (Pannu et 
al., 1998). The library files for the cofactor and inhibitors were generated with the help of 
the Prodrg server but had to be manually revised to ensure the correct ligand geometry. 
During model building two neighboring turns at the edge of the protein (A215-Q219 and 
K250-R267) showed two alternative conformations in the electron density map. Both 
orientations could be built into the electron density. This distortion of the protein fold 
most likely is caused by a crystal contact in proximity of a twofold axis of symmetry.  
Consequently, these symmetry related regions of the two protein monomers interact 
with each other (Figure 25).  
Within this interface, the two acidic side chains E256 avoid each other due to repulsive 
Coulomb forces. Since there is only one molecule in the asymmetric unit of this crystal 
form, both conformations are represented in the electron density. The final models of the 
binary complexes containing all 399 residues of YpFabV and 5 remaining recombinant 
amino acids, which were not removed by the thrombin cleavage, plus NADH and solvent 
molecules, reached Rcryst/Rfree factors of 18.1/21.6% and 16.8/21.2% for the wild-type and 
T276S variant of YpFabV, respectively. The ternary complex crystal structures with PT172 
and PT173 are characterized by Rcryst/Rfree factors of 17.6/22.1% and 18.8/22.8%, 
respectively. 
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Figure 25: Alternate conformations in the cleaved YpFabV structures 
A) Two YpFabV molecules sharing a crystal contact with alternate conformations within regions A215 to 
Q219 and K250 to R267 (residues shown as sticks, only backbone) B) Detailed view of the alternate 
conformations (backbone only, shown as lines) with repulsive E256 side chain interactions (shown as sticks). 
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3.2.2.3  Validation 
The models of the cleaved YpFabV structures were validated using the Molprobity server 
(Chen et al., 2010). None of the structures had any outliers in bond lengths and angles. 
The RMSD values of the bond lengths were 0.007 Å, 0.007 Å, 0.014 Å and 0.015 Å and of 
the bond angles 1.08°, 1.07°, 1.48° and 1.51° for the binary structures of YpFabV wild-type 
and the T267S variant and the ternary complexes with PT172 and PT173, respectively. 
Only the ternary PT172 complex contains one Cβ outlier and none of the structures 
showed an outlier in the Ramachandran plot (Ramachandran et al., 1963). The 
percentage of residues in the most favored area of the plot was 97.8% for the binary 
complex of the wild-type protein and 97.3% for the three remaining structures (Table 17). 
To evaluate the accuracy of ligand fitting, the pose of the 2-pyridone inhibitors was 
examined in their refined 2Fo-Fc and OMIT 2Fo-Fc electron density maps at a σ-level of 1.0 
(Figure 26). The OMIT maps were generated in phenix.refine by refinement including 
simulated annealing using the fully refined model without the bound inhibitor. The OMIT 
map clearly revealed the presence of ring substituents like the amide carbonyl group at 
the A-ring or the chlorine at the B-ring and even the hexyl group at the meta position of 
the A-ring was visible in its entire length, suggesting that the inhibitors had been placed 
adequately. 
 
Figure 26: Evaluation of inhibitor fitting 
A) Inhibitor PT172 modeled into the YpFabV T276S structure, B) Inhibitors PT172 and PT173 in their 2Fo-Fc 
map at a σ-level of 1.0, shown as OMIT map and in the refined state  
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3.3 Enoyl-ACP reductase FabV from B. pseudomallei (BpFabV) 
3.3.1 Crystallization 
The recombinant FabV from B. pseudomallei was expressed and purified analogously to 
YpFabV (cf. 3.1 and Supplemental Figure 57). Crystallization trials were carried out with 
the commercially available screens Hampton Crystal Screens I+II (Hampton Research), 
Hampton Index Screen (Hampton Research), Emerald Wizard Screens I+II (Emerald 
Biostructures), Nextal PEG Screen (Qiagen), Protein complex Screen (Qiagen), OptiMix 
Screens 3+4 (TOPAZ) and the self-generated Salt screen I and PEG pH 6.5 screen. The 
screening trials in sitting drop vapor diffusion setups were performed with BpFabV at 
various concentrations (5-50 mg/ml) and buffers (FabV protein buffer, ddH2O, with 
different amounts of NaCl). The screens were performed for apo BpFabV but also with the 
addition of NADH or NAD+ and with the promising inhibitors PT404 and PT113. In contrast 
to YpFabV, BpFabV only crystallized very rarely in the screens and most of the crystals 
were not reproducible. Only three salt-based crystallization conditions yielded plate-like 
crystals - 3 M sodium formate with 100 mM imidazole pH 8.0, 2 M ammonium sulfate 
with 100 mM MES pH 6.0 and 1.7 M potassium/sodium tartrate (Figure 27). 
 
Figure 27: Crystallization conditions of apo BpFabV 
 Only the sodium formate condition was reproducible in hanging drop setups. The 
crystallization with sodium formate was successful for a broad range of pH values and 
buffers. Only at very acidic pH values (100 mM sodium actetate pH 4.6) salt instead of 
protein crystals were obtained. The crystals from this condition as well as the crystals 
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from the ammonium sulfate screen condition diffracted to a resolution of at least 2 Å. 
Although both crystal forms were grown in co-crystallization trials, the solved structures 
revealed that the protein crystallized only in its apo-form. 
3.3.2 Data collection and Structure solution 
For the x-ray diffraction experiments, the crystals were cryo-cooled in their mother liquor 
supplemented with up to 20% glycerol. The diffraction dataset of the crystal from the 
sodium tartrate condition could be collected at the in-house x-ray generator (MicroMax-
007 HF, Rigaku) at a wavelength of 1.54 Å to a resolution of 1.85 Å (the dataset will be 
referred to as BpFabV1). The diffraction dataset of the crystal grown in the ammonium 
sulfate condition was collected at beamline MX14.1 at Bessy II at a wavelength of 0.918 Å 
and reached a resolution of 1.9 Å (the dataset will be referred to as 
dataset/crystal/structure BpFabV2). Both datasets were indexed and integrated in 
iMosflm (Battye et al., 2011) and scaled in Scala (Evans, 2006) (Table 18). Although both 
crystallization conditions included high salt concentrations, the two crystal forms are 
characterized by a different space group. The crystal BpFabV1 crystallized in space group 
P1211 with unit cell dimensions of a= 55.1 Å, b= 55.3 Å and c= 73.8 Å and angles α=γ= 90° 
and β= 108.3°. Data quality was assessed using the Scala report files. At a resolution of 
1.85 Å the dataset reached a completeness of 98.1 % with 7.4-fold redundancy and Rmerge 
values of 5.3% and 15.9% for the entire resolution range and the highest resolution shell, 
respectively. In addition, the I/σI values of 26.2 and 10.6 for the overall dataset and the 
highest resolution shell were very good. The second crystal form BpFabV2 crystallized in 
space group P212121 with unit cell parameters a= 48.6 Å, b= 93.3 Å and c= 100.9 Å and 
α=β=γ= 90°. The dataset was 100% complete and displayed a 3.7-fold redundancy. The 
Rmerge was 4.8% and 18.7% and the I/σI 16.8 and 5.9 for the overall dataset and the 
highest resolution shell, respectively. Both structures could be solved by molecular 
replacement with using the program Phaser (McCoy et al., 2007). In the case of BpFabV1 
the structure of the cleaved YpFabV structure served as a search model. The overall 
structure of YpFabV fit very well into the BpFabV1 density. The differing residues were 
changed manually in Coot (Emsley and Cowtan, 2004) to meet the BpFabV sequence and 
the entire model improved step by step with intermediary cycles of maximum likelihood 
refinement, which was performed predominantly in phenix.refine (Adams et al., 2010). 
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Table 18: Data collection and refinement statistics of the BpFabV structures 
 
bpmFabV apo 1 bpmFabV apo 2 (MES) 
Data collection   
Wavelength (Å) 1.54 0.918 
Space group P1211 P212121 
Unit cell parameters 
  
    a/b/c (Å) 55.1/55.3/73.8 48.6/93.3/100.9 
    α/β/γ 90°/108.32°/90° 90°/90°/90° 
Resolution (Å) 36.73-1.85 35.01-1.90 
Total reflections 238,235 135,326 
Unique reflections 32,297 36,997 
Completeness (%)* 98.1 (96.2) 100 (100) 
Redundancy* 7.4 (7.2) 3.7 (3.6) 
Rmerge (%)* 5.3 (15.9) 4.8 (18.7) 
<I/σ(I)*> 26.2 (10.6) 16.8 (5.9) 
Refinement 
  
Total number of atoms 3,637 3,544 
Rcryst (%) 14.8 17.5 
Rfree (%) 17.3 21.0 
RMSD from ideal 
  
    Bond length (Å) 0.006 0.006 
    Bond angles (°) 1.049 1.042 
Average B-values (Å2 and # of 
atoms)   
    All atoms (3,637) 15.7 (3,544) 27.4 
    Protein (3,024) 13.5 (3,084) 25.9 
    Water (589) 26.5 (398) 34.7 
    Glycerin (6) 47.2 (18) 44.9 
    MES 
 
(24) 42.7 
    S04 
 
(20) 82.6 
Ramachandran plot  
Most favored/allowed/disallowed 
(%) 
 
97.3/2.5/0.2 97.3/2.5/0.2 
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The final model included the complete BpFabV sequence and three recombinant residues. 
Apart from solvent molecules no ligand was bound to the protein. The refinement 
converged at Rcryst and Rfree factors of 14.8% and 17.3%, respectively. The structure of the 
second dataset BpFabV2 could subsequently be solved using the refined structure of 
BpFabV1 as search model for the molecular replacement approach. The model was 
manually improved and refined as described before. The crystal of BpFabV2 was obtained 
in a co-crystallization trial with PT404 and NAD+. During model building an electron 
density in the active site was initially interpreted as PT404, which would have been 
unusual because diphenyl ether inhibitors are known to bind to the protein in a ternary 
complex together with the cofactor. However, the inhibitor could not be fit into the 
additional electron density, which could finally be explained by the presence of a MES 
buffer molecule at this position. In Figure 28 the MES molecule is depicted in its 2Fo-Fc 
OMIT map at a contour level of 1.0σ. The binding of a MES molecule in the active site 
might interfere with successful co-crystallization of ligands in the binding pocket for this 
crystallization condition. The final model contained the complete BpFabV sequence 
including seven recombinant residues and solvent molecules and Rcryst and Rfree factors of 
17.5% and 21.0%, respectively. 
 
Figure 28: MES molecule in the active site of BpFabV2  
The electron density is shown as a 2Fo-Fc - OMIT map with a contour level of 1σ. 
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3.3.3 Validations of the two BpFabV apo structures 
The quality of the two different BpFabV apo structures was evaluated with the help of the 
Molprobity server (Chen et al., 2010). The RMSD values of the bond lengths and angles 
were 0.006 Å/0.006 Å and 1.049°/1.042° for the structures BpFabV1 and BpFabV2, 
respectively. These values are quite low, which is due to the tight restraints used by the 
phenix.refine program. The clash score of both structures with around 7 is very low. The 
structures show no Cβ outliers.  
 
Figure 29: Ramachandran plot for (A) BpFabV1 and (B) BpFabV2 
The most favored region is framed in cyan and the accepted region in blue. 
There was one outlier in the Ramachandran statistics in each structure. In BpFabV1 the 
outlier was L226 and in BpFabV2 it was Asp80, the latter lies near the border to the 
accepted area in the Ramachandran plot (Figure 29). In both cases 97.3% of the residues 
are within the most favored region of the plot. There are three unusual rotamers in 
BpFabV1 and one in BpFabV2. Two out of three rotamer outliers in BpFabV1, Y225 and 
Q229, lie next to the Ramachandran outlier L226. This accumulation of geometrical 
outliers indicates a problem in the structure at this region. First it was evaluated if the 
model is actually supported by the electron density, which was the case. In the 
comparison with the second BpFabV structure differences in the orientation of this loop 
(Y225-T321) could be detected (Figure R19A). The distortion of the loop could be 
explained by a crystal contact at the turn. Residue Q320 of the neighboring molecule in 
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the crystal would clash with Q229 and therefore pushes this residue back, which leads to 
the distortion of the whole loop (Figure 30 B+C). Since the loop is part of the binding 
pocket of FabV and contains the active site residue Y225, one of the rotamer outliers, the 
structure BpFabV1 was not used for structural analysis and comparisons with further 
FabV structures were performed with BpFabV2 instead. 
 
Figure 30: Loop distortion in BpFabV1 by crystal contact 
A) Overall structures of BpFabV1 (blue) and BpFabV2 (yellow), the distortion is marked by an arrow. B) 
Crystal contact between BpFabV (blue) and a neighboring molecule in the crystal (magenta), with BpFabV2 
superimposed onto BpFabV1. C) Zoom into the clashing region. 
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3.4 Enoyl-ACP reductase FabI from B. pseudomallei (BpFabI) 
To develop a new antibacterial against B. pseudomallei targeting the enoyl-ACP reduction 
step of FAS-II both enoyl-ACP reductases, i.e. FabV and FabI, of this organism have to be 
inhibited. Therefore also BpFabI was expressed and purified for co-crystallization 
attempts with new inhibitors. 
3.4.1 Expression 
The gene for BpFabI was cloned and ligated into the expression vector (pET23b) by Nina 
Liu (Liu et al., 2011). For gene amplification during cloning she used the B. mallei strain 
ATCC 23344. This was possible since the sequences of FabI from B. mallei and B. 
pseudomallei are 100% identical. The vector contains the bpfabI gene with a C-terminal 
hexahistidine tag under the control of a T7 promotor and an additional ampicillin 
resistance gene. To test the expression of BpFabI, the pET23b construct was transformed 
into BL21 (DE3) and BL21 (DE3) pLysS E. coli cells. The test expression at small scale was 
performed at 25 °C with an induction of expression at an OD600 of 0.6 with 1mM IPTG. 
Samples after 2, 5 and 20 hours were analyzed via SDS-PAGE (Figure 31). 
 
Figure 31: SDS-PAGE of cell lysate from the expression test of BpFabI in pLysS E.coli cells at 25 °C 
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 The recombinant BpFabI protein has a size of 29 kDa. At the height of the 25 kDa marker 
band a very prominent band appeared 2 hours after induction which is interpreted as the 
FabI construct. The highest expression was already observed after 5h, which decreased in 
the 20 hours sample. There was no obvious difference between BL21 (DE3) and BL21 
(DE3) pLysS. Therefore the high scale expression was performed in BL21 (DE3) at 25 °C for 
5 hours. Later on also high scale expression at 15 °C for 20 hours was successful. 
3.4.2 Buffer optimization using the Thermofluor analysis 
The first small scale purification (cf. 2.2.2 and 3.4.3) was completed in a preliminary gel 
filtration buffer (30 mM PIPES pH 6.8, 150 mM NaCl and 1 mM EDTA), which was used 
previously by our collaborators for BpFabI. The protein was soluble in this buffer. 
However, since the protein should be very stable and homogenous for crystallization in its 
buffer, a Thermofluor analysis (2.2.3.2) was conducted with the Thermofluor buffer 
screen. In the buffer screen no buffer led to a higher melting temperature than the 
reference buffer (preliminary gel filtration buffer) with a melting temperature of 52 °C. 
 
Figure 32: Thermofluor analysis on BpFabI 
 To exclude the possibility that the thermal stability of BpFabI in the reference buffer was 
caused by the higher salt content (150 mM NaCl), further screens were performed with 
the addition of 300 mM and 500 mM salt. The melting temperatures increased with 
higher salt concentrations. The highest melting temperature (56 °C) was observed in 100 
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mM Bistris pH 6.5 and 500 mM NaCl. The effect of the increased salt concentration is 
nicely illustrated in the melting curves of BpFabI in Bistris pH 6.5 (Figure 32). The buffer 
alone with a melting temperature of 51 °C shows no improvement compared to the 
reference buffer. Upon addition of 300 mM and 500 mM NaCl, the melting temperature 
rises to 53 °C and 56 °C, respectively. Applying these results, the gel filtration buffer was 
changed to 20 mM Bistris pH 6.5, 500 mM NaCl and 1 mM EDTA. 
3.4.3 Purification 
As previously described for FabV also BpFabI was purified with a two-step protocol using 
chromatography techniques. The C-terminally hexahistidine-tagged protein was extracted 
from the cell lysate in a nickel affinity chromatography step followed by a polishing size-
exclusion chromatography step. 
 
Figure 33: Purification of BpFabI 
A) Chromatogram of a Histrap purification with gradient elution, absorption at 280nm (black) and 260nm 
(red), % Elution buffer (blue).  B) SDS-PAGE of a Histrap purification: (1) Load, (2) Flowthrough, (3-7) Extra 
wash, (8-14) Elution peak. C) Chromatogram of a size exclusion chromatography, absorption at 280nm 
(black) and 260nm (red). B) SDS PAGE of a size exclusion chromatography: (1) Load-(3-9) main peak, (10-14) 
shoulder of main peak. 
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The affinity chromatography was prevalently carried out with HisTrap FF crude columns 
(GE healthcare) at different ÄKTA chromatography systems (Figure 33A). The cleared cell 
lysate was loaded on the equilibrated column and unbound sample washed out by 20 
column volumes of binding buffer. A second washing step with slightly elevated imidazole 
concentrations was utilized to remove unspecifically binding contaminants, either with a 
separate washing buffer with 60 mM imidazole and 1 M NaCl (example in Figure 33) or a 
gradient up to 6% elution buffer. The elution of the bound protein was accomplished 
either in a gradient elution to 100% elution buffer (500 mM imidazole) (example in Figure 
33) or a step elution with 50% elution buffer. The step elution had the advantage that the 
peak was concentrated in a smaller volume so that further concentration of the sample 
for the following size-exclusion chromatography was not necessary. The SDS-PAGE of 
samples from each step of the purification showed that BpFabI was highly concentrated 
in the elution peak with only few contaminants in the fractions (Figure 33B). The 
following size-exclusion chromatography was carried out using a HiLoad Superdex 200 
26/60 gel filtration column with a maximal sample volume of 10 ml (2.2.2.4). The elution 
profile exhibited one major peak with a shoulder at higher elution volumes (Figure 
33C+D). Analysis of the peak fractions in SDS-PAGE revealed that the main peak consisted 
of BpFabI of high purity (99%) represented by a thick band at the height of the 25 kDa 
marker band. However, the shoulder contained an impurity with an estimated molecular 
mass of about 40 kDa. Hence, the fractions of the shoulder were excluded from the pure 
protein sample. The pure fractions were concentrated to up to 30 mg/ml, flash-frozen in 
liquid nitrogen and stored at -80 °C. 
3.4.4 Crystallization 
In the PDB database an apo structure of BpFabI had already been deposited (PDB code 
3EK2), which was crystallized in 10% PEG 6000 and 100 mM HEPES pH 7.0. In a first 
crystallization attempt it was tried to reproduce this crystallization condition. However, 
this approach was not successful. Therefore small-scale sitting drop vapor diffusion 
screens were performed using BpFabI at a concentration of 12 mg/ml with the addition of 
2 mM NAD+ with the Hampton Crystal Screens I+II (Hampton Research) and Wizard 
screens I+II (Emerald Biostructures). Due to various hits in PEG-based crystallization 
conditions also the Screens Hampton Index Screen (Hampton Research), Nextal PEGs 
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(Qiagen) and OptiMix Screen 4 (TOPAZ) as well as the self designed PEG pH 6.5 Screen 
were conducted and yielded further crystal hits in PEG conditions. During the 
optimization attempts in hanging drop vapor diffusion setups mainly two different PEG 
conditions generated reproducibly single, rod-shaped crystals of suitable size. The first 
condition contained PEG 1000 and PEG 8000, each at concentrations of 6-12%. The 
second one includes a PEG with small molecular weight (PEG 300, PEG 400 or PEG 550 
MME) at concentrations of 20-30% with a buffer at pH 6.5 (MES or Bistris). Crystals of 
both crystal forms diffracted better than 2 Å in x-ray diffraction experiments.  The 
reproducibility of the two crystal forms was dependent on the protein batch. Initial 
electron density maps derived from the first datasets of BpFabI revealed the presence of 
weak traces of NAD+. Hence, crystallization was repeated with apo BpFabI to obtain a 
clean apo BpFabI dataset.  
 
Figure 34: Crystallization condition of BpFabI in its apo form (A) and in the ternary complexes with the 
cofactor NAD
+
 and the inhibitor triclosan (TCL) (B), PT02 (C), PT404 (D), PT12 (E) or PT155 (F). 
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The occupancy for NAD+ or NADH in structures resulting from crystallization trials of the 
binary complexes remained low and did not allow successful model building.  
Since a set of potential crystallization conditions was established, the actual goal, the co-
crystallization with inhibitors (triclosan, PT02, PT12, PT155 and PT404) was approached. 
For co-crystallization attempts BpFabI (10-30 mg/ml) was incubated for one hour with a 
tenfold molar excess of NAD+ and either pure inhibitor (5 mg/ml, for triclosan and PT02) 
or inhibitor dissolved in DMSO (100 mg/ml) in a tenfold molar excess (for PT12, PT155 
and PT404). Crystallization was achieved with the established crystallization conditions, 
with the exception of the co-crystallization with PT155. Here crystals were obtained in a 
small-scale crystallization screen with the Nextal PEG screen (Qiagen) and provided the 
crystals for the diffraction experiment (20% PEG 3350 and 200 mM (NH4)2HPO4) (Figure 
34). 
3.4.5 Data collection and Structure solution 
Prior to data collection, the crystals were soaked in cryo solutions containing elevated 
PEG concentrations and 10-25% of the cryo-protectant glycerol and subsequently cryo-
cooled in liquid nitrogen. 
3.4.5.1  MR of BpFabIapo  
The diffraction dataset of apo BpFabI was collected at Beamline ID29 of the ESRF at a 
wavelength of 0.918 Å and reached a resolution of 1.65 Å (Table 19). The diffraction 
images were indexed and integrated in XDS (Kabsch, 2010) and scaled in Scala (Evans, 
2006). The analysis revealed that BpFabI crystallized in space group I222 with unit cell 
parameters a= 74.7 Å, b= 75.2 Å, c= 85.7 Å and α=β=γ= 90° including one FabI chain in the 
asymmetric unit. The dataset reached a completeness of 96.6% with a 4.4-fold 
redundancy. The Rmerge was 6.1% and 70.2% and the I/σI 13.1 and 2.2 for the overall 
dataset and the highest resolution shell, respectively. Phasing was achieved by molecular 
replacement in Phaser (CCP4, 1994; McCoy et al., 2007) with the published BpFabI 
structure (PDB code 3EK2) as the search model. The search model contained residues M1-
M258 of the BpFabI sequence (the complete sequence would contain 263 residues) with 
a gap of nine residues between residue L193 and F203, representing the flexible substrate 
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binding loop. By manual model building in Coot (Emsley and Cowtan, 2004) with 
intermediary cycles of maximum likelihood refinement in phenix.refine (Adams et al., 
2010) the model was improved and adapted to the electron density map. 
Table 19: Data collection and refinement statistics of the BpFabI apo structure and ternary inhibitor 
complexes 
 BpFabI apo BpFabI+TCL BpFabI+PT02 BpFabI+PT404 BpFabI+PT12 BpFabI+PT155 
Data collection 
   
   
Wavelength (Å) 0.918 0.918 0.918 0.918 1.54 1.54 
Space group I222 P1 I222 I222 I222 I222 
Unit cell parameters 
      
    a/b/c (Å) 74.7/75.2/85.7 70.4/ 99.9/139.9 69.6/112.0/262.8 74.6/75.1/86.4 74.6/75.9/89.6 74.3/76.0/89.4 
    α/β/γ 90°/90°/90° 82.87°/89.20°/78.13° 90°/90°/90° 90°/90°/90° 90°/90°/90° 90°/90°/90° 
Resolution (Å) 37.62 - 1.65 69.38 - 2.6 43.98 - 2.6 43.19 - 1.8 29.0 -1.6 38.0 - 1.8 
Total reflections 125,427 417,582 197,779 160,232 150,403 108,611 
Unique reflections 28,203 112,071 32,230 22,817 32,015 22,291 
Completeness (%)* 96.6 (98.3) 98.5 (97.9) 100 (100) 99.9 (99.9) 98.9 (99.8) 100 (100) 
Redundancy* 4.4 (4.3) 3.7 (3.8) 6.1 (6.2) 7.0 (6.7)) 4.7 (4.3) 4.9 (4.5) 
Rmerge (%)* 6.1 (70.2) 10.6 (52.5) 21 (117) 7,2 (63.7) 3.7 (14.7) 6.9 (26.1) 
Rpim 3.0 (35.6) 6.4 (31.3) 9.6 (52) 3,0 (26,5) 1.9 (7.9) 3.5 (13.7) 
<I/σ(I)*> 13.1 (2.2) 8.9 (3.2) 9.0 (2.5) 15.4 (3.1) 21.8 (7.5) 14.6 (5.0) 
Refinement 
      
Total number of 
atoms 
2,163 31,921 6,046 2,139 2,302 2,354 
Rcryst (%) 15.9 19.4 22.1 17.5 13.2 13.7 
Rfree (%) 18.6 25.3 28.0 
20.9 
 
17.3 16.2 
RMSD from ideal 
      
    Bond length (Å) 0.006 0.008 0.008 0.006 0.021 0.007 
    Bond angles (°) 1.042 1.070 1.135 1.147 1.890 1.130 
Average B-values 
(Å2 and # of atoms)       
    All atoms (2,163) 26.4 (31,945) 66.3 (6,046) 84.1 (2,139) 36.2 (2,302) 19.9 (2,367) 13.8 
    Protein (1,936) 25.1 (30,400) 67.6 (5,745) 85.8 (1,915) 35.7 (1,917) 17.7 (1,957) 11.8 
    NAD(H) 
 
(704) 53.4 (132) 60.3 (44) 38.0 (44) 13.9 (44) 11.0 
    Water (227) 37.3 (561) 36.9 (118) 41.5 (153) 39.5 (318) 34.1 (343) 25.6 
    Glycerin 
   
(6) 56.8 
  
    Inhibitor 
 
(272) 558.0 (51) 63.9 (21) 42.3 (23) 20.3 (23) 11.2 
Ramachandran plot  
Most favored 
/allowed/disallowed 
(%) 
 
98.1/1.9/0.0 97.3/2.7/0.0 95.8/4.2/0.0 97.3/2.7/0.0 97.6/2.4/0.0 97.3/2.7/0.0 
During model building the gap of the search model could be closed since there was 
convincing electron density for the substrate binding loop present. The reason for the 
stabilization of this, in other apo FabI structures usually flexible, loop, is most likely due to 
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a crystal contact. (Figure 35) The final model of the apo structure includes 255 residues 
and 227 water molecules. The first and the seven last amino acids of the BpFabI sequence 
were not represented in the electron density map. The model reached Rcryst and Rfree 
factors of 15.9% and 18.6%, respectively. 
 
Figure 35: Stabilization of the substrate-binding loop by crystal contacts 
A) Overview of the crystal contacts stabilizing the substrate-binding loop. B) Detailed view of the hydrogen 
bond interactions (dashed line) at the crystal contact 
3.4.5.2  MR of ternary inhibitor complexes of BpFabI 
The first two ternary inhibitor complexes containing BpFabI with triclosan or PT02 and 
NAD+ had been co-crystallized with the PEG 1000/PEG 8000 condition. The diffraction 
datasets were collected at the beamlines ID21 and ID23 at the ESRF at a wavelength of 
0.918 Å and to a resolution of 2.6 Å Table 19). The datasets were indexed, integrated and 
scaled using XDS (Kabsch, 2010) or iMosflm (Battye et al., 2011) and Scala (Evans, 2006). 
Analysis of the data showed that the original space group of the apo FabI seemed to be 
disrupted due to the interaction with the inhibitor. The triclosan complex could only be 
indexed in space group P1 with unit cell dimensions of a= 70.4 Å, b= 99.9 Å, c= 139.9 Å 
and α= 82.9°, β= 89.2° and γ= 78.1° and a Matthew’s coefficient of 2.21 Å3/Da data is 
characterized by a completeness of 98.5% with a 3.7-fold redundancy and showed an 
Rmerge of 10.6% and 52.5% as well as I/σI values of 8.9 and 3.2 for the entire dataset and 
the highest resolution shell, respectively. The PT02 complex crystallized in space group 
I222 as observed for the apo BpFabI structure but had differing unit cell constants with a= 
69.4 Å, b= 112.0 Å and c= 262.8 Å and three BpFabI chains in the asymmetric unit. The 
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dataset was 100% complete with 6.1-fold redundancy and an Rmerge of 21% and 117%. 
These Rmerge values are extraordinary high. Since the Rmerge value increases with higher 
redundancy, the Rpim value was used in this case to determine the high resolution edge, 
since this measure for data quality is independent of the multiplicity of the data. The Rpim 
of the dataset was 9.6% and 52% for the overall dataset and the highest resolution shell, 
respectively. Another indication for the data quality at a certain resolution is the I/σI, 
which was still 2.5 in the highest resolution shell. 
The inhibitor complexes containing PT12 or PT404 had been crystallized with the second 
established crystallization condition using PEG 400 as a precipitant and the 4-pyridone 
inhibitor PT155 was co-crystallized with a new PEG condition (20% PEG 3350 and 200 mM 
(NH4)2HPO4). All three crystals diffracted much better than the co-crystals obtained with 
triclosan and PT02. The datasets were collected at beamline MX14.1 at Bessy II (PT404) at 
a wavelength of 0.918 Å to a resolution of 1.8 Å and at the in-house x-ray generator 
(MicroMax-007 HF, Rigaku) at a wavelength of 1.54 Å to a maximal resolution of 1.6 Å 
(PT12) and 1.8 Å (PT155). Indexing and integration was conducted in iMosflm (Battye et 
al., 2011) and Scaling in Scala (Evans, 2006). These ternary inhibitor complexes 
crystallized in the same space group, I222, as apo FabI and also the unit cell parameter 
were in the same range (cf. data statistics Table 19). The datasets exhibited completeness 
of 98.9-100% with an at least 4.7-fold redundancy. The Rmerge for the complete dataset 
and the highest resolution shell was 7.2%/63.7%, 3.7%/14.7% and 6.9%/26.1% for the 
PT404, PT12 and PT155 dataset, respectively. The average I/σI value in the outer shell was 
greater than 3 in all three datasets. 
The structures were solved by molecular replacement in Phaser (McCoy et al., 2007) using 
either the refined apo BpFabI structure or an already solved and refined ternary complex 
structure as a search model. The structures were improved in alternating cycles of manual 
model building in Coot (Emsley and Cowtan, 2004) and maximum likelihood refinement in 
phaser.refine (predominantly) (Adams et al., 2010) and Refmac5 (Pannu et al., 1998). NCS 
restraints during refinement proved to be very beneficial for the structures with several 
protein chains in the asymmetric unit such as the PT02 complex and especially for the 
triclosan structure with 16 BpFabI chains. The ligands were fitted into the electron density 
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and refined with the help of library files which were created by the PRODRG server 
(Schuttelkopf and van Aalten, 2004). 
The final complex structures contained 255-257 residues of the BpFabI sequence (cf. apo 
BpFabI) the cofactor NAD+, the respective inhibitor and solvent molecules such as water 
or glycerol. The refinement of the complex structures including triclosan, PT02, PT404, 
PT12 and PT155 reached Rcryst/Rfree values of 19.4%/25.3%, 22.1%/28.0%, 17.5%/20.9%, 
13.2%/17.3 and 13.7%/16.3%, respectively. 
3.4.6 Validation of the BpFabI structures 
The quality of the refined structures was evaluated utilizing the Molprobity server, which 
analyses the protein geometry and potential clashes in the structure. 
3.4.6.1  BpFabIapo 
The high resolution of the BpFabI apo structure is also reflected in very good quality 
markers. The RMSD values of bond lengths and angles are 0.006 Å and 1.042°, 
respectively. There is no outlier in the rotamers, the Cβ deviation or the Ramachandran 
plot. 98.0% of the residues are in the most favored region of the Ramachandran plot. The 
Molprobity clash score, describing the number of serious steric overlaps (> 0.4 Å) per 
1000 atoms, is only 4.2.  
3.4.6.2  Ternary complexes of BpFabI with Inhibitors 
Similarly, the quality of the ternary inhibitor complexes is highly dependent on the 
respective resolution of the structure. The RMSD values for bond lengths and angles are 
all in an acceptable range and vary from 0.006 Å to 0.021 Å and from 1.070° to 1.890°, 
respectively. There is only one residue with a Cβ deviation greater than 0.25 Å and no 
Ramachandran outlier. The fraction of residues in the most favored part of the 
Ramachandran plot for the ternary complex with triclosan, PT02, PT404, PT12 and PT155 
were 97.3%, 95.8%, 97.3%, 97.6% and 97.3%, respectively. The clash score varied from 
3.4 (PT12) to 16.7 (PT02). For these geometric quality markers the structures containing 
triclosan and PT02 which were obtained at a lower resolution of only 2.6 Å benefited 
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from the NCS refinement in phenix.refine. The complex structure with PT02 showed three 
rotamer outliers whereas the triclosan structure contained two unusual rotamers. 
The quality of ligand fitting of the cofactor and the inhibitors was evaluated with the help 
of OMIT maps (Figure 36). The OMIT maps were generated in a refinement cycle of the 
fully refined structure in phenix.refine, which included a simulated annealing step. In the 
coordinates for this refinement, the ligand was deleted. In Figure 36 the ligands are 
depicted in their 2Fo-Fc OMIT map at a σ-level of 1.0. All ligands were adequately 
represented in the OMIT maps.  
 
Figure 36: Validation of ligand fitting. 
The ligands NAD
+
 (from the PT12 complex structure) (A), triclosan (TCL) (B), PT02 (C), PT404 (D), PT12 and 
PT155 (F) are shown in their electron density map (2Fo-Fc OMIT map) at a contour level of 1σ. 
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4. Discussion 
4.1 Structural characterization of FabV as potential drug target 
The enoyl-ACP reductase FabV might be a promising target for drug design approaches 
against Gram-negative pathogens such as Y. pestis or B. pseudomallei carrying this 
isoenzyme. In this study crystal structures of the recently discovered FabV could be solved 
in various states. The structure of FabV from B. pseudomallei (BpFabV) was determined in 
its apo form, whereas structures of the T276S variant and the wild type of FabV from Y. 
pestis (YpFabV) contained the cofactor NADH in a binary complex. Furthermore the 
structure of the T276S variant of YpFabV could also be obtained with its cofactor and a 2-
pyridone inhibitor (PT172 and PT173) bound in a ternary complex. The structural 
information could be used to characterize the idiosyncratic features of FabV in the 
context of the SDR superfamily and explore its potential as drug target. 
4.1.1 Overall structure (apo –binary – ternary) 
 
Figure 37: Structure of YpFabV 
A) The YpFabV binary complex is depicted as ribbon diagram with helices in red (η =310 helix), β-strands in 
yellow and loop regions in green. B) Superposition of apo BpFabV (green) and YpFabV in the binary (light 
blue) and ternary (yellow) complex. 
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The structure of apo BpFabV and YpFabV binary and ternary complexes show a common 
overall structure in the superposition (Figure 37). The structural similarity was analyzed 
with secondary structure matching (SSM) (PDBeFOLD server, (Krissinel and Henrick, 
2004)). Although BpFabV and YpFabV share only 75% sequence identity, 95% of the 
secondary structure elements overlap in the SSM analysis. The apo BpFabV structure 
(green) could be aligned to the binary (blue) and ternary (yellow) YpFabV structures with 
RMSD values of 0.98 Å and 0.94 Å, respectively, based on the Cα alignment. The 
comparison of both YpFabV complexes among each other exhibited an RMSD of 0.48 Å. 
Neither the origin in different species nor the different ligand bound states of the 
structures cause major changes in the overall structure. 
The overall structure of FabV displays typical features of the SDR superfamily. 
Predominantly the N-terminal part of the polypeptide chain is folded in a Rossmann fold 
with eight parallel β-strands in a β-sheet flanked by three and four α-helices on each side. 
The Rossmann fold generates the NADH binding site (Buehner et al., 1973). The C-
terminal part contains the catalytic residues and builds up the substrate-binding pocket 
thereby providing substrate specificity. This part in the SDR proteins is usually smaller 
compared to FabV.  
A structural comparison against the Protein Data Bank (PDB) with SSM revealed the 
highest similarity of the binary YpFabV complex with structures of E. coli FabI in complex 
with NAD+ and triclosan (EcFabItcl) (PDB ID: 1C14, 1QG6 and 1QSG; (Qiu et al., 1999; 
Stewart et al., 1999; Ward et al., 1999)). With a sequence identity to EcFabItcl of only 17% 
(sequence alignment shown in Supplemental Figure 58), YpFabV shares 50% of its 
secondary structure with FabI (Figure 38A). The most similar part is the Rossmann fold, 
although the Rossmann fold in EcFabItcl contains one β-strand and one α-helix less than 
YpFabV (Figure 38B+C). The active site pocket shows more differences. The core of the 
active site pocket is retained but several additional structural elements of FabV (yellow in 
Figure 38 B+C), which is about 140 residues longer than FabI, are folded around the active 
site pocket. Three β-hairpin structures (β1/β2, β7/β8 and β9/β10) are located around the 
entry of the pocket. The extended β-hairpin β9/β10 is covering the helix α9, which 
corresponds to the proposed ACP interaction site of FabI (Chan and Vogel, 2010). The 
substrate-binding loop (violet in Figure 38 B+C) is located N-terminal relative to the ACP 
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interaction site and builds up helix α8 in FabV. In FabI this loop is proposed to be flexible 
until a ligand such as triclosan binds and interacts hydrophobically with the protein 
leading to the ordering of the loop into a helix.  
 
Figure 38: Structural comparison of YpFabV (binary complex containing NADH) with EcFabI (ternary 
complex containing NAD
+
 and triclosan) 
A) Superposition of the binary YpFabV structure (light blue) and the ternary EcFabItcl (brown) complex (PDB 
ID 1C14) shown as ribbon diagram. B)/C) Topology diagram of YpFabV (binary) (B) and EcFabItcl (C) with 
similar secondary structure elements illustrated in blue and the differing structural elements in yellow, the 
substrate-binding loop is highlighted in violet.  
In contrast to the observations made for FabI, this helix is already in its closed helical 
conformation when the cofactor is bound in FabV. Furthermore, behind the structural 
elements carrying the catalytic residue Y235 (around η1) four additional helices (α11, 
α12, α13 and α14) are covering the active site. These extended additional elements are 
probably the reason why FabV does not need further stabilization of the active site by 
oligomerization interfaces as it is known from other members of the SDR family such as 
FabI or FabL. SDR proteins usually form dimers or tetramers. There is one notable 
exception, the monomeric structure of the SDR family member porcine testicular 
carbonyl reductase (PTCR) was shown to be a monomer in solution but is stabilized 
differently compared to FabV by a 41-residue insertion interacting with the two long 
helices, which usually form the four-helix bundle interface (Q-interface) conserved in the 
SDR superfamily (Ghosh et al., 2001).  
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4.1.2 The active site 
 
Figure 39: Sequence alignment of BpFabI, BpFabV and YpFabV 
Sequence alignment (ClustalW, (Thompson et al., 1994)) of BpFabI, BpFabV and YpFabV. The cofactor 
binding motif is shown in a blue box with described interaction partners of the cofactor highlighted in 
yellow. The active site region is highlighted in a yellow box with the catalytic residues marked by red 
asterisks. The substrate-binding loop is marked in a green box and the potential FAD binding site of FabV in 
a violet box. Secondary structure elements are indicated by arrows and spirals for -strands and -helices, 
respectively and shown above (BpFabI ternary) and below (YpFabV binary) the sequence. 310helixes are 
labeled with η and β-turns with TT. The conserved residues are highlighted in the blue boxes with the most 
conserved residues colored in white with a red background.  
 
The SDR superfamily is a very diverse superfamily, with low sequence identities among 
the members. The subfamilies are classified by certain cofactor binding- and active site 
motifs (Kallberg et al., 2002). The divergent subfamily, composed of enoyl-thioester 
reductases as FabI or FabL, exhibits an active site motif of YxxMxxxK. Although FabV is 
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closely related to FabI, it does not share this motif of the divergent subfamily but exhibits 
two additional residues in between the catalytic Y235 and K244 with no methionine in an 
Y(x)8K motif (cf. yellow box in sequence alignment in Figure 39 and Supplemental Figure 
58 and Figure 59) . The remaining subfamilies have even shorter active site motives with 
YxxxK and YxxxN (Kavanagh et al., 2008).   
 
Figure 40: Active site of FabV 
A) Ribbon diagram of YpFabV (binary) (light blue) with active site residues and cofactor in all-bond 
representation (violet). B) Active site residues of YpFabV (binary) and cofactor shown in all-bond 
representation with hydrogen bonds as dashed lines. C) Superposition of the active site residues and 
cofactor of YpFabV (binary) (blue) and EcFabItcl (brown). D) The conserved residue K245 interacts with N237 
and W236 (teal) and thereby stabilizes the position of the active site residues Y235 and K244 (violet) 
relative to each other. E) Superposition of the active site residues and cofactor of apo BpFabV (green), 
YpFabV binary (light blue) and ternary (yellow) complexes. 
 
In FabV the catalytic residues are part of the C-terminal region of the protein, which is 
building the binding pocket in vicinity to the nicotinamide ring of the NADH cofactor 
(depicted in binary YpFabV structure in Figure 40). The hydroxyl group of Y235 interacts 
via a water molecule with the 2’ ribose hydroxyl group of the nicotinamide ribose. The 
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water molecule probably binds in place of the substrate. K244 interacts with both 
hydroxyl groups of the ribose and keeps the cofactor in place for catalysis. Moreover it is 
thought to be involved in re-protonation of Y235 after reduction of the enoyl substrate. A 
third residue, Y225, is proposed to play a major role in substrate accommodation in the 
active site. In the superposition with EcFabItcl (Figure 40C) the FabV active site residues 
Y225, Y235 and K244 display the same 3D conformation as the EcFabItcl counterparts 
Y146, Y156 and K163. The additional two residues between Y235 and K244 have no 
impact on the active site geometry. Although the active site motif is not retained in FabV, 
the structural geometry of the catalytic site is conserved.  
Residue K245 was found to be conserved in FabV from various species but not in other 
enoyl-ACP reductases. A mutation of this residue in B. mallei FabV to methionine resulted 
in a 10-fold decreased substrate affinity but unchanged cofactor binding (Lu and Tonge, 
2010). It was therefore proposed that K245 is interacting with the substrate in the binding 
pocket. The crystal structures of FabV, however, revealed, that K245 does not point into 
the binding pocket but is located on the surface of the protein (Figure 40D). It interacts 
with the side chain of N237 and the backbone carbonyl of W236 (teal in Figure 4D) and 
thereby holds the loop carrying Y235 next to K244 (violet in Figure 40D) in place, 
stabilizing the position of the catalytic residues to each other. It seems to have an indirect 
effect on substrate binding by maintaining the active site geometry. This additional 
stabilization might be necessary in FabV because of the larger distance between Y235 and 
K244 in the sequence and is therefore not conserved in FabI.  
A comparison of the active site residues in the apo-structure with the binary and ternary 
complexes of FabV, reveals that Y225 assumes the same conformation in all three 
structures whereas Y235 and K244 of apo BpFabV (green) are shifted in their orientation 
compared to the YpFabV structures (binary: blue, ternary: yellow) (Figure 40E). A 
probable reason for this shift might be the missing interaction to the cofactor in the apo 
structure. A closer look into the active site of the apo BpFabV structure shows that the 
shifted position of Y235 is stabilized by a hydrogen bond to the backbone nitrogen of 
P282 at the C-terminal end of the substrate- binding loop on the opposite side of the 
substrate-binding pocket (Figure 41A). K244 interacts with the sulfate moiety of a bound 
MES buffer molecule, which in turn interacts with V273, therefore this residue also 
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interacts across the binding pocket. The interaction to MES is an artificial feature of the 
crystal structure. The comparison to a newly published apo FabV structure from 
Xanthomonas oryzae ( XoFabV, PDB ID 3s8m (Li et al., 2011))(in light orange in Figure 41B) 
showed that the Y225 and Y235 conformation is the same but K244 point towards the 
NADH position as in the complex structures of YpFabV. 
 
Figure 41: Active site residues in FabV apo structures 
A) Interactions of the catalytic residues of apo BpFabV. B) Superposition of the active site residues of apo 
BpFabV and apo XoFabV (PDB ID 3s8m).  
4.1.3 Stabilization of the substrate- binding loop  
An interesting feature of the active site of FabV, especially concerning drug development 
based on triclosan, is the closed, helical substrate-binding loop (helix α8) of FabV. The 
substrate-binding loop (T276-M284, highlighted in a green box in the sequence alignment 
in Figure 39 and Supplemental Figure 58 and Figure 59) is closed in all three forms, the 
apo, the binary and ternary complexes; however, in the binary complex of YpFabV the 
substrate-binding loop is shifted about 3 Å deeper into the substrate binding pocket 
compared to the other structures (Figure 42A). In EcFabItcl the helical conformation is 
stabilized by additional hydrophobic contacts to the bound triclosan molecule at the 
center of the helix. This interaction is missing in apo BpFabV and the binary YpFabV 
structure. In FabV the additional structural elements (depicted in yellow in Figure 42B) 
are folded around the active site pocket especially the substrate-binding loop (depicted in 
violet in Figure 42B). The N-terminal part of the substrate binding loop is stabilized by a 
hydrogen bond network involving water molecules, residues from the edge of the 
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Rossmann fold including T51, E75, S86, G87, and N90, NADH, residues from the additional 
structural elements such as the hairpin β1/β2 (F10, C12) and helix α14 (L373) (violet in 
Figure 42C).  
 
Figure 42: Stabilization of the substrate-binding loop in FabV 
A) Superposition of apo BpFabV (green) and YpFabV in the binary (light blue) and ternary (yellow) complex 
with the substrate binding-loop highlighted. B) Ribbon diagram of the YpFabV binary complex in blue with 
the additional structural elements of FabV colored in yellow and the substrate-binding loop in violet. The 
cofactor is drawn in all-bond representation. C) The substrate-binding loop (yellow) stabilization by van der 
Waals interactions (cyan residues with transparent spheres) and hydrogen bonds (dashed lines and violet 
residues). 
 
Importantly the center of the helix is stabilized by hydrogen bond interactions from the 
carbonyl oxygen of F10 to the carbonyl group of T276 and the hydroxyl group of S280, 
which is mediated by an ordered water molecule. The C-terminal half of the substrate-
binding loop is entangled in van der Waals interactions (cyan in Figure 42C). The 
hydrophobicly interacting residues are part of the following helix α9 (P286 and L289), of 
helix α10 (C305) and the loop carrying the catalytic residue Y235 (I230, T231, I234 and 
Y235). The other half of hydrophobicly interacting amino acids is located on additional 
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structural elements of FabV. A140 interacts from β7 and L166 and R167 from hairpin 
β9/β10. W349, Y366, F370 and F374 originate from the additional C-terminal α-helices 
α12 and α14. Binding of the cofactor does not seem to be essential for substrate-binding 
loop stabilization, since the loop is already helical in the apo BpFabV structure.  
4.1.4 NADH binding 
The second determining motif for subfamily assignment in the SDR superfamily is the 
glycine-rich cofactor binding motif of the Rossmann fold, more precisely on the loop 
between strand β1 and helix α1 in FabI and the corresponding strand β3 and helix α2 in 
FabV (cf. blue box in sequence alignment in Figure 39 and Supplemental Figure 58 and 
Figure 59). The motif was defined as GxxxxxSxA (Kallberg et al., 2002). The alignments 
depicted in Figure 39 (BpFabI, BpFabV and YpFabV) and Supplemental Figure 58 (YpFabV 
and EcFabItcl) differ in this region. The alignment of YpFabV with EcFabItcl requires no gap 
whereas the alignment of BpFabI, BpFabV and YpFabV inserts a gap of 4 residues in this 
motif. Since the secondary structure elements align well in the sequence alignment in 
Figure 39, it seems that the loop connecting β3 and α2 is shorter in FabV compared to 
FabI, but can provide similar interactions (interacting residues are marked yellow in the 
blue box in Figure 39). Therefore also this motif is not retained in FabV. If FabV, which is 
closely related to FabI, shall be assigned to the same subfamily of diverse SDR proteins, 
the motifs have to be revised. Otherwise FabV has to be grouped into a separate 
subfamily of “even more diverse” SDR proteins. 
The cofactor NADH is not only bound by interactions with amino acids from the 
Rossmann fold. NADH is involved in a tight hydrogen bond network and further stabilized 
by hydrophobic contacts to surrounding residues (analyzed with the help of Ligplot+ 
(Laskowski and Swindells, 2011; Wallace et al., 1995)). An overview of all interactions of 
NADH in the YpFabV binary complex is depicted in Figure 43A with the residues 
interacting via hydrogen bonds depicted in violet and the hydrophobically interacting 
residues in cyan. The hydrogen bond network is illustrated in detail in Figure 43 B-D. The 
adenine ring of NADH (N6 and N1) is stabilized by hydrogen bonds to the side chain of 
D111 and the carbonyl oxygen of G110. A solvent water molecule mediates hydrogen 
bonds to the carbonyl group of R143 and the hydroxyl of S141. The hydroxyl groups of the 
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adenine ribose interact with the main chain nitrogen atom of F74 and the hydroxyl group 
and main chain nitrogen of S50. The pyrophosphate group is entangled in a hydrogen 
bond network involving two water molecules and one sodium ion (Figure 43C).  
 
Figure 43: Cofactor binding of YpFabV 
A) Schematic overview of the interactions of NADH (yellow) with YpFabV; residues providing van der Waals 
interactions are displayed in cyan and hydrogen bonds in violet. B)/C)/D) Detailed hydrogen bond 
interactions (dashed lines) of the adenine ring and the ribose (B), the pyrophosphate (C) and the 
nicotinamide ring and the neighboring  ribose (D).  
 
The sodium ion mediates interactions from both phosphate groups (OAZ and O5*) to the 
carbonyl and hydroxyl groups of S138, the carbonyl group of G54 and the carbonyl group 
of T51. T51 also interacts with its hydroxyl group directly to O5* and via a water bridge to 
OAB of the adenine phosphate. The oxygen OAC of this phosphate interacts with the 
backbone as well as with the side chain nitrogen of Q227 via a water molecule. The 
nicotinamide phosphate interacts via its oxygen OAZ with the backbone nitrogen of Y53 
and via the OAY oxygen with the hydroxyl group of T276. The catalytic residues Y235 and 
K244 are involved in interactions with the nicotinamide ribose (Figure 43D). The cofactor 
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is stabilized by interactions of the side chain of K244 to both hydroxyl groups of the ribose 
and a water-mediated hydrogen bond of the Y235 hydroxyl to the 2’ hydroxyl group. The 
second hydroxyl group is further stabilized by a water mediated interaction to the 
backbone of Y137 and L139. The amide group of the nicotinamide ring is interacting with 
the carbonyl to the backbone nitrogen of V274 and with the amino group to the hydroxyl 
of T276. 
 
Figure 44: OMIT electron density map of NADH (YpFabV binary) 
A) 2Fo-Fc - OMIT map (contour level 1σ) of the NADH molecule. B) Zoomed view of the OMIT map of the 
nicotinamide ring. 
 
During model building the question arose, whether the NADH, applied in the co-
crystallization trial, is still in the reduced form or if it might have been oxidized to NAD+. 
Most FabI structures had been co-crystallized with NAD+ (and an inhibitor). Structurally 
NADH differs from NAD+ only in a slight kink of the nicotinamide ring. The oxidized 
nicotinamide ring of NAD+ is in a planar, aromatic conformation. From the experimental 
data with the best resolution of about 2 Å, it is difficult to judge if the ring is planar or 
slightly kinked (Figure 44). During refinement the conformation of NADH is influenced by 
the geometric restrains given in the library file of the molecule. However, even when the 
nicotinamide ring was defined to be planar, it deviated from planarity after a refinement 
cycle. Another indication that the structures contain NADH rather than NAD+ is the fact 
that YpFabV never crystallized with NAD+ but only in the presence of NADH. Moreover 
the inhibitors, which were co-crystallized with the T276S variant of YpFabV, preferred 
binding in the presence of NADH compared to NAD+. Since there was no indication that 
the cofactor is present in the crystal structure in the oxidized form, it was modeled as 
NADH.  
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4.1.1.1  Influence of the T276S variant on NADH binding 
The T276S variant of YpFabV in the binary complex shows no changes in the protein 
structure or the cofactor position in comparison to the wild type protein. The structures 
can be aligned with an RMSD value of only 0.27 Å according to the SSM analysis (Krissinel 
and Henrick, 2004). Structural comparison of the binary wild type YpFabV complexes 
containing the hexahistidine-tag with the cleaved protein yielded a larger RMSD value of 
0.55 Å. The amino acids threonine and serine only differ in one methyl group, which is 
missing in serine. Although it does not display major structural changes, the T276S variant 
behaves differently than the wild type protein in enzyme kinetics (Carla Neckles, 
unpublished data (Neckles, 2012)). The Kd values of the T276S variant for NADH and the 
substrate analog trans-2-dodecenoyl-CoA (ddCoA) were 4.2 ± 0.05 μM and 32.9 ± 0.4 μM, 
respectively. The wild type Kd values for NADH and ddCoA were 13 ± 0.8 μM and 13 ± 0.7 
μM, respectively. These changes in affinity are also reflected in a modified mechanism. 
The wild type YpFabV, displaying comparable Kd values for substrate and cofactor, 
catalyzes the enoyl reduction in a random Bi Bi mechanism, where either the substrate or 
the cofactor could bind first. The T276S variant, with an about 10-fold higher affinity for 
the cofactor than for the substrate, catalyzes the reaction in an ordered Bi Bi mechanism 
with the cofactor binding first and leaving last (Carla Neckles, unpublished data (Neckles, 
2012)). Interestingly, FabV from B. mallei (BmFabV) was reported to catalyze the reaction 
in an ordered Bi Bi mechanism (Lu and Tonge, 2010). A superposition of the residues 
interacting with NADH, does not indicate changes in the conformation which could lead 
to a loss/gain of interactions (Figure 45A). The residues T276 and S276 are retained in the 
same position and can both interact with the cofactor (Figure 45B). There is no 
substantial change in the distance between the interacting atoms. Since there is no 
influence on the conformation of the protein structure or the ligand position, another 
explanation might be differing interactions to solvent molecules, since many interactions 
of FabV to the cofactor are mediated by water molecules. The interaction-mediating 
solvent molecules described above are all retained in the T276S variant structure, 
however, there are two additional water molecule in the vicinity of S276 in the active site, 
which are not present in the wild type structure, since they are extruded by the additional 
methyl group of T276 (Figure 45C). One of these water molecules mediates an additional 
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interaction between the sulfhydryl group of C305 and the oxygen atoms OAY and OAZ of 
the nicotinamide phosphate group (Figure 45D). This additional interaction might not be 
the sole background of the higher NADH affinity of the T276S variant. The analysis of 
solvent molecules in protein structures is highly dependent on the resolution of the 
experimental data. The higher the resolution, the more solvent molecules become visible 
in the electron density. At a resolution of 2 Å most of the defined water molecules in the 
active site should be visible in the active site. 
 
Figure 45: Impact of T276S variant on NADH binding 
A) Superposition of NADH-interacting residues in the YpFabV binary complexes of the wild type (light blue) 
and the T276S variant (cyan) in all-bond representation. NADH is shown in yellow. B) Hydrogen bonds 
(dashed lines) of T267 and S276. C) Water molecules (colored according to the structure) in the vicinity to 
the T276 methyl group. D) Additional hydrogen bond interaction of the T276S variant. 
 
At this point it can not be ruled out that additional water molecules which have not been 
observed in the crystal structure affect cofactor binding. The differing cofactor affinity of 
the variant also has an influence on inhibitor binding. The 2-pyridone inhibitor PT171 
(corresponding to PT173, but without the amino group at the ortho position of the B-ring, 
cf. Table 20) showed an IC50 value of 6 ± 1 µM for the variant but > 50 µM for the wild 
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type. The 2-pyridone inhibitors might prefer binding to the variant because the affinity is 
increased in the presence of NADH versus NAD+ (Carla Neckles, unpublished data, 
(Neckles, 2012)). In contrast, the diphenyl ether inhibitors derived from triclosan usually 
bind in a ternary complex with NAD+. Apart from the increased NADH affinity of the 
variant, also changes in the set of bound solvent molecules in the active site might 
influence ligand affinities.  
4.1.5 Inhibitor binding  
The 2-pyridone inhibitors PT172 and PT173 inhibit the YpFabV variant with higher affinity 
compared to triclosan. Triclosan inhibits the variant with a Ki value of 71 ± 4 µM, whereas 
PT172 and PT173 exhibit Ki values of 2.1 ± 0.4 µM and 1.5 ± 0.3 µM, respectively (cf. Table 
20).  
Table 20: Inhibitors of the T276S variant (Hirschbeck et al., 2012) 
The cLogP was determined with ChemBioDraw Ultra 12.0 
Inhibitor Structure 
Molecular 
weight (Da) 
clogP Ki (µM) 
triclosan 
 
289.54 5.53 71±4 
PT172 
 
303.83 5.54 2.1±0.4 
PT173 
 
298.20 4.00 1.5±0.3 
 
The elevated NADH affinity favors the binding of the 2-pyridone inhibitors, but on the 
other hand impairs the binding of the diphenyl ether inhibitor triclosan. For BmFabV a Ki 
value for triclosan of 0.4 µM was reported (Lu and Tonge, 2010) and for YpFabV IC50 values 
of 5 ± 1 µM and >50 µM have been determined for the wild type and the variant, 
respectively (Carla Neckles, unpublished data (Neckles, 2012)). Since the diphenyl ether 
inhibitors prefer binding in the presence of NAD+, the tight binding of NADH in the variant 
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may reduce its affinity. The 2-pyridone inhibitors contain a hexyl-chain at the meta 
position of the A-ring (the pyridone ring). Structure-activity relationship studies on 
diphenyl ether inhibitors in FabI revealed a favorable effect of an alkyl-chain on binding 
since it is mimicking the enoyl substrate in the active site (Lu and Tonge, 2008; Luckner et 
al., 2010). Unfortunately diphenyl ether inhibitors are susceptible to drug metabolism in 
phase II conjugation reactions. Triclosan was reported to be conjugated at the 2’-hydroxyl 
group to glucuronide and sulfate conjugates (DeSalva et al., 1989). Therefore inhibitors 
with a 2-pyridone scaffold where explored for binding in FabV, since it showed promising 
inhibitory results in FabI from S. aureus, Toxiplasma gondii and B. anthracis (Tipparaju et 
al., 2008; Tipparaju et al., 2010; Yum et al., 2007). Another favorable feature of the 2-
pyridone scaffold is a reduction of the logP value compared to the diphenyl ether 
scaffold. One additional issue of the diphenyl ether inhibitors is their high hydrophobicity. 
It is not surprising that a hydrophobic molecule binds with high affinity to the substrate 
binding pocket of the enoyl-ACP reductases since the substrate itself is hydrophobic, but 
high hydrophobicity impairs the oral bioavailability of a potential drug candidate. PT172 
and PT173 display clogP values of 5.54 and 4.00 (cf. Table 20), respectively; their diphenyl 
ether counterparts (with the same substituents) would have clogP values of 6.95 and 
5.69, respectively. 
The ternary complexes of the YpFabV variant showed no major structural changes in the 
overall structure compared to the binary complex. The structures can be aligned with an 
RSMD of 0.2 Å (SSM). Since binding of triclosan and other slow binding inhibitors to FabI 
leads to ordering of the substrate-binding loop, it is interesting to observe that the 
substrate binding loop moves out of the binding pocket upon inhibitor binding in FabV 
(Figure 46). The loop shifts about 3 Å out of the binding pocket and affects also the 
conformation of the interacting β hairpin β1/β2.  This movement is necessary to 
accommodate the inhibitor in the active site. 
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Interestingly, the apo BpFabV structure shares the open conformation of the substrate-
binding loop with the ternary complex. The interaction to the cofactor seems to pull the 
helix deeper into the pocket. A closer view of the binding pocket of the ternary complexes 
shows that the two serine residues S276 and S279 interact with two water molecules in 
between the substrate-binding loop and the inhibitor (Figure 47A). Therefore the 
hydrophobic interaction between the helix and the inhibitor, as it is known from FabI and 
triclosan, cannot be formed. Notably the mutated residue S276 is involved in the 
interaction. The two water molecules replace the direct interactions of S276 to the 
cofactor at the amide and the phosphate group in the binary complex of the variant (cf. 
Figure 45B). The position of the cofactor itself is conserved in the binary and ternary 
complexes (cf. Figure 46). Since both T276 and S276 can form direct interactions to the 
cofactor, one might speculate that also T276 could form the hydrogen bond to the 
solvent water molecules in a ternary complex. 
The binding mode of the 2-pyridone inhibitors in FabV is reminiscent to the binding of 
triclosan in FabI. It interacts with its keto group via two hydrogen bonds with the hydroxyl 
groups of Y235 and the nicotinamide ribose (Figure 47A). Furthermore the pyridone ring 
of the inhibitors forms a parallel displaced π-π stacking interaction with the nicotinamide 
ring of the cofactor. The superposition of both inhibitors shows that the pyridone ring (A-
ring) assumes the same position in both structures, whereas the B-ring of PT172 is tilted 
Figure 46: The substrate-binding 
loop shifts upon inhibitor binding 
Superposition of the YpFabV T276S 
variant binary (lght blue) and 
ternary (yellow) structure with 
highlighted substrate binding loops. 
PT173 (dark grey) and the NADH 
cofactors (yellow / light blue) are 
shown in all-bonds representation.  
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about 24° into the depth of the binding pocket (Figure 47B). The position of the hexyl 
chains is slightly flexible, which is also reflected in a rather diffuse electron density map of 
this part of the inhibitor. All interacting residues of PT172 and PT173 are depicted in 
Figure 47 C and D. PT173 interacts hydrophobically with A140, T221, Y225, A273 and 
M285. Due to the shifted B-ring, PT172 forms hydrophobic contacts additionally to M196. 
The hexyl chain of PT172 also interacts with H232, but since this part of the inhibitor was 
modeled into an ill-defined electron density in both inhibitors, this could also be the case 
for PT173. With the amino group at the meta position of the B-ring PT173 forms hydrogen 
bonds to two solvent water molecules; one of them mediates a hydrogen bond 
interaction to the carbonyl group of S141 and the hydroxyl group of S155. The shift of the 
B-ring out of the pocket is probably due to this additional interaction, rather than steric 
hindrance.  
 
Figure 47: Inhibitor binding of PT172 and PT173 in YpFabV 
A) PT172 (light grey) interacts through hydrogen bonds (dashed lines) with FabV and NADH and in a π-
stacking interaction with NADH. The substrate binding loop is highlighted in yellow. B) Superposition of 
bound PT172 and PT173. C)/D) Residues interacting with PT172 (C) and PT173 (D) via hydrogen bonds 
(violet) and van der Waals contacts (cyan with transparent spheres). 
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The increased NADH affinity of the YpFabV variant might have facilitated obtaining a 
stable ternary complex for crystallization with respect to these rapid reversible inhibitors 
of FabV with rather low affinity. Although the 2-pyridone inhibitors, described in the 
ternary complexes do not bind with the same affinity to wild type YpFabV, the structural 
characterization of the ternary variant structure reveal a promising binding mode of the 
inhibitors and how the protein structure reacts upon inhibitor binding, which might help 
to design improved inhibitors for the FabV binding pocket.  
4.1.6 Potential ACP interaction site 
Despite the low sequence identity and the difference in size, the active site and the 
binding pocket of FabV is very similar to FabI. The binary complex of YpFabV is most 
similar to the triclosan-bound form of FabI (cf. Figure 38A), which is characterized by the 
closed, helical conformation of the substrate-binding loop. The usually flexible substrate-
binding loop is thought to interact hydrophobicly with the substrate thereby closing the 
pocket. In FabV this “closing mechanism” is already observed in the binary complex and 
the active site pocket is surrounded by additional structural elements such as the three β-
hairpins (β1/β2, β7/β8 and β9/β10) and the helices α11, α12, α13 and α14. The question 
therefore arises how the substrate enters this very close active site. 
In FabI two entry sites have been described, the “minor portal” and the wider “major 
portal” (Rozwarski et al., 1999). In an EcFabI-ACP complex structure the acyl-panthetein 
adduct was not visible in the electron density, but it could be modeled by molecular 
dynamic simulations and was proposed to enter the active site through the minor portal 
(Rafi et al., 2006). In the analysis of solvent channels in the binary YpFabV complex 
structure with MOLE and CAVER (Petrek et al., 2007; Petrek et al., 2006) both entry 
channels could be confirmed (Figure 48A). The minor portal however, is constrained by 
the tight substrate-binding loop conformation and the β hairpin β9/β10 and therefore 
very narrow. Another aspect of the substrate entry is a binding site for the acyl-carrier 
protein ACP. There is no defined interaction motif for ACP, which is reasonable since ACP 
interacts with a variety of different enzymes involved in fatty acid biosynthesis and 
phospholipid metabolism, however all interactions are characterized by low affinity 
binding (low µM range). The small, acidic protein was reported to interact via its acidic 
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residues on helix αII with its interaction partners, i.e. to patches containing 
electropositive sites combined with hydrophobic areas. In the EcFabI-ACP complex 
structure ACP binds to basic residues in helix α8 of FabI, C-terminal to the substrate-
binding loop  (Chan and Vogel, 2010; Parris et al., 2000; Rafi et al., 2006; Zhang et al., 
2003a; Zhang et al., 2003b).  
 
Figure 48: Hypothetical substrate-binding mechanism 
A) Potential entry channels of the YpFabV binary complex (calculated with Caver) through the minor and 
major portals, shown as grey surfaces. B) Detailed view of the potential interaction site: basic residues are 
shown in magenta, hydrophobic residues in brown and the substrate-binding loop is highlighted in yellow. 
C) Hypothetical view towards substrate binding: The PT173-complex structure is colored according to its 
temperature factors (red=high, blue=low) with the basic residues K4, R6 and R8 in all-bond representation 
on strand β1. The ACP could interact through its acidic residues with the basic residues of the N-terminal β-
hairpin and thereby moving the connected substrate-binding loop (red) out of the pocket and opening the 
major portal for the substrate.  
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This helix is buried in FabV by the extended β hairpin β9/β10. Furthermore the basic 
residues, which are interacting with ACP in FabI are not conserved in FabV. Therefore a 
substrate entry through the minor portal seems implausible.  
The second option is the entry through the major portal, which is the only side of the 
FabV binding pocket that is not covered by one of the additional structural element of this 
extended enoyl-ACP reductase isoform. In a complex structure of the M. tuberculosis 
isoform of FabI, InhA, with a C16 substrate analog, the N-acetyl cysteamine moiety, which 
would be physiologically coupled to ACP, points towards the major portal (Rozwarski et 
al., 1999). In vicinity to the major portal a potential ACP interaction site could be 
determined on the β-hairpin β1/β2 (Figure 48B). On the strand β1 three prominent basic 
residues (K4, R6 and R8, depicted in violet), which are conserved among FabVs from 
different species (cf. Supplemental Figure 59, blue asterisks) could interact with the acidic 
ACP, while the enoyl substrate could enter the active site pocket via a patch of solvent-
exposed hydrophobic residues (depicted in brown) on the strand β2 and the upper part of 
the substrate-binding loop (depicted in yellow). The substrate-binding loop dynamics also 
support this hypothesis. In the ternary inhibitor structures the substrate-binding loop and 
the connected β-turn of hairpin β1/β2 are the only structural elements affected by 
inhibitor binding. Since the 2-pyridone inhibitors PT172 and PT173 with their hexyl chain 
could also be interpreted as substrate analogues, it seems probable that the same 
opening of these structures will occur upon substrate binding. Notably this opening 
movement broadens the major portal but not the minor portal. A potential binding 
mechanism is illustrated in Figure 48 C. According to this hypothesis ACP interacts with 
the basic residues on strand β1, which might move towards the ACP upon binding. This 
outward movement is carried over to substrate binding, which broadens the major portal. 
The enoyl substrate can now enter the active site via the hydrophobic patch on strand β2 
through the opened major portal.  
  
Discussion 
 
106 
 
4.1.7 Potential FAD binding site 
The authors of the paper characterizing the apo structure of the X. oryzae FabV (XoFabV) 
discussed a potential FAD binding site close to the C-terminus of FabV. The FAD binding 
motif FGFxxxxxDY can be found among residues F373-Y383 in YpFabV and is conserved in 
various species (shown in the violet box in the sequence alignments in Figure 39 and 
Supplemental Figure 58 and Figure 59). Despite the binding motif the authors could not 
show FAD binding to XoFabV in isothermal titration calorimetry (ITC) or co-crystallization 
trials (Li et al., 2011). However, in the description of a FabV homolog in Euglena gracilis, a 
hint for a potential FAD interaction was noticed. In this protozoon the mitochondrial 2-
trans-enoyl-CoA reductase with a protein sequence identity of 46% to YpFabV was 
reported to be a enoyl-CoA reductase involved in wax ester fermentation in mitochondria 
under anaerobic conditions (Hoffmeister et al., 2005). When the enzyme was purified 
natively from E. gracilis, it lost its activity if the purification buffers contained no FAD as 
additive. When the protein was recombinantly expressed in E. coli, the protein did not 
depend on FAD to retain activity. In the crystal structure of YpFabV the FAD motif is 
located lateral to the Rossmann fold, N-terminal to the last β-strand β14 (Figure 49).  
 
Figure 49: Potential FAD binding site 
The YpFabV binary structure (blue) is shown with the catalytic Y235 and the cofactor in violet and the 
residues of the FAD binding motif in yellow in all-atoms representation. 
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The binding site is not in vicinity to the NADH or the catalytic center of FabV. This 
structural separation together with the result, that the recombinant mitochondrial 2-
trans-enoyl-CoA reductase as well as the XoFabV exhibit the same activity with and 
without FAD lead to the conclusion that FAD has no functional role in the catalytic activity 
of FabV. For the FAS-II system in mycobacteria it was reported that the distinct enzymes 
of the elongation cycle interact with each other and that this complex formation is 
relevant for the function of the pathway (Cantaloube et al., 2011; Veyron-Churlet et al., 
2004). If this is also true for the FAS-II system in other species, the FAD interaction might 
be involved in complex formation of FabV with other enzymes of the FAS-II pathway.  
4.2 Functional considerations on FabV 
The pronounced distinctions of FabV, compared to the SDR enoyl-ACP reductases FabI 
and FabL, especially the elongated active site motif, led to the question if FabV might 
have a distinct function or differing substrate specificity. Particularly in species possessing 
FabV along with FabI, FabV could adopt a specialized function. The increased size might 
indicate substrate specificity for longer enoyl substrates, as it is known from the FabI 
homolog InhA in M. tuberculosis. InhA has an elongated substrate binding loop generating 
an extended binding pocket, which is essential for the binding of substrates with a length 
of up to C56, which are utilized in mycolic acid synthesis (Dessen et al., 1995). The 
extended active site motif in FabV was suggestive of a different active site geometry, 
which might be an adaptation to a chemically different substrate such as unsaturated 
fatty acids. However, the structural data presented in this study reveal that the active site 
geometry of FabV matches with FabI and also the core of the binding pocket is 
structurally conserved. The additional structural elements could be attributed to the 
stabilization of the active site pocket of FabV and thereby facilitate its monomeric state. 
As the sole enoyl-ACP reductase in many species, such as Y. pestis or V. cholerae, it has to 
take over the function of FabI. Another indication that it assumes the same substrate 
specificity is the fact that P. aeruginosa FabV can compensate the inhibition of FabI (Zhu 
et al., 2010). On the other hand the mitochondrial 2-trans-enoyl-CoA reductase, a FabV 
homolog in the protozoon Euglena gracilis, was described to assume a different function 
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compared to FabV (Hoffmeister et al., 2005). The usage of Coenzyme A as carrier of the 
substrate instead of ACP indicated that this fatty acid biosynthesis pathway might be a 
reversal β-oxidation. The corresponding step of the β-oxidation is catalyzed by the acyl-
CoA dehydrogenase/acyl-CoA oxidase in an oxidative and irreversible step. The reverse 
reaction therefore needs to be catalyzed by another enzyme. However, this change in 
function is associated with the active site motif Y(X6)K, corresponding to FabI, not FabV. 
Therefore a specialization of FabV might be possible but there is no indication in the 
literature that it differs in function from FabI in the context of the FAS-II pathway. 
The occurrence of four distinct enzymes, catalyzing the same step of the FAS-II elongation 
cycle might have originated in the environmental presence of FabI inhibitors, generating a 
selection pressure for organisms with alternative enzymes for this step. In fact several 
natural products, such as vinaxanthone from Penicillium sp. (Zheng et al., 2009), 
cephalochromin from an unspecified microbial origin (Zheng et al., 2007) or aquastatin A 
from Sporothrix sp. FN611 (Kwon et al., 2009), have been reported to inhibit FabI. One 
very interesting case is the FabV homolog BatG in Pseudomonas fluorescens, which shares 
58% identity with YpFabV but exhibits the  Y(X6)K active site motif from FabI (Mattheus et 
al., 2010). P. fluorescens produces the FabI inhibitor kalimantacin/batumin. The enoyl-
ACP reductase BatG is encoded in the batumin biosynthesis cluster. P. fluorescens gains a 
selection advantage over competing bacteria by inhibiting the FAS-II system via the 
antibacterial batumin; it protects itself from the harmful effect of batumin since it 
possesses BatG as a mechanism of self-resistance.  
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4.3 Structural characterization of BpFabI as potential drug target 
B. pseudomallei possesses the enoyl-ACP reductase isoenzymes FabI and FabV. In order to 
characterize the structures of the complete set of enoyl-ACP reductases of this pathogen 
and explore the potential to generate inhibitors targeting both enzymes with sufficient 
affinity, crystal structures of BpFabI in the apo form and in the ternary complex with the 
cofactor NAD+ and a selection of five different inhibitors were solved.  
4.3.1 Overall structure  
 
Figure 50: Overall structure of BpFabI 
A) BpFabI apo monomer depicted in two orientations as ribbon diagram with α-helices in red (η =310 
helix), β-strands in yellow and loop regions in green. B) Tetrameric assembly of apo BpFabI, colored 
according to chain, with the P-Interface (C) and Q-interface indicated (D). 
 
The apo structure of BpFabI shows the typical fold of FabI as a member of the diverse 
subfamily of SDR proteins (Figure 50A). The Rossmann fold provides stability to the 
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protein and builds up the NADH binding site. It is composed of a seven-stranded β-sheet 
with the typical strand order “3-2-1-4-5-6-7”. It is surrounded by three α-helices on each 
side. In the apo protein the helices α1, α2, α3, α4, α5 and α8 are forming an α-helical 
coating of the β-sheet. The ternary complexes contain an additional helix at the 
substrate-binding loop (α7); therefore in the complex structures the last helix involved in 
the Rossmann fold is helix α9. The Rossmann fold of FabI contains one β-strand and one 
α-helix less than FabV. Due to the three β-hairpin structures at the active site pocket of 
FabV the order of the sheet is extended to “14-5-4-3-6-11-12-13”. Remarkably the last β-
strand β14 of FabV returns to the beginning of the β-sheet. In contrast to FabV, the active 
site pocket in FabI is formed only by helical structures and loop regions from the C-
terminal half of the polypeptide chain. β-strands are restricted to the Rossmann fold. The 
comparison of the newly solved apo BpFabI structure to the already deposited structure 
“3ek2” revealed minor changes in the overall structure. The alignment of both structures 
with the PDBeFOLD server in an SSM approach exhibited an RMSD value of 0.45 Å 
(Krissinel and Henrick, 2004). In both structures the N-terminal residue M1 was missing. 
At the C-terminus the last 5 and 7 residues were not represented in 3ek2 and BpFabI258, 
indicating that the C-terminus is not involved in interactions within the protein or through 
crystal contacts with other protein molecules and remains flexible.  One difference 
between the structures is the substrate-binding loop. While this flexible loop ranging 
from K193 to A197 is not present in the 3ek2 structure, it is defined as loop in an open 
conformation in the apo BpFabI structure, since it is stabilized by a crystal contact (cf. 
Figure 35). 
BpFabI exhibits the typical tetrameric oligomerization state of FabIs and SDR proteins in 
general. For FabI two characteristic interfaces have been described, the P and the Q 
interface (Figure 50B-D) (Baldock et al., 1998b). The interfaces of the apo BpFabI were 
analyzed with the PDBe PISA server (Protein Interfaces, Surfaces and Assemblies) 
(Krissinel and Henrick, 2007). The larger Q-interface contains 32 hydrogen bonds and 8 
salt bridges. Table 21 contains the interactions from one molecule. Due to a two-fold axis 
of symmetry the interactions are mirrored in the second monomer. The Q-interface 
involves the helices α4/α5 and α6, which are connecting the Rossmann fold and the 
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active site pocket of FabI as “backbone” helices, and loop β3-α3. It buries a surface area 
of 1587.5 Å2 and yields a gain of solvation free energy of ΔiG = -22.3 kcal/mol. 
Table 21: Molecular interactions stabilizing Q-interface defined by PDBe PISA server  
(all interactions mirrored in molecule 2) 
Hydrogen bonds Salt bridges 
Monomer1    Dist. [Å]     Monomer 2     Monomer 1     Dist. [Å]     Monomer 2   
ARG 110[ NH1]    2.93   VAL  65[ O  ]  ARG 110[ NE ]    2.94   ASP  68[ OD1]  
ARG 110[ NH2]    2.89   VAL  65[ O  ]  ARG 110[ NH2]    2.83   ASP  68[ OD1]  
ARG 110[ NE ]    2.94   ASP  68[ OD1]  ARG 110[ NH1]    2.88   ASP 118[ OD1]  
ARG 110[ NH2]    2.83   ASP  68[ OD1]  ARG 110[ NH1]    3.24   ASP 118[ OD2]  
SER 176[ OG ]    2.74   ASP 103[ OD1]  
LYS 129[ NZ ]    2.91   LEU 105[ O  ]  
LYS 129[ NZ ]    3.89   ASP 106[ O  ]  
LYS 129[ NZ ]    2.91   LEU 108[ O  ]  
ARG 110[ NH1]    2.88   ASP 118[ OD1]  
ARG 110[ N  ]    3.20   TYR 122[ OH ]  
TYR 172[ OH ]    2.76   GLY 148[ O  ]  
ARG 171[ NH2]    3.03   ALA 149[ O  ]  
ARG 171[ NE ]    3.08   GLU 150[ O  ]  
TYR 172[ OH ]    3.46   ARG 151[ O  ]  
ILE 153[ N  ]    3.31   TYR 172[ OH ]  
LEU 105[ N  ]    3.88   SER 176[ OG ] 
 
The smaller P-interface involves residues at the strand β7, A179 at end of helix α6 and 
R218 on loop α7-α8. The interface is stabilized by 12 hydrogen bonds and 4 salt bridges, 
again in a two-fold axis of symmetry (cf. Table 22). It covers a surface area of 1318.7 Å2 
and leads to a gain of solvation free energy of ΔiG = -18.4 kcal/mol. 
Table 22: Molecular interactions stabilizing P-interface defined by PDBe PISA server  
 (all interactions mirrored in molecule 2) 
Hydrogen bonds Salt bridges 
 Monomer 1     Dist. [Å]    Monomer 2     Monomer 1     Dist. [Å]     Monomer 2   
ALA 179[ N  ]    3.50   PRO 215[ O  ]  HIS 246[ ND1]    2.97   GLU 243[ OE1]  
ARG 218[ NH2]    2.79   SER 238[ O  ]  HIS 246[ ND1]    3.40   GLU 243[ OE2]  
ASP 248[ N  ]    3.29   GLY 239[ O  ]  
SER 249[ N  ]    2.94   GLY 239[ O  ]  
HIS 246[ ND1]    2.97   GLU 243[ OE1]  
HIS 246[ N  ]    2.95   GLU 243[ OE2]  
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4.3.2 Active site and NADH binding 
Many crystal structures of FabI from E. coli or other pathogens are deposited in the PDB. 
Most of the structures are ternary complex structures with triclosan or another inhibitor. 
Only few FabI structures represent the apo form of the enzyme.  In Figure 51 A the 
superposition of BpFabI with the two apo FabI structures of S. aureus (PDB ID 4alm), 
SaFabI (Schiebel et al., 2012)  and Aquifex aeolicus (PDB ID 2p91), AaFabI, is illustrated.  
 
Figure 51: Active site of BpFabI 
A)/B) Superposition of apo BpFabI (orange) with apo AaFabI (PDB ID 2p91; magenta) and apo SaFabI (PDB ID 
4alm; green) in a ribbon diagram (A) and all-bonds representation of the active site residues (B). 
C)/D) Superposition of apo BpFabI (orange) with the ternary (PT12) BpFabI complex (teal) and the ternary 
triclosan complexes of SaFabI (PDB ID 4all; yellow) and EcFabI (PDB ID 1c14; lilac) in a ribbon diagram (C) 
and all-bonds representation of the active site residues and NADH (D). 
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While the Rossmann fold is stable and similar in the three structures the active site 
pocket is less stringently ordered in the apo structures, especially in SaFabI, which 
exhibits different conformations in the four chains of the crystal structure (Schiebel et al., 
2012). The differences in the substrate binding pockets are reflected in the high RMSD 
values of the structural alignment (SSM) to SaFabI and AaFabI of 1.30 Å and 0.96 Å, 
respectively. The active site motif of the diverse subfamiliy of SDR proteins in BpFabI is 
Y(x)6K. The catalytic residues Y156 and K163 show the same conformation in the AaFabI 
and the BpFabI apo structure (Figure 51 B). This is also the case for the third characteristic 
residue in the FabI active site, Y146, which is thought to be involved in stabilization of the 
substrate. The active site residues of apo SaFabI (shifted by one residue in sequence: 
Y147, Y157 and K164) assume a different orientation due to the flexibility of SaFabI in the 
active site region. The superposition of apo BpFabI with ternary complexes of BpFabI 
(PT12), SaFabI (triclosan) and EcFabI (triclosan) the active site pocket reveal an increased 
similarity compared to the quite flexible apo-structures (Figure 51C). The ternary complex 
structure of BpFabI with PT12 was chosen for this comparison due to its higher resolution 
compared to the triclosan complex structure. Only the open substrate binding loop of the 
apo BpFabI exhibits a differing conformation. The RMSD value of the structural alignment 
(SSM) of the apo and ternary BpFabI structures is 0.54 Å. The alignment of the ternary 
BpFabI with the ternary triclosan complexes of EcFabI (1c14) (Qiu et al., 1999) and SaFabI 
(4all) (Schiebel et al., 2012) exhibited RMSD values of 0.67 Å and 1.07 Å, respectively. 
Even though the RMSD value of the superposition with the ternary SaFabI is quite high, 
the active site residues of all four structures are well aligned (Figure 51D). In the ternary 
structures K163 (K164 in SaFabI) interacts with the hydroxyl groups of the NADH cofactor 
and Y156 with the inhibitors (cf. 0). It seem that the active site residues in the apo 
structures are already in the right position for catalysis, when the binding pocket is not 
disordered as in SaFabI; in contrast to the catalytic residues in the apo structure of 
BpFabV, where Y235 has to be recruited into the active position by cofactor binding. 
However, this is not the case for all FabI structures. A binary structure (containing NAD+) 
of the FabI homolog InhA of M. tuberculosis (2aq8) (Oliveira et al., 2006) exhibits Y158 in 
a shifted orientation compared to the ternary complexes, thus a general rule cannot be 
derived. 
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The cofactor binding motif “GxxxxxSxA“ of the divergent superfamily of SDR proteins is 
present in BpFabI in the sequence GLLSNRSIA (starting with G13) (displayed in the blue 
box in Figure 39). The stretch is mainly involved in the binding of the pyro-phosphate 
group and the adenine-ribose of NAD+. As in FabV the cofactor in the ternary BpFabI 
complexes is bound through a tight hydrogen bond network involving several solvent 
water molecules and additional hydrophobic contacts. The binding site of BpFabI was 
analyzed in the PT12-complex structure (highest resolution) with the help of Ligplot+ 
(Laskowski and Swindells, 2011).  
 
Figure 52: Cofactor binding of BpFabI 
A) Schematic overview of the interactions of NADH (yellow) within BpFabI; residues providing van der Waals 
interactions are shown in cyan and hydrogen bonds in violet. B)/C)/D) Detailed hydrogen bond interactions 
(dashed lines) of the adenine ring and the ribose with the protein and solvent molecules (B).the 
pyrophosphate (C) and the nicotinamide ring as well as the ribose (D).  
 
An overview of all interactions to the oxidized cofactor NAD+ is illustrated in Figure 52 A 
with the amino acids interacting via hydrogen bonds in violet and the residues involved in 
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hydrophobic interactions in cyan. The adenine ring (N6 and N1) forms hydrogen bonds to 
the side chain of D64 and the backbone nitrogen of V65. Two solvent water molecules are 
bridging the hydrogen bonds from the backbone nitrogen of G13 to both adenine-ribose 
hydroxyl groups and N3 in the adenine ring (Figure 52B). The phosphate next to the 
nicotinamide ring is bound with its oxygen OAZ via a water bridge to the carbonyl oxygen 
of G13, the hydroxyl group of S91 and the backbone nitrogen of A21. A second hydrogen 
bond from this atom is formed with the main chain nitrogen of I20. The hydroxyl group of 
T194 (hidden in the background in Figure 52C) interacts with the oxygen OAY of the same 
phosphate moiety.  The second phosphate, next to the adenine ring, forms a hydrogen 
bond with its oxygen OAB to the backbone nitrogen of A196 and interacts through its 
oxygen OAC via a water bridge with the hydroxyl groups of S16 and S19 and the backbone 
nitrogen of L195 (Figure 52C). At the other end of the cofactor the amide group forms 
hydrogen bonds to the backbone nitrogen and carbonyl moiety of I192. The nicotinamide 
ribose binds with both hydroxyl groups to the catalytic residue K163. Furthermore, 
residues H90, I92 and T143 interact through their carbonyl groups and the hydroxyl group 
(T143) via a water bridge with a hydroxyl moiety (oxygen OBF) of the nicotine-ribose 
(Figure 52D).  
 In general the active site pocket and the catalytic residues as well as the cofactor binding 
site are quite conserved among FabIs from different species and also in BpFabI no major 
variation of the isoenzyme could be observed.  Therefore BpFabI is a suitable target for a 
series of triclosan-derived inhibitors developed for FabI enzymes of different pathogens 
(Lu et al., 2009; Lu and Tonge, 2008, 2010; Luckner et al., 2010; Schiebel et al., 2012) 
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4.3.3 Inhibitor binding and substrate-binding loop dynamics 
To explore the binding pocket of BpFabI for drug design, the enzyme was co-crystallized in 
ternary complexes with the oxidized cofactor NAD+ and a selection of 5 different 
triclosan-based inhibitors with various substituents at different positions of the A- and B-
ring of the inhibitors. Furthermore apart from the well-established diphenyl ether scaffold 
(triclosan, PT02, PT12, and PT144) a 4-pyridone inhibitor was included in the study. The 
slow onset inhibitors triclosan, PT02 and PT404 inhibit BpFabV with low-nanomolar 
affinities and a high residence time (tR) in the enzyme (unpublished data, Weixuan Yu and 
Carla Neckles; and (Liu et al., 2011)), whereas the rapid reversible inhibitors PT12 and the 
4-pyridone inhibitor PT155 exhibit an approximately 100-fold decreased affinity (cf. Table 
23). 
Table 23: Inhibitors of BpFabI (unpublished data, Weixuan Yu and Carla Neckles (Neckles, 2012); and (Liu 
et al., 2011)) 
cLogP determined with ChemBioDraw Ultra 12.0, tR = residence time, N/A = not measurable, ND = not determined. 
Inhibitor Structure 
Molecular 
weight (Da) 
cLogP Ki (nM) 
Slow 
onset? 
tR 
(min) 
triclosan 
 
289.54 5.53 1.57±0.13 yes 83 
PT02 
 
228.29 4.88 1.30±0.01 yes ND 
PT12 
 
315.36 6.21 361.47±58.31 no N/A 
PT404 
 
311.69 5.02 0.837±0.2 yes ND 
PT155 
 
314.42 3.26 
IC50 
0.14 ± 0.02µM 
[BpFabI] = 30 nM 
no N/A 
 
The overall structure of the ternary complexes is very similar apart from the substrate-
binding loop (Figure 53A). According to the hypothesis, that the slow binding behavior of 
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FabI inhibitors originates from the recruitment of the otherwise flexible substrate-binding 
loop, the loop should exhibit the closed, helical conformation for the slow onset inhibitors 
triclosan, PT02 and PT404. The hydrophobic residues A196 and A197 form hydrophobic 
contacts to the B-ring of the inhibitor, shown for triclosan in Figure 53B. This interaction 
was also observed in the presence of the rapid reversible inhibitor PT12, which should, 
according to the hypothesis, be bound in a binding pocket with an open substrate-binding 
loop, as shown for the ternary structure with PT155 (Figure 53A and Figure 54). This is the 
first time that the closed substrate-binding loop is observed in a FabI complex structure 
with a rapid reversible inhibitor.  
 
 
Figure 53: Substrate binding loop in ternary BpFabI complexes 
A) Superposition of apo BpFabI and the ternary complexes with the substrate-binding loop and NAD
+ 
(grey) 
highlighted in all-bonds representation. B) Hydrophobic interactions of A196 and A197 (cyan) to the B ring 
of triclosan (black); NAD
+
 is shown in yellow. 
 
The interactions of the inhibitors with BpFabI in the ternary complexes are illustrated in 
detail in Figure 54 with residues forming hydrogen and halogen bonds in violet and amino 
acids involved in hydrophobic interactions depicted in cyan. Triclosan interacts in its 
known binding mode. The hydroxyl group of the A-ring forms hydrogen bonds to the 
hydroxyl group of the catalytic residue Y156 and the hydroxyl group of the nicotinamide-
ribose (Figure 54A). The chloride substituent at the para position of the B ring forms a 
halogen bond to the carbonyl group of A95. The A-ring interacts in a parallel displaced π-π 
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stacking with the nicotinamide ring of NAD+. The π-stacking interaction is a central 
feature of all inhibitors, described in this study. Triclosan interacts through hydrophobic 
contacts with G93, I100, the active site residue Y146 and A196, A197, I200 and F203 on 
the substrate-binding (Figure 54B). PT02 contains no substituents at the B ring but a 
hydroxyl group and a propyl chain in the meta position at the A-ring. The hydroxyl group 
interacts with the hydroxyl groups of Y156 and the ribose (Figure 54C). Due to the missing 
substituents, the B-ring is more deeply located in the pocket (cf. Figure 55 A) and 
interacts therefore additionally with F94, A95, M159 and K163 in the depth of the pocket 
but loses some of the hydrophobic interactions at the opposite side including I100, A197 
and I200 (Figure 54D). Although the interaction to A196 and I200 on the substrate-
binding loop is lost, PT02 is a slow onset inhibitor. PT12 possesses a hexyl chain at the 
meta position of the A-ring and a nitro group at the para position of the B-ring. The nitro 
group is bridged via a water molecule to the carbonyl oxygen of A95 (Figure 54E). With 
the hexyl chain PT12 recruits additional hydrophobic interactions to P154 in the cavity, 
which is thought to accommodate the growing acyl chain of the substrate. Due to the 
bulky nitro group, the B-ring cannot enter the pocket as deep as PT02 and interacts 
hydrophobically with F94, A95 and I100 and I200 (Figure 54F). The interactions of PT12 to 
BpFabI do not essentially differ from a slow onset inhibitor such as PT02 or triclosan.  
So far, there is no hint in the structure why PT12 causes a closure of the substrate-binding 
loop even though it is a rapid reversal inhibitor. One potential explanation might be a 
contribution to the stabilization of the helical, closed form of the loop by crystal contacts, 
which could be shown to stabilize the loop already in the apo form of BpFabI (cf. Figure 
35).  
 
Figure 54: Inhibitor binding in BpFabI (see following page) 
Binding of (A/B) triclosan, (C/D) PT02, (E/F) PT12, (G/H) PT404 and (I/J) PT155 to BpFabI: Residues 
interacting via hydrogen bonds (blue dashed lines) and halogen bonds (green dashed line, in A) (A/C/E/G/I) 
are shown in violet and via van der Waals contacts in cyan with transparent spheres (B/D/F/H/J). 
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Figure 55: Comparison of inhibitor conformation 
Superposition of inhibitors bound in ternary BpFabI complexes. 
The slow onset inhibitor PT404 also possesses the nitro group at the B-ring but with an 
additional chloride at the ortho position. The A-ring exhibits a fluorine substituent at the 
para position and the alkyl chain is shorter (C2). Remarkably in the model of the PT404 
ternary structure the nitro group shows interactions through hydrogen bonds bridged by 
water molecules with G93, A95 as well as delusively with R97, and not only to A95 as 
observed in the PT12 structure (Figure 54G). The superposition of the bound inhibitors 
(Figure 55B) shows no shift of the B-ring or the nitro group, which could explain the 
differing interactions. Both hydrogen bond mediating water molecules can be found in 
the two structures. The superposition of residues G93, A95 and R97 of the two ternary 
complexes reveals a difference in the interacting side chain of R97 (Figure 56). There is no 
clear electron density for this residue in both structures, indicating that it is flexible. A 
strong interaction would keep the side chain fixed in one conformation. This interaction is 
therefore not evident in both structures. The interaction of PT12 to the second water 
molecule, which would provide the interaction to G93, is with 4.0 Å too far apart for a 
regular hydrogen bond (maximum 3.6 Å). Already the contact of PT404 to the bridging 
water molecule with a distance of 3.4 Å is quite weak. Thus the only convincing hydrogen 
bond interaction of the nitro group in both inhibitors is the contact to A95.  
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Figure 56: Interactions of the p-nitro moieties of PT12 and PT404 with their surrounding environment 
The interactions of the nitro group of PT12 (lilac) and PT404 (light grey) with their surrounding residues are 
shown in all-bonds representation. Water molecules and hydrogen bonds (dashed lines) of the ternary 
complexes are colored according to the color of the inhibitor. The distance highlighted in the red box 
exceeds the usual length of a hydrogen bond and was therefore not considered as an interaction. 
 
The 4-pyridone inhibitor PT155 contains an amino moiety at the para position of the B-
ring and a methyl moiety at the ortho position of ring B and the para position of ring A, 
attached to the pyridone nitrogen. Additionally it contains a hexyl group at the meta 
position of the A ring, as in PT12. Apart from the hydrogen bonds of the keto group of the 
pyridone ring to the hydroxyl groups of Y156 and the nicotinamide-ribose, it forms a 
direct hydrogen bond with its amino group to the carbonyl oxygen of A95 (Figure 54I). 
With the hexyl chain and the ring substituents, PT155 attracts hydrophobic interactions 
from the depth of the pocket (G93, A94, I100, Y146, P154, N155, M159, I200 and F203) 
but does not recruit the interactions with the center of the substrate-binding loop 
(missing: A196 and A197) (Figure 54J). The substrate-binding loop is in an open 
conformation as in the apo structure, which is in agreement with the slow onset 
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hypothesis since PT155 was shown to be a rapid reversible inhibitor (Table 23). 
Superpositions with the inhibitors PT404, triclosan and PT12 show that the position of the 
A-ring is conserved but the B-ring is slightly bent out of the pocket at the bulky methyl 
substituent (Figure 55 C, D and E). Interestingly the rapid reversible inhibitors contain a 
hexyl chain at the meta position of the A-ring whereas the slow onset inhibitors have 
shorter substituents at this position. Previously it could be shown for BpFabI that the 
optimal alkyl chain length at this position is a C2 chain (Liu et al., 2011). The fact that the 
binding of the rapid reversible inhibitor PT12 led to the closure of the substrate-binding 
loop, whereas the 4-pyridone inhibitor PT155 bound in an open pocket in the crystal 
structure, might indicate that PT12 is “closer“ to be a slow onset inhibitor. The crystal 
contact at the substrate binding loop might lower the number of interactions required to 
stabilize the substrate-binding loop in the closed helical form, since it supports the 
stabilized conformation. The inhibitor PT404 exhibited the best inhibition among the 
selection of inhibitors used in this study in in vitro experiments which is in good 
agreement with our structural analysis since it forms the highest number of hydrogen 
bond interactions and hydrophobic contacts in the crystal structures. The ethyl group is 
an optimal alkyl adduct and the fluorine substituent nicely fills a small cavity between 
A197 and F203. Furthermore the chlorine residue at the ortho position of ring B 
constrains the flexibility of the rings to each other, reducing the loss of entropy upon 
binding. A variety of additional inhibitors (diphenyl ethers, 2- and 4-pyridones) are 
available for future structural characterization. These structures may be necessary to 
address open questions which arose from the initially solved structures, such as the 
closure of the substrate-binding loop upon binding of the rapid reversible inhibitor PT12 
or the differing formation of hydrogen bonds of the para-nitro groups of the B ring. 
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4.4  Future perspective: Inhibitors targeting FabI and FabV  
The conserved active site pocket of the described FabV structures compared to FabI 
provides the potential to develop inhibitors that are active against both isoenzymes. 
Although FabV could only be co-crystallized with two 2-pyridone inhibitors (PT172 and 
PT173), the binding mode of these compounds corresponds to the binding of the diphenyl 
ether inhibitors in FabI, and therefore it is probable that also the diphenyl ethers and 4-
pyridone inhibitors bind in a comparable conformation. Furthermore, the opened binding 
pocket of the ternary FabV complex structures can be used for modeling or docking 
approaches to develop new higher affinity inhibitors to the active site pocket of FabV. 
In some cases also inhibitors targeting the unrelated isoenzymes FabI and FabK could be 
developed. Kitagawa et al. combined a 4-pyridone inhibitor, targeting FabI and a 
phenylimidazole inhibitor, targeting FabK to one molecule gaining a dual inhibitor, which 
could be shown to have potent antibacterial activity against S. pneumonia (FabI +FabK) 
(Kitagawa et al., 2007). An even more encouraging example is an aminopyridine inhibitor 
from GSK (GlaxoSmithKline), a precursor of the clinical candidate AFN-1252 (cf. Figure 7), 
which was reported to inhibit FabI and FabK and exhibited potent antibacterial activity 
against S. pneumonia and S. aureus without possessing an additional moiety for the 
inhibition of the flavo-protein FabK (Payne et al., 2002). If it is possible to target the non-
related FabK with the same compound as FabI, it should be feasible to adapt the 
triclosan-based inhibitors to the structurally similar active site pocket of FabV. 
The inhibition of the target enzyme is not the only factor which has to be taken into 
account during antibacterial drug development. Oral bioavailability of the agent and the 
penetration of the bacterial cell wall, especially in case of Gram-negative pathogens, are 
crucial factors. Christopher Lipinski described key properties of drugs which are affecting 
the pharmacokinetics (absorption, distribution, metabolism and excretion) of the agent in 
the human body (Lipinski et al., 2001). The “Lipinski rule of 5” state that a compound 
should not possess more than 5 hydrogen bond donors and 10 acceptors, the molecular 
weight of the compound should not exceed 500 Da and the partition coefficient logP 
(octanol/water) should not be higher than 5, to be an orally bioavailable drug.  
Antibacterial drugs, however, could be shown to be an exception of the rule of five in 
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various properties (cf. Table 24) (O’Shea and Moser, 2008). The authors compared 
physicochemical properties of drugs in general with antibacterials active against Gram-
positives only and antibacterials active against Gram-negatives. Interestingly, 
antibacterial drugs are larger, especially the compounds that are solely active against 
Gram-positives have an average molecular weight of 813 Da compared to 338 Da in 
general drugs. 
 
Table 24: Comparison of averaged physiochemical properties of general drugs and antibacterials with 
different spectrum (data from (O’Shea and Moser, 2008)) 
Compound 
property 
General drugs 
(without 
antibacterials) 
Antibacterials with only 
Gram-positive activity 
Antibacterials 
with 
Gram-negative 
activity 
MW (Da) 338 813 414 
clogP 2.7 2.1 -0.1 
clogD7.4 1.6 -0.2 -2.8 
PSA (polar surface 
area) (Å2) 
70 243 165 
H-donor 1.6 7.1 5.1 
H-acceptor 4.9 16.3 9.4 
 
The size of antibacterials against Gram negatives is also elevated to 414 Da in average. 
With the size consequently also the number of hydrogen bond donors and acceptors is 
increased. Another difference is the reduced hydrophobicity of antibacterial drugs. The 
authors were also taking the clogD7.4 into account, the octanol/water partition coefficient 
at physiological pH, which is on average lower by a value of 2 than the clogP. For agents 
active against Gram-negatives the average clogP and clogD7.4 were -0.1 and -2.8, 
respectively, the compounds are thus very polar compared to general drugs.  A reason for 
the difference in properties is the origin of antibacterial drugs. Most antibacterials are 
large and complex natural products, whereas the general drugs were often discovered 
from chemical small molecule libraries designed for easy synthetic chemistry. The usage 
of chemical libraries instead of natural product libraries in screenings for antibacterials 
probably contributed to the lack of new antibacterials in the last decades. However, not 
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only the spectrum but also the target location of the antibacterial drug is decisive for its 
properties. Most of the drugs against Gram-negatives act outside the inner membrane, 
i.e. in the periplasmatic space. Agents with cytoplasmatic targets (as the FAS-II enzymes) 
have to traverse the inner membrane and therefore have to exhibit some lipophilicity. 
Analysis of the agents active against cytoplasmic targets in Gram-negatives (6 chemical 
classes) revealed molecular masses ranging from 337 to 586 Da, and logP values of -0.5 to 
3.0 (Silver, 2011). Remarkably only 2 (tetracycline and chloramphenicol) of the 6 classes 
which are passively diffusing into the Gram-negative cytoplasm (in E. coli) are natural 
products, the remaining classes are synthetics. 
Concerning the triclosan-based inhibitors in this study, the greatest problem to meet 
these conditions is the high hydrophobicity of the compounds. The clogP value of the 
diphenyl ether inhibitors is around 5. A switch to the pyridone scaffold, which is also less 
susceptible to drug metabolism in phase II conjugation reactions, would lead to the 
reduction of the logP values of the inhibitors. The 4-pyridone inhibitor PT155 exhibits a 
clogP of only 3.26 (cf. Table 23). A possibility to further reduce the hydrophobicity might 
by to introduce additional nitrogen atoms into the ring system or attach polar 
substituents. The long alkyl chain could be shortened to 2-3 carbon atoms, since a longer 
chain length does not improve the affinities in BpFabI (Liu et al., 2011) or YpFabV (Carla 
Neckles, unpublished data (Neckles, 2012). An oxygen atom (ether) could be introduced 
into the alkyl-chain as it can be observed in the clinical trial candidate CG400549 (cf. 
Figure 7). The 4-pyridone scaffold is of particular interest in the approach to generate 
inhibitors against both isoenzymes, FabI and FabV, since the 4-pyridine agents PT156 and 
PT157 exhibited promising IC50 values of <1µM for BpFabI, BpFabV and YpFabV (Carla 
Neckles, unpublished data (Neckles, 2012), compounds synthesized by Dr. Pan Pan).  
The structural data presented in this thesis as well as the kinetic data of our collaborators 
Carla Neckles, Nina Liu and Weixuan Yu (Prof. Peter Tonge’s laboratory, Stony Brook 
University, NY), hold a lot of promise that an effective inhibitor against FabV or maybe 
also against both isoenzymes, FabI and FabV can be derived from the previously 
developed triclosan-based inhibitors. 
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6. Appendix 
6.1 Supplemental Figures 
 
Figure 57: Purification of BpFabV 
A) Chromatogram of a Histrap purification with a step gradient, absorption at 280 nm (black) and 260 nm 
(red), % Elution buffer (blue). B) SDS-PAGE of Histrap purification: (1) Load, (2) Flowthrough, (3) wash out 
unbound sample, (4-10) elution. C) Chromatogram of size exclusion chromatography, absorption at 280 nm 
(black) and 260 nm (red). B) SDS PAGE of size exclusion chromatography: (1) aggregate peak (at approx.120 ml) 
(2-11) main peak. 
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Figure 58: Sequence alignment of YpFabV and EcFabI 
Sequence alignment (ClustalW, (Thompson et al., 1994)) of YpFabV and EcFabI with the cofactor binding 
motif shown in a blue box and with the described interaction partners of the cofactor highlighted in yellow. 
The active site region is highlighted in a yellow box with the catalytic residues marked by red asterisks. The 
substrate-binding loop is marked with a green box and the potential FAD binding site of FabV in a lilac box. 
Secondary structure elements are indicated by arrows and spirals for -strands and -helices, respectively 
and shown above (YpFabV binary) and below (EcFabItcl) the sequence. 310helixes are labeled with η and β-
turns with TT. The conserved residues are highlighted in the blue boxes with the most conserved residues 
colored in white with a red background.  
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Figure 59: Sequence alignment of FabV proteins from different species 
Sequence alignment (ClustalW, (Thompson et al., 1994)) of FabV from different species with the cofactor 
binding motif shown in a blue box and with the described interaction partners of the cofactor highlighted in 
yellow. The active site region is highlighted in a yellow box with the catalytic residues marked by red 
asterisks. The substrate-binding loop is marked with a green box and the potential FAD binding site of FabV 
in a lilac box. The conserved basic residues (potential ACP interaction) are marked with blue asterisks. 
Secondary structure elements are indicated by arrows and spirals for -strands and -helices, respectively 
and shown above (YpFabV binary) the sequence. 310helixes are labeled with η and β-turns with TT. The 
conserved residues are highlighted in blue boxes with the most conserved residues colored in white with a 
red background.  
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6.2  Abbreviations 
Table 25: Abbreviations 
AA Acrylamide 
AA/ BAA Acrylamid/bisacrylamide 
AccABCD Acetyl-CoA Carboxylase 
ACP Acyl-carrier protein 
Amp Ampicillin 
APS Ammonium peroxydisulfate 
ATP Adenosine-5'-triphosphate 
BAA Bisacrylamide 
BESSY Berliner Elektronen-Speicherring Gesellschaft für Synchrotronstrahlung 
CCD Charge-coupled device 
CoA  Coenzyme A 
Coot Crystallographic Object-Oriented Toolkit 
CV Column volume 
Da Dalton 
DMSO Dimethyl sulfoxide (DMSO) 
DNA Deoxyribonucleic acid 
DSSP Define Secondary Structure of Proteins 
DTT Dithiothreitol (DTT) 
EDTA Ethylenediaminetetraacetic acid 
ESRF European Synchrotron Radiation Facility 
FabA β-hydroxydecanoyl-ACP dehydratase/isomerase 
FabB β-ketoacyl-ACP synthase II 
FabD Malonyl-CoA-ACP transacetylase 
FabF β-ketoacyl-ACP synthase I 
FabG β-ketoacyl-ACP reductase 
FabH β-ketoacyl-ACP synthase III 
FabI Enoyl-ACP reductase I 
FabK Enoyl-ACP reductase II 
FabL Enoyl-ACP reductase III 
FabM Trans-2-cis-3-enoyl-ACP isomerase 
FabV Enoyl-ACP reductase IV 
FabZ β-hydroxyacyl-ACP dehydratase 
FAS Fatty acid biosynthesis 
FPLC Fast Protein Liquid Chromatography 
IC50 half maximal inhibitory concentration 
IMAC Immobilized Metal Affinity Chromatography 
IPTG Isopropyl-β-thiogalactoside 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
Ki inhibition constant 
LB Luria broth 
MDR Multi-drug resistant 
MES 2-(N-morpholino)ethanesulfonic acid 
MR Molecular Replacement 
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MWCO Molecular weight cut off 
NADH Nicotinamide adenine dinucleotide 
NCS Noncrystallographic symmetry 
NTA Nitrilotriacetic acid 
OD Optical density 
PAGE Polyacrylamide gel electophoresis 
PDB Protein Data Bank 
PEG Polyethylenglycol 
PEG Polyethylene glycol 
RMSD Root mean square deviation 
SDR Short chain Dehydrogenase/Reductase 
SDS Sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEC Size exclusion chromatography 
SIRAS Single isomorphous replacement with anomalous scattering 
SSM Secondary Structure Matching 
TED Triscarboxymethylethylenediamine 
TEMED Tetramethylethylenediamine 
TEMED Tetramethylethylenediamine 
TLS Translation, Libration, Screw motion 
TCL Triclosan 
Tris Tris(hydroxymethyl)aminomethane 
XDR extensively drug resistant 
XDS X-ray Detector Software 
 
Amino acids 
Table 26: Abbreviations of amino acids 
Alanine A 
Arginine R 
Asparagine N 
Asparatic acid D 
Cysteine C 
Glutamic acid E 
Glutamine Q 
Glycine G 
Histidine H 
Isoleucine I 
Leucine L 
Lysine K 
Methionine M 
Phenylalanine F 
Proline P 
Serine S 
Threonine T 
Tryptophan W 
Tyrosine Y 
Valine V 
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6.4  DNA and amino acid sequences of protein constructs 
The vector part of the constructs is shown in blue and the mutation in the T276S variant 
of YpFabV is marked in yellow and red. 
YpFabV wild type 
DNA sequence: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGCTCGAGA
TGATTATAAAACCACGTGTACGCGGCTTTATCTGTGTGACAGCTCATCCGACGGGCTGTGAAGCCAACGTC
AAGAAGCAGATCGACTACGTCACAACAGAAGGCCCAATCGCTAATGGTCCTAAAAGAGTATTAGTGATTG
GTGCGTCAACTGGATACGGGTTAGCAGCCCGGATCACAGCAGCATTTGGTTGTGGCGCCGATACGCTGGG
CGTTTTCTTTGAACGCCCCGGTGAAGAAGGCAAACCCGGAACCTCCGGTTGGTACAATAGCGCGGCTTTCC
ACAAATTTGCGGCACAGAAAGGCTTGTACGCAAAAAGCATCAACGGCGATGCGTTCTCTGATGAGATCAA
ACAACTGACTATCGATGCTATCAAGCAAGATCTGGGTCAAGTTGATCAGGTTATCTATAGCCTTGCTTCACC
ACGACGCACCCATCCGAAAACGGGCGAAGTGTTTAACTCGGCACTGAAACCTATCGGTAATGCTGTTAATT
TGCGTGGTCTGGACACCGATAAAGAAGTTATCAAGGAATCGGTCTTGCAACCGGCAACACAAAGCGAGAT
CGACAGTACAGTGGCCGTCATGGGTGGCGAAGACTGGCAGATGTGGATTGACGCTCTGTTGGACGCTGGC
GTACTGGCCGAAGGGGCACAAACGACAGCATTCACCTATCTAGGCGAAAAAATTACTCACGATATTTACTG
GAACGGTTCCATTGGCGCAGCCAAAAAAGATCTGGACCAGAAGGTGCTGGCTATCCGCGAGAGCCTGGCG
GCTCACGGCGGTGGCGATGCTCGCGTATCCGTATTAAAAGCAGTCGTGACCCAAGCCAGCTCTGCCATTCC
AATGATGCCTCTGTATTTATCATTGCTATTTAAAGTGATGAAAGAGAAAGGCACTCACGAAGGCTGCATCG
AGCAGGTCTATTCCCTGTATAAAGACAGCCTGTGCGGCGATTCACCGCATATGGACCAAGAAGGTCGTCTG
CGGGCTGATTACAAAGAATTGGATCCTGAAGTCCAAAATCAGGTTCAGCAGTTGTGGGATCAGGTTACCAA
CGACAACATTTATCAGCTAACTGATTTCGTTGGTTATAAATCAGAGTTCCTAAATCTGTTCGGTTTCGGTATT
GACGGTGTGGATTATGATGCAGACGTTAACCCTGATGTAAAAATCCCTAACTTGATTCAGGGTTAA 
Amino acid sequence: 
MGSSHHHHHHSSGLVPRGSHMLEMIIKPRVRGFICVTAHPTGCEANVKKQIDYVTTEGPIANGPKRVLVIGAST
GYGLAARITAAFGCGADTLGVFFERPGEEGKPGTSGWYNSAAFHKFAAQKGLYAKSINGDAFSDEIKQLTIDAIK
QDLGQVDQVIYSLASPRRTHPKTGEVFNSALKPIGNAVNLRGLDTDKEVIKESVLQPATQSEIDSTVAVMGGED
WQMWIDALLDAGVLAEGAQTTAFTYLGEKITHDIYWNGSIGAAKKDLDQKVLAIRESLAAHGGGDARVSVLKA
VVTQASSAIPMMPLYLSLLFKVMKEKGTHEGCIEQVYSLYKDSLCGDSPHMDQEGRLRADYKELDPEVQNQVQ
QLWDQVTNDNIYQLTDFVGYKSEFLNLFGFGIDGVDYDADVNPDVKIPNLIQG 
 
YpFabV T265S 
DNA sequence: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGCTCGAGA
TGATTATAAAACCACGTGTACGCGGCTTTATCTGTGTGACAGCTCATCCGACGGGCTGTGAAGCCAACGTC
AAGAAGCAGATCGACTACGTCACAACAGAAGGCCCAATCGCTAATGGTCCTAAAAGAGTATTAGTGATTG
GTGCGTCAACTGGATACGGGTTAGCAGCCCGGATCACAGCAGCATTTGGTTGTGGCGCCGATACGCTGGG
CGTTTTCTTTGAACGCCCCGGTGAAGAAGGCAAACCCGGAACCTCCGGTTGGTACAATAGCGCGGCTTTCC
ACAAATTTGCGGCACAGAAAGGCTTGTACGCAAAAAGCATCAACGGCGATGCGTTCTCTGATGAGATCAA
ACAACTGACTATCGATGCTATCAAGCAAGATCTGGGTCAAGTTGATCAGGTTATCTATAGCCTTGCTTCACC
ACGACGCACCCATCCGAAAACGGGCGAAGTGTTTAACTCGGCACTGAAACCTATCGGTAATGCTGTTAATT
TGCGTGGTCTGGACACCGATAAAGAAGTTATCAAGGAATCGGTCTTGCAACCGGCAACACAAAGCGAGAT
CGACAGTACAGTGGCCGTCATGGGTGGCGAAGACTGGCAGATGTGGATTGACGCTCTGTTGGACGCTGGC
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GTACTGGCCGAAGGGGCACAAACGACAGCATTCACCTATCTAGGCGAAAAAATTACTCACGATATTTACTG
GAACGGTTCCATTGGCGCAGCCAAAAAAGATCTGGACCAGAAGGTGCTGGCTATCCGCGAGAGCCTGGCG
GCTCACGGCGGTGGCGATGCTCGCGTATCCGTATTAAAAGCAGTCGTGTCCCAAGCCAGCTCTGCCATTCC
AATGATGCCTCTGTATTTATCATTGCTATTTAAAGTGATGAAAGAGAAAGGCACTCACGAAGGCTGCATCG
AGCAGGTCTATTCCCTGTATAAAGACAGCCTGTGCGGCGATTCACCGCATATGGACCAAGAAGGTCGTCTG
CGGGCTGATTACAAAGAATTGGATCCTGAAGTCCAAAATCAGGTTCAGCAGTTGTGGGATCAGGTTACCAA
CGACAACATTTATCAGCTAACTGATTTCGTTGGTTATAAATCAGAGTTCCTAAATCTGTTCGGTTTCGGTATT
GACGGTGTGGATTATGATGCAGACGTTAACCCTGATGTAAAAATCCCTAACTTGATTCAGGGTTAA 
Amino acid sequence: 
MGSSHHHHHHSSGLVPRGSHMLEMIIKPRVRGFICVTAHPTGCEANVKKQIDYVTTEGPIANGPKRVLVIGAST
GYGLAARITAAFGCGADTLGVFFERPGEEGKPGTSGWYNSAAFHKFAAQKGLYAKSINGDAFSDEIKQLTIDAIK
QDLGQVDQVIYSLASPRRTHPKTGEVFNSALKPIGNAVNLRGLDTDKEVIKESVLQPATQSEIDSTVAVMGGED
WQMWIDALLDAGVLAEGAQTTAFTYLGEKITHDIYWNGSIGAAKKDLDQKVLAIRESLAAHGGGDARVSVLKA
VVSQASSAIPMMPLYLSLLFKVMKEKGTHEGCIEQVYSLYKDSLCGDSPHMDQEGRLRADYKELDPEVQNQVQ
QLWDQVTNDNIYQLTDFVGYKSEFLNLFGFGIDGVDYDADVNPDVKIPNLIQG 
 
BpFabV 
DNA sequence: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGCTCGAGA
TGATCATCAAACCGCGCGTACGCGGCTTCATCTGCGTCACCACCCACCCCGCCGGCTGCGCGGCGAGCGTT
CGCGAGCAGATCGCGTACGTCGCCCGCCGCGGCCCGATCGAGCGCGGCCCGAAGAAGGTGCTCGTGATC
GGCGCGTCGACGGGCTACGGGCTCGCCGCGCGCATCGCCGCCGCGTTCGGCGCGGGCGCGGCGACGCTC
GGGGTGTTCTTCGAGCGCGCGCCGGCGGACGCGAAGCCCGGCACGGCCGGCTGGTACAACAGCGCGGCG
TTCCACGACGAAGCGGCCGCGCGCGGCCTCCAGGCGACGAGCGTCAACGGCGACGCGTTCTCCGACGAGA
TCAAGCACAAGACGATCGATGCGATCCGGCGCGATCTCGGGCAGGTGGACCTTGTCGTCTACAGCGTCGC
CGCGCCGCGCAGGACGCATCCGAAAACGGGCGTCACGCATCAGTCGACGTTGAAGCCGATCGGCCACGCG
GTGCGGCTGCGCGGCATCGATACGGACAACGAGGCGATCAAGGAAACGCTGCTGCAGCCGGCCACGCCC
GACGAGATCGCGGACACGGTCGCCGTGATGGGCGGCGAGGACTGGCGCATGTGGATCGACGCGCTCGAT
GCGGCGGGAGTGCTTGCCGACGGCGCGAAGACGACCGCGTTCACGTATCTGGGCGAGCAGGTCACGCAC
GACATCTACTGGAACGGCTCGATCGGCGAAGCGAAGAAGGATCTCGACCGCACCGTGCTCGCGCTGCGCG
GCAAGCTCGCCGCGCGCGGCGGCGACGCGCGCGTCTCGGTGCTGAAGGCGGTCGTCACGCAGGCGAGCT
CCGCGATCCCGATGATGCCGCTCTACCTGTCGCTGCTCTTCAAGGTGATGAAGGCGCGCGGCACGCATGAA
GGCTGCATCGAGCAGGTCGACGGCCTGTTGCGCGACAGCCTGTACGGCGCGCAGCCGCACGTCGACGCCG
AAGGCCGGCTGCGCGCGGACCGCCTCGAGCTCGATCCGGCCGTGCAGGCGCGCGTGCTCGAGCTGTGGG
ACCAGGTGACGGACGACAATCTGTATACGCTCACCGATTTCGCCGGCTACAAGGCCGAATTCCTGCGCCTG
TTCGGCTTCGGGATCGACGGCGTCGATTACGATGCGCCTGTCGAGCCGAACGTACGGATTCCGAATCTGAT
CGAATGA 
 
Amino acid sequence: 
MGSSHHHHHHSSGLVPRGSHMIIKPRVRGFICVTTHPAGCAASVREQIAYVARRGPIERGPKKVLVIGASTGYG
LAARIAAAFGAGAATLGVFFERAPADAKPGTAGWYNSAAFHDEAAARGLQATSVNGDAFSDEIKHKTIDAIRR
DLGQVDLVVYSVAAPRRTHPKTGVTHQSTLKPIGHAVRLRGIDTDNEAIKETLLQPATPDEIADTVAVMGGED
WRMWIDALDAAGVLADGAKTTAFTYLGEQVTHDIYWNGSIGEAKKDLDRTVLALRGKLAARGGDARVSVLKA
VVTQASSAIPMMPLYLSLLFKVMKARGTHEGCIEQVDGLLRDSLYGAQPHVDAEGRLRADRLELDPAVQARVL
ELWDQVTDDNLYTLTDFAGYKAEFLRLFGFGIDGVDYDAPVEPNVRIPNLIE 
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PaFabV 
DNA sequence: 
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGCTCGAGA
TGATCATCAAACCGCGCGTGCGTGGCTTCATCTGCGTCACTACCCATCCGGCAGGCTGCGAGGCCAACGTC
AAGCAACAGATCGACTACGTCGAGGCCAAGGGCCCCGTCGTCAACGGACCGAAGAAGGTCCTGGTCATCG
GTTCCTCCACCGGCTATGGCCTGGCTGCCCGCATCACCGCCGCGTTCGGTTCCGGCGCCGATACCCTCGGG
GTGTTCTTCGAGCGTCCGGGCAGCGAGAGCAAGCCGGGCACCGCCGGCTGGTACAACTCGGCGGCCTTCG
AGAAGTTCGCCCACGAGAAAGGCCTGTATGCCCGCAGCATCAATGGCGACGCTTTCTCCGACGAGGTGAA
GCGGCTGACCATCGAGACCATCAAGCGCGATCTCGGCAAGGTCGACCTGGTGGTCTACAGCCTGGCCGCG
CCGCGCCGTACCCATCCGAAGAGCGGCGAAGTGTTCTCCTCGACCCTCAAGCCGATCGGCAAGTCGGTCA
GCTTCCGTGGCCTGGACACCGACAAGGAAGTGATCAAGGACGTGGTCCTGGAGGCGGCCAGCGACCAGG
AGGTCGCCGATACCGTTGCGGTGATGGGCGGCGAGGACTGGCAGATGTGGATCGACGCGCTGCTGGAGG
CCGACGTGCTGGCCGACGGCGCGAAGACCACCGCGTTCACCTACCTGGGCGAGAAGATCACCCACGACAT
CTACTGGAACGGTTCCATCGGCGCAGCCAAGAAGGATCTCGACCAGAAGGTCCTCGGTATCCGCGACAAG
CTCGCCCCGCTGGGCGGCGACGCGCGCGTCTCGGTGCTCAAGGCGGTGGTGACCCAGGCCAGCTCGGCG
ATCCCGATGATGCCGCTGTACCTGTCGCTGCTGTTCAAGGTGATGAAGGAGCAGGGTACCCACGAAGGTT
GCATCGAGCAGGTCGACGGCCTGTACCGGGAGAGCCTGTACGGCGCCGAGCCGCGCCTCGACGAGGAAG
GCCGCCTGCGTGCCGACTACAAGGAACTGCAGCCGGAAGTGCAGTCCCGTGTCGAGGAGCTGTGGGACA
AGGTAACCAACGAGAACCTTTACGAATTGACCGACTTCGCCGGCTACAAGAGCGAGTTCCTCAACCTGTTC
GGTTTCGAGGTCGCTGGGGTCGACTACGAGCAGGACGTCAACCCGGACGTGCAGATCGCCAACCTGATCC
AGGCCTGA 
Amino acid sequence: 
MGSSHHHHHHSSGLVPRGSHMIIKPRVRGFICVTTHPAGCEANVKQQIDYVEAKGPVVNGPKKVLVIGSSTGY
GLAARITAAFGSGADTLGVFFERPGSESKPGTAGWYNSAAFEKFAHEKGLYARSINGDAFSDEVKRLTIETIKRDL
GKVDLVVYSLAAPRRTHPKSGEVFSSTLKPIGKSVSFRGLDTDKEVIKDVVLEAASDQEVADTVAVMGGEDWQ
MWIDALLEADVLADGAKTTAFTYLGEKITHDIYWNGSIGAAKKDLDQKVLGIRDKLAPLGGDARVSVLKAVVTQ
ASSAIPMMPLYLSLLFKVMKEQGTHEGCIEQVDGLYRESLYGAEPRLDEEGRLRADYKELQPEVQSRVEELWDK
VTNENLYELTDFAGYKSEFLNLFGFEVAGVDYEQDVNPDVQIANLIQA 
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BpFabI 
 
DNA sequence: 
 
ATGGGCTTTCTCGACGGTAAACGTATTCTGCTGACGGGCCTCTTGTCGAACCGTTCGATCGCTTACGGCATC
GCCAAGGCGTGCAAGCGCGAAGGCGCCGAGCTGGCGTTCACCTACGTCGGCGATCGCTTCAAGGATCGCA
TCACCGAGTTCGCGGCCGAGTTCGGCAGCGAACTCGTGTTCCCGTGCGATGTCGCCGACGATGCGCAGAT
CGATGCGCTCTTCGCGTCGCTGAAGACGCACTGGGATTCGCTCGACGGCCTCGTCCACTCGATCGGCTTCG
CGCCGCGCGAGGCGATCGCGGGCGACTTCCTCGACGGCCTCACGCGCGAGAACTTCCGCATCGCGCACGA
CATCTCCGCATACAGCTTCCCCGCGCTCGCGAAGGCGGCGCTGCCGATGCTGTCGGACGATGCGTCGCTGC
TCACGCTGTCGTATCTCGGCGCGGAGCGGGCGATCCCGAACTACAACACGATGGGCCTCGCGAAGGCGGC
GCTCGAGGCGAGCGTGCGCTATCTCGCGGTGTCGCTCGGCGCGAAGGGCGTGCGCGTGAACGCGATCTC
GGCGGGCCCGATCAAGACGCTCGCGGCAAGCGGCATCAAGAGCTTCGGCAAGATCCTCGATTTCGTCGAG
AGCAACTCGCCGCTCAAGCGCAACGTGACGATCGAGCAGGTCGGCAACGCGGGCGCGTTCCTGCTGTCGG
ACCTCGCGAGCGGCGTCACGGCCGAAGTCATGCACGTCGACTCGGGCTTCAACGCGGTGGTGGGCGGGA
TGGCCGGCCTCGAGGAATAAAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA 
 
Amino acid sequence: 
 
MGFLDGKRILLTGLLSNRSIAYGIAKACKREGAELAFTYVGDRFKDRITEFAAEFGSELVFPCDVADDAQIDALFASLKTHWDS
LDGLVHSIGFAPREAIAGDFLDGLTRENFRIAHDISAYSFPALAKAALPMLSDDASLLTLSYLGAERAIPNYNTMGLAKAALEA
SVRYLAVSLGAKGVRVNAISAGPIKTLAASGIKSFGKILDFVESNSPLKRNVTIEQVGNAGAFLLSDLASGVTAEVMHVDSGF
NAVVGGMAGLEEKLAAALEHHHHHH 
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6.5 Thermofluor Screen 
Table 27: Thermofluor screen 
A1  100mM citrate pH 4.5 E1  100mM Cacodylate pH 6.0 
A2  100mM Bis-Tris pH 7.0 E2  100mM Bis-Tris propane pH 7 
A3  100mM Imidazole pH6.5 E3  100mM MOPS pH 7.0 
A4  100mM Hepes pH 8.0 E4  100mM BICINE pH 9.0 
A5  100mM Tris pH 8.5 E5  100mM Glycylglycine pH 8.5 
A6 
 
Reference E6  Reference 
B1  100mM acetate pH 4.6 F1  100mM Cacodylate pH 6.5 
B2  100mM ADA pH 6.5 F2  100mM PIPES pH 6.5 
B3  100mM Imidazole pH 8.0 F3  100mM MOPS pH 7.5 
B4  100mM HEPES pH8.5 F4  100mM Tris pH 7.0 
B5  100mM Tris pH 9 F5  100mM CHES pH 9.0 
B6   Reference F6   Water 
C1  100mM MES pH 5.5 G1  100mM Bis-Tris pH 5.5 
C2  100mM ADA pH 7.0 G2  100mM PIPES pH 7.0 
C3  100mM Na/K PO4 pH 6.8 G3  100mM HEPES pH 7.0 
C4  100mM BICINE pH 8.0 G4  100mM Tris pH 7.5 
C5  100mM TAPS pH 8.0 G5  100mM CHES pH 9.5 
C6   Reference G6   Water 
D1  100mM MES pH 6.5 H1  100mM Bis-Tris pH 6.5 
D2  100mM Bis-Tris propane pH 6 H2  100mM PIPES pH 7.5 
D3  100mM Na/K-PO4 pH 7.55 H3  100mM HEPES pH 7.5 
D4  100mM BICINE pH 8.5 H4  100mM Tris pH 8.0 
D5  100mM TAPS pH 9.0 H5  100mM CAPS pH 9.8 
D6   Reference H6   Water 
 
6.6 Crystallization screens 
Table 28: Salt Screen I 
A1 2,2 M Sodium formate 0,1 M Imidazole pH 8.0 
A2 2,5 M Sodium formate 0,1 M Imidazole pH 8.0 
A3 2,8 M Sodium formate 0,1 M Imidazole pH 8.0 
A4 3 M Sodium formate 0,1 M Imidazole pH 8.0 
A5 3,3 M Sodium formate 0,1 M Imidazole pH 8.0 
A6 2,2 M Sodium formate 0,1 M Sodium acetate pH 4.6 
A7 2,5 M Sodium formate 0,1 M Sodium acetate pH 4.6 
A8 2,8 M Sodium formate 0,1 M Sodium acetate pH 4.6 
A9 3 M Sodium formate 0,1 M Sodium acetate pH 4.6 
A10 3,3 M Sodium formate 0,1 M Sodium acetate pH 4.6 
A11 2,2 M Potassium formate 0,1 M Imidazole pH 8.0 
A12 2,5 M Potassium formate 0,1 M Imidazole pH 8.0 
B1 2,8 M Potassium formate 0,1 M Imidazole pH 8.0 
B2 3 M Potassium formate 0,1 M Imidazole pH 8.0 
B3 3,15 M Potassium formate 0,1 M Imidazole pH 8.0 
Appendix 
 
147 
 
B4 2,2 M Potassium formate 0,1 M Sodium acetate pH 4.6 
B5 2,5 M Potassium formate 0,1 M Sodium acetate pH 4.6 
B6 2,8 M Potassium formate 0,1 M Sodium acetate pH 4.6 
B7 3 M Potassium formate 0,1 M Sodium acetate pH 4.6 
B8 3,15 M Potassium formate 0,1 M Sodium acetate pH 4.6 
B9 3 M Sodium formate 0,1 M Glycyl-glycine pH 8.5 
B10 3 M Potassium formate 0,1 M Glycyl-glycine pH 8.5 
B11 3 M Sodium formate 0,1 M Citric acid pH 4.0 
B12 3 M Potassium formate 0,1 M Citric acid pH 4.0 
C1 2 M Ammonium sulfate 0,1 M TRIS pH 8.5 
C2 1,8 M Ammonium sulfate 0,1 M TRIS pH 8.5 
C3 1,6 M Ammonium sulfate 0,1 M TRIS pH 8.5 
C4 2,2 M Ammonium sulfate 0,1 M TRIS pH 8.5 
C5 2,5 M Ammonium sulfate 0,1 M TRIS pH 8.5 
C6 3 M Ammonium sulfate 0,1 M TRIS pH 8.5 
C7 2 M Ammonium sulfate 0,1 M Imidazole pH 8.0 
C8 2 M Ammonium sulfate 0,1 M Sodium acetate pH 4.6 
C9 2 M Ammonium sulfate 0,1 M BICINE pH 9.0 
C10 2 M Ammonium sulfate 0,1 M Glycyl-glycine pH 8.5 
C11 2 M Sodium nitrate 0,1 M Sodium acetate pH 4.6 
C12 1,8 M Sodium nitrate 0,1 M Sodium acetate pH 4.6 
D1 1,6 M Sodium nitrate 0,1 M Sodium acetate pH 4.6 
D2 2,2 M Sodium nitrate 0,1 M Sodium acetate pH 4.6 
D3 2,5 M Sodium nitrate 0,1 M Sodium acetate pH 4.6 
D4 3 M Sodium nitrate 0,1 M Sodium acetate pH 4.6 
D5 2 M Sodium nitrate 0,1 M Imidazole pH 8.0 
D6 2 M Sodium nitrate 0,1 M TRIS pH 8.5 
D7 2 M Sodium nitrate 0,1 M BICINE pH 9.0 
D8 2 M Sodium nitrate 0,1 M Glycyl-glycine pH 8.5 
D9 1 M Sodium malonate 0,1 M Sodium acetate pH 4.6 
D10 1,2 M Sodium malonate 0,1 M Sodium acetate pH 4.6 
D11 1,5 M Sodium malonate 0,1 M Sodium acetate pH 4.6 
D12 1,7 M Sodium malonate 0,1 M Sodium acetate pH 4.6 
E1 1,4 M Sodium malonate 0,1 M Imidazole pH 8.0 
E2 1,4 M Sodium malonate 0,1 M Sodium citrate pH 5.6 
E3 1,4 M Sodium malonate 0,1 M TRIS pH 8.5 
E4 1 M Sodium malonate pH 6.0 0,1 M Sodium citrate pH 5.6 
E5 1,2 M Sodium malonate pH 6.0 0,1 M Sodium citrate pH 5.6 
E6 1,5 M Sodium malonate pH 6.0 0,1 M Sodium citrate pH 5.6 
E7 1,7 M Sodium malonate pH 6.0 0,1 M Sodium citrate pH 5.6 
E8 1,4 M Sodium malonate pH 6.0 0,1 M Imidazole pH 8.0 
E9 1,4 M Sodium malonate pH 6.0 0,1 M TRIS pH 8.5 
E10 1 M Na/K tartrate 
   
E11 1,3 M Na/K tartrate 
   
E12 1,5 M Na/K tartrate 
   
F1 1,7 M Na/K tartrate 
   
F2 2 M Na/K tartrate 
   
F3 1 M Na/K tartrate 0,1 M TRIS pH 8.5 
F4 1,3 M Na/K tartrate 0,1 M TRIS pH 8.5 
F5 1,5 M Na/K tartrate 0,1 M TRIS pH 8.5 
F6 1,7 M Na/K tartrate 0,1 M TRIS pH 8.5 
F7 1 M Ammonium nitrate 0,1 M TRIS pH 8.5 
F8 2 M Ammonium nitrate 0,1 M TRIS pH 8.5 
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F9 2,5 M Ammonium nitrate 0,1 M TRIS pH 8.5 
F10 4 M Ammonium nitrate 0,1 M TRIS pH 8.5 
F11 2,5 M Ammonium nitrate 0,1 M Sodium acetate pH 4.6 
F12 1 M Potassium fluoride 
   
G1 1 M Potassium iodide 0,1 M TRIS pH 8.5 
G2 1,2 M Potassium iodide 0,1 M TRIS pH 8.5 
G3 1,5 M Potassium iodide 0,1 M TRIS pH 8.5 
G4 1 M Potassium phosphate dibasic 0,1 M Sodium acetate pH 4.6 
G5 1,5 M Potassium phosphate dibasic 0,1 M Sodium acetate pH 4.6 
G6 2 M Potassium phosphate dibasic 0,1 M Sodium acetate pH 4.6 
G7 2,5 M Potassium phosphate dibasic 0,1 M Sodium acetate pH 4.6 
G8 3 M Potassium phosphate dibasic 0,1 M Sodium acetate pH 4.6 
G9 1 M Potassium phosphate dibasic 0,1 M TRIS pH 8.5 
G10 1,5 M Potassium phosphate dibasic 0,1 M TRIS pH 8.5 
G11 2 M Potassium phosphate dibasic 0,1 M TRIS pH 8.5 
G12 2,5 M Potassium phosphate dibasic 0,1 M TRIS pH 8.5 
H1 3 M Potassium phosphate dibasic 0,1 M TRIS pH 8.5 
H2 1 M Sodium tartrate 0,1 M Imidazole pH 8.0 
H3 1,2 M Sodium tartrate 0,1 M Imidazole pH 8.0 
H4 1,5 M Sodium tartrate 0,1 M Imidazole pH 8.0 
H5 1,8 M Sodium tartrate 0,1 M Imidazole pH 8.0 
H6 2 M Sodium tartrate 
   
H7 0,5 M Sodium thiocyanate 
   
H8 0,7 M Sodium thiocyanate 
   
H9 1 M Sodium thiocyanate 
   
H10 0,7 M Sodium thiocyanate 0,1 M Sodium acetate pH 4.6 
H11 0,8 M Sodium thiocyanate 0,1 M Sodium acetate pH 4.6 
H12 0,9 M Sodium thiocyanate 0,1 M Sodium acetate pH 4.6 
 
Table 29: PEG pH 6.5 Screen 
A1 0,1 M MES pH 6.5 23 % PEG 2000 MME 
   
A2 0,1 M MES pH 6.5 28 % PEG 2000 MME 
   
A3 0,1 M MES pH 6.5 33 % PEG 2000 MME 
   
A4 0,1 M MES pH 6.5 20 % PEG 3000 
   
A5 0,1 M MES pH 6.5 25 % PEG 3000 
   
A6 0,1 M MES pH 6.5 30 % PEG 3000 
   
A7 0,1 M MES pH 6.5 20 % PEG 4000 
   
A8 0,1 M MES pH 6.5 25 % PEG 4000 
   
A9 0,1 M MES pH 6.5 30 % PEG 4000 
   
A10 0,1 M MES pH 6.5 20 % PEG 6000 
   
A11 0,1 M MES pH 6.5 25 % PEG 6000 
   
A12 0,1 M MES pH 6.5 30 % PEG 6000 
   
B1 0,1 M MES pH 6.5 20 % PEG 200 
   
B2 0,1 M MES pH 6.5 24 % PEG 200 
   
B3 0,1 M MES pH 6.5 28 % PEG 200 
   
B4 0,1 M MES pH 6.5 30 % PEG 200 
   
B5 0,1 M MES pH 6.5 20 % PEG 350 MME 
   
B6 0,1 M MES pH 6.5 25 % PEG 350 MME 
   
B7 0,1 M MES pH 6.5 30 % PEG 350 MME 
   
B8 0,1 M MES pH 6.5 20 % PEG 400 
   
B9 0,1 M MES pH 6.5 25 % PEG 400 
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B10 0,1 M MES pH 6.5 30 % PEG 400 
   
B11 0,1 M MES pH 6.5 20 % PEG 550 MME 
   
B12 0,1 M MES pH 6.5 25 % PEG 550 MME 
   
C1 0,1 M MES pH 6.5 30 % PEG 550 MME 
   
C2 0,1 M MES pH 6.5 20 % PEG 1000 
   
C3 0,1 M MES pH 6.5 25 % PEG 1000 
   
C4 0,1 M MES pH 6.5 30 % PEG 1000 
   
C5 0,1 M MES pH 6.5 20 % PEG 1500 
   
C6 0,1 M MES pH 6.5 25 % PEG 1500 
   
C7 0,1 M MES pH 6.5 30 % PEG 1500 
   
C8 0,1 M MES pH 6.5 20 % PEG 5000 MME 
   
C9 0,1 M MES pH 6.5 25 % PEG 5000 MME 
   
C10 0,1 M MES pH 6.5 30 % PEG 5000 MME 
   
C11 0,1 M MES pH 6.5 23 % PEG 2000 MME 0,05 M Calcium chloride 
C12 0,1 M MES pH 6.5 28 % PEG 2000 MME 0,05 M Calcium chloride 
D1 0,1 M MES pH 6.5 33 % PEG 2000 MME 0,05 M Calcium chloride 
D2 0,1 M MES pH 6.5 20 % PEG 3000 0,05 M Calcium chloride 
D3 0,1 M MES pH 6.5 25 % PEG 3000 0,05 M Calcium chloride 
D4 0,1 M MES pH 6.5 30 % PEG 3000 0,05 M Calcium chloride 
D5 0,1 M MES pH 6.5 20 % PEG 550 MME 0,05 M Calcium chloride 
D6 0,1 M MES pH 6.5 25 % PEG 550 MME 0,05 M Calcium chloride 
D7 0,1 M MES pH 6.5 30 % PEG 550 MME 0,05 M Calcium chloride 
D8 0,1 M MES pH 6.4 28 % PEG 2000 MME 
   
D9 0,1 M MES pH 6.4 33 % PEG 2000 MME 
   
D10 0,1 M MES pH 6.4 25 % PEG 3000 
   
D11 0,1 M MES pH 6.4 30 % PEG 3000 
   
D12 0,1 M MES pH 6.4 25 % PEG 550 MME 0,05 M Calcium chloride 
E1 0,1 M MES pH 6.4 30 % PEG 550 MME 0,05 M Calcium chloride 
E2 0,1 M MES pH 6.3 28 % PEG 2000 MME 
   
E3 0,1 M MES pH 6.3 33 % PEG 2000 MME 
   
E4 0,1 M MES pH 6.3 25 % PEG 3000 
   
E5 0,1 M MES pH 6.3 30 % PEG 3000 
   
E6 0,1 M MES pH 6.3 25 % PEG 550 MME 0,05 M Calcium chloride 
E7 0,1 M MES pH 6.3 30 % PEG 550 MME 0,05 M Calcium chloride 
E8 0,1 M MES pH 6.6 28 % PEG 2000 MME 
   
E9 0,1 M MES pH 6.6 33 % PEG 2000 MME 
   
E10 0,1 M MES pH 6.6 25 % PEG 3000 
   
E11 0,1 M MES pH 6.6 30 % PEG 3000 
   
E12 0,1 M MES pH 6.6 25 % PEG 550 MME 0,05 M Calcium chloride 
F1 0,1 M MES pH 6.6 30 % PEG 550 MME 0,05 M Calcium chloride 
F2 0,1 M MES pH 6.7 30 % PEG 2000 MME 0,04 M Calcium chloride 
F3 0,1 M MES pH 6.7 30 % PEG 3000 0,04 M Calcium chloride 
F4 0,1 M MES pH 6.7 30 % PEG 550 MME 0,04 M Calcium chloride 
F5 0,1 M MES pH 6.7 30 % PEG 2000 MME 0,03 M Calcium chloride 
F6 0,1 M MES pH 6.7 30 % PEG 3000 0,03 M Calcium chloride 
F7 0,1 M MES pH 6.7 30 % PEG 550 MME 0,03 M Calcium chloride 
F8 0,1 M MES pH 6.5 30 % PEG 2000 MME 0,02 M Calcium chloride 
F9 0,1 M MES pH 6.5 30 % PEG 3000 0,02 M Calcium chloride 
F10 0,1 M MES pH 6.5 30 % PEG 550 MME 0,02 M Calcium chloride 
F11 0,1 M MES pH 6.5 30 % PEG 2000 MME 0,01 M Calcium chloride 
F12 0,1 M MES pH 6.5 30 % PEG 3000 0,01 M Calcium chloride 
G1 0,1 M MES pH 6.5 30 % PEG 550 MME 0,01 M Calcium chloride 
G2 0,1 M MES pH 6.5 30 % PEG 2000 MME 0,06 M Calcium chloride 
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G3 0,1 M MES pH 6.5 30 % PEG 3000 0,06 M Calcium chloride 
G4 0,1 M MES pH 6.5 30 % PEG 550 MME 0,06 M Calcium chloride 
G5 0,1 M MES pH 6.5 25 % PEG 4000 0,05 M Calcium chloride 
G6 0,1 M MES pH 6.5 30 % PEG 4000 0,05 M Calcium chloride 
G7 0,1 M MES pH 6.5 25 % PEG 6000 0,05 M Calcium chloride 
G8 0,1 M MES pH 6.5 30 % PEG 6000 0,05 M Calcium chloride 
G9 0,1 M MES pH 6.5 20 % PEG 200 0,05 M Calcium chloride 
G10 0,1 M MES pH 6.5 24 % PEG 200 0,05 M Calcium chloride 
G11 0,1 M MES pH 6.5 20 % PEG 350 MME 0,05 M Calcium chloride 
G12 0,1 M MES pH 6.5 25 % PEG 350 MME 0,05 M Calcium chloride 
H1 0,1 M MES pH 6.5 20 % PEG 400 0,05 M Calcium chloride 
H2 0,1 M MES pH 6.5 25 % PEG 400 0,05 M Calcium chloride 
H3 0,1 M MES pH 6.5 25 % PEG 1000 0,05 M Calcium chloride 
H4 0,1 M MES pH 6.5 30 % PEG 1000 0,05 M Calcium chloride 
H5 0,1 M MES pH 6.5 25 % PEG 1500 0,05 M Calcium chloride 
H6 0,1 M MES pH 6.5 30 % PEG 1500 0,05 M Calcium chloride 
H7 0,1 M MES pH 6.5 20 % PEG 5000 MME 0,05 M Calcium chloride 
H8 0,1 M MES pH 6.5 25 % PEG 5000 MME 0,05 M Calcium chloride 
H9 0,1 M MES pH 6.5 30 % PEG 5000 MME 0,05 M Calcium chloride 
H10 0,1 M MES pH 6.5 30 % PEG 2000 MME 0,05 M magnesium chloride low 
H11 0,1 M MES pH 6.5 30 % PEG 3000 0,05 M magnesium chloride low 
H12 0,1 M MES pH 6.5 30 % PEG 550 MME 0,05 M magnesium chloride low 
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